

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2004, 10:55:48 ; Search time 60 Seconds
(without alignments)
3569.517 Million cell updates/sec

Title: US-09-903-216-2

Perfect score: 4022

Sequence: 1 MAQRNNAKSSGNSSSSSGSS.....IVDVHPELTPQRRSLPAI 758

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq_29Jan04:*

1: Geneseq1990s:*

2: Geneseq1990s:*

3: Geneseq2000s:*

4: Geneseq2001s:*

5: Geneseq2002s:*

6: Geneseq2003as:*

7: Geneseq2003bs:*

8: Geneseq2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	4022	100.0	758	4	AAB83919 A human a
2	4022	100.0	758	6	ABG72365 Human asp
3	4022	100.0	758	6	ADA00639 Human asp
4	1353.5	33.7	265	6	ABU92053 Human pro
5	1334	33.2	255	2	AAY33642 Human lab
6	1320	32.8	255	5	Aau85544 Clone #48
7	1320	32.8	255	6	ABU9516 Human lun
8	1320	32.8	255	6	ABU66419 Lung canc
9	933	23.2	422	4	ABB61986 Drosophil
10	274.5	6.8	369	4	AAB73682 Human oxi
11	271.5	6.8	236	3	AAB43327 Human ORF
12	262	6.5	284	6	ABM68322 Photorhab
13	241	6.0	104	4	Aau29679 Novel hum
14	218.5	5.4	299	6	ABU21099 Protein e
15	217.5	5.4	324	4	Aau28081 Novel hum
16	215	5.3	47	4	Aau31979 Novel hum
17	204.5	5.1	3111	4	ABB60327 Drosophil
18	203.5	5.1	562	2	AAR70491 Leucocyto
19	199	4.9	109	4	AAB73672 Human oxi
20	199	4.9	783	2	AAR05804 C-termina
21	197.5	4.9	1018	2	AAR98747 P. vivax
22	197.5	4.9	1018	2	AAR97039 A. secreta
23	197.5	4.9	1018	4	AAG66528 Plasmodiu
24	197.5	4.9	1132	2	AAR97866 Chicken l
25	196.5	4.9	355	6	ABU23196 Protein e

26	191.5	4.8	1881	3	AAY44506 Streptoco
27	191.5	4.8	1881	6	ABU01047 S. pneumo
28	190.5	4.7	778	3	AAG46504 Arabidops
29	190.5	4.7	788	4	ABE68264 Drosophil
30	190.5	4.7	1162	3	AAY96255 Kaposi's
31	190.5	4.7	1162	3	AAY58500 HHV8 ORF
32	190.5	4.7	1162	4	AAB62331 Amino aci
33	190.5	4.7	1162	5	ABB05621 Kaposi's
34	190	4.7	360	2	AAB03627 Human fol
35	189.5	4.7	304	6	ABU17264 Protein e
36	189.5	4.7	312	6	ADA36728 Acinetoba
37	189.5	4.7	1616	6	ABU35669 Protein e
38	189.5	4.7	1616	7	ABO23515 Mycoplasma
39	189	4.7	3263	4	ABB67210 Drosophil
40	187.5	4.7	1192	4	ABB59642 Drosophil
41	186.5	4.6	412	2	AAW03626 Human thy
42	186	4.6	49	6	ADA56732 Human sec
43	186	4.6	49	6	ADA40577 Human sec
44	186	4.6	49	6	ABR47638 Human sec
45	186	4.6	50	2	AAY01148 Secreted

ALIGNMENTS

RESULT 1
AAB83919
ID AAB83919 standard; protein; 758 AA.
XX
AC AAB83919;
XX
DT 23-JUL-2001 (first entry)
XX
DE A human aspartyl (asparaginyl) beta-hydroxylase (HAAH).
XX
KW Epidermal growth factor-like domain; EGF-like domain; cancer;
KW human aspartyl beta-hydroxylase; HAAH; malignant neoplasm; tumour.
XX
OS Homo sapiens.
XX
PN WQ200135102-A2.
XX
PD 17-MAY-2001.
XX
PF 08-NOV-2000; 2000WO-US030738.
XX
PR 08-NOV-1999; 99US-00436184.
XX
PS (RHOD-) RHODE ISLAND HOSPITAL LIFESPAN PARTNER.
XX
Wands JR, De La Monte SM, Ince N, Carlson RI;
WPI: 2001-329171/34.
N-PSDB; AAF69811.
Diagnosing malignant neoplasm in a mammal, involves contacting mammalian sample with antibody that binds to human aspartyl beta-hydroxylase polypeptide to form antigen-antibody complex and detecting the complex.
Disclosure; Page 5; 76pp; English.

The present sequence represents a human aspartyl (asparaginyl) beta-hydroxylase (HAAH) enzyme. Epidermal growth factor (EGF)-like domains of polypeptides are hydroxylated by HAAH enzymes. HAAH is used in the method of the invention. The specification describes a method for diagnosing a malignant neoplasm in a mammal. The method comprises contacting a body fluid with an antibody which binds to HAAH polypeptide under complex forming conditions, and detecting the antigen-antibody complex. The method is useful for diagnosing and prognosing a malignant neoplasm in a body fluid e.g. central nervous system (CNS)-derived body fluid, blood, serum, urine, saliva, sputum, lung effusion, and ascites fluid of mammal, where the neoplasm is derived from endodermal tissue and is selected from colon cancer, breast cancer, pancreatic cancer, liver cancer, cancer of

CC factor (EGF)-like domain. The methods are useful for diagnosing neoplasms
CC in a mammal, inhibiting tumour growth in a mammal, conferring an immune
CC response to a brain tumour cell (e.g. glioma, glioblastoma, astrocytoma
CC or haemangioma) in a mammal, for conferring immune response to a
CC pancreatic carcinoma cell and for inducing a HAAH-specific immune
CC response in a mammal. The method is useful for diagnosing malignant
CC neoplasms derived from endodermal tissue, e.g. colon cancer, breast
CC cancer, pancreatic cancer, liver cancer and cancer of the bile ducts. The
CC method is also useful for diagnosing neoplasms of central nervous system
CC (CNS) e.g. primary malignant CNS neoplasms of both neuronal and glial
CC cell origin and metastatic CNS neoplasms, and for diagnosing brain
CC tumours e.g. glioma, glioblastoma, astrocytoma or haemangioma. The
CC present sequence represents human HAAH
XX Sequence 758 AA;

Query Match 100.0%; Score 4022; DB 6; Length 758;
Best Local Similarity 100.0%; Pred. No. 8.1e-311;
Matches 758; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAQRKNAKSSGSSSGSGSGSTAGSSSPGARRETTHGHKNGKRGKGLSGTSFFTFWV 60
DB 1 MAQRKNAKSSGSSSGSGSGSTAGSSSPGARRETTHGHKNGKRGKGLSGTSFFTFWV 60

QY 61 IALLGVWTSVAVVWFDLVYEEVLKGLGIYDADGDFDVEDDAKVLGLKERSTSEPAVP 120
DB 61 IALLGVWTSVAVVWFDLVYEEVLKGLGIYDADGDFDVEDDAKVLGLKERSTSEPAVP 120

QY 121 PEEAPHTPEEQVPVEAPQNIIEAKEQIQLSLHEMVHAEHVEGDIQQEDGPTGEQ 180
DB 121 PEEAPHTPEEQVPVEAPQNIIEAKEQIQLSLHEMVHAEHVEGDIQQEDGPTGEQ 180

QY 181 QEDDEFLMATDVDDRETLEPEVSHETSHVETVSQDCNQDMEMMSQENPDSE 240
DB 181 QEDDEFLMATDVDDRETLEPEVSHETSHVETVSQDCNQDMEMMSQENPDSE 240

QY 241 PVVEDERLHDDTDDVTYQVEQAVYPLENEGIEITEVTAPDPVEDSQVIVEEVS 300
DB 241 PVVEDERLHDDTDDVTYQVEQAVYPLENEGIEITEVTAPDPVEDSQVIVEEVS 300

QY 301 FVVEEQVEVPPETNRKTDDEQKAKVKKKPKLNKFDKTIKAEALDAEKLKRGKIEA 360
DB 301 FVVEEQVEVPPETNRKTDDEQKAKVKKKPKLNKFDKTIKAEALDAEKLKRGKIEA 360

QY 361 VNAFELVKYQSPRARKYKQACEDDLAEKRSNEVLRGAIETQYEVASLPDVPADLLK 420
DB 361 VNAFELVKYQSPRARKYKQACEDDLAEKRSNEVLRGAIETQYEVASLPDVPADLLK 420

QY 421 LSLKRRSDRQQFLGHRGSLLTQLRLVQLFPNDTSLKNDLGVGYLLIGDNDNAKKYVEV 480
DB 421 LSLKRRSDRQQFLGHRGSLLTQLRLVQLFPNDTSLKNDLGVGYLLIGDNDNAKKYVEV 480

QY 481 LSVTPNDGFAKHVGHFILKAQNKIAESIPLYKEGIESGDPGTDGDFYHLGDAMORVGN 540
DB 481 LSVTPNDGFAKHVGHFILKAQNKIAESIPLYKEGIESGDPGTDGDFYHLGDAMORVGN 540

QY 541 KEAYKMYELGHKRGHGFASVWQSRSLYVNGVGLKAPWMTPKETGYTELKSLERNWKLIRDE 600
DB 541 KEAYKMYELGHKRGHGFASVWQSRSLYVNGVGLKAPWMTPKETGYTELKSLERNWKLIRDE 600

QY 601 GLAVMDKAKGLFPEDENLREKGDWSQFTLWQGRNENACKGAPKTCTTLEKFPETTCG 660
DB 601 GLAVMDKAKGLFPEDENLREKGDWSQFTLWQGRNENACKGAPKTCTTLEKFPETTCG 660

QY 661 RRGQIKYISIMHPCHTVWPHGPTNCRRLMHLGLVPIKEGCKIRCANETRTWEGKVLIED 720
DB 661 RRGQIKYISIMHPCHTVWPHGPTNCRRLMHLGLVPIKEGCKIRCANETRTWEGKVLIED 720

QY 721 DSFEHEWQDASSFRLLIFIVDVWHPPELTPOQRSLPAI 758
DB 721 DSFEHEWQDASSFRLLIFIVDVWHPPELTPOQRSLPAI 758

RESULT 3
ADA00639
ID ADA00639 standard; protein; 758 AA.
XX ADA00639;
AC
DT 06-NOV-2003 (first entry)
XX
DE Human aspartyl (asparaginy1) beta-hydroxylase (HAAH).
XX
KW Tumour growth inhibition; human aspartyl (asparaginy1) beta-hydroxylase;
KW HAAH hydroxylation; NOTCH polypeptide;
KW epidermal growth factor-like repeat; EGF-like repeat; tumour cell;
KW malignant neoplasm; colon cancer; breast cancer; pancreatic cancer;
KW liver cancer; cancer of the bile duct; cancer the central nervous system;
KW CNS; cytostatic; enzyme; human.
XX
OS Homo sapiens.
XX
EN US2003031670-A1.
XX
PD 13-FEB-2003.
XX
PF 08-NOV-1999; 99US-00436184.
XX
PR 08-NOV-1999; 99US-00436184.
XX
PA (WAND/) WANDS J R.
PA (DMON/) DE LA MONTE S M.
PA (INCE/) INCE N.
PA (CARL/) CARLSON R I.
XX
PI Wands JR, De La Monte SM, Ince N, Carlson RI;
XX
XX WPI; 2003-605701/57.
XX N-PSDB; ADA00640.
XX
PT Inhibiting tumor growth or killing tumor cells (e.g. cancer of the colon,
PT breast, pancreatic, liver or the central nervous system), by
PT administering an inhibitor of the human aspartyl (asparaginy1) beta-
PT hydroxylase.
XX
PS Disclosure; Page 2; 30pp; English.
XX
CC The present invention relates to a method for inhibiting tumour growth in
CC a mammal. The method comprises administering to the mammal a compound,
CC which inhibits the expression or enzymatic activity of a human aspartyl
CC (asparaginy1) beta-hydroxylase (HAAH). The compound may inhibit HAAH
CC hydroxylation of a NOTCH polypeptide. In particular, the compound may
CC inhibit hydroxylation of an epidermal growth factor (EGF)-like repeat
CC sequence in a NOTCH polypeptide. The methods are useful for inhibiting
CC tumour growth or killing tumour cells, or for diagnosing or
CC prognosticating a malignant neoplasm. In particular, the tumour or
CC neoplasm is colon cancer, breast cancer, pancreatic cancer, liver cancer,
CC cancer of the bile ducts, or cancer or tumour of the central nervous
CC system (CNS). The present sequence represents HAAH.
XX
SQ Sequence 758 AA;

Query Match 100.0%; Score 4022; DB 6; Length 758;
Best Local Similarity 100.0%; Pred. No. 8.1e-311;
Matches 758; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAQRKNAKSSGSSSGSGSGSTAGSSSPGARRETTHGHKNGKRGKGLSGTSFFTFWV 60
DB 1 MAQRKNAKSSGSSSGSGSGSTAGSSSPGARRETTHGHKNGKRGKGLSGTSFFTFWV 60

QY 61 IALLGVWTSVAVVWFDLVYEEVLKGLGIYDADGDFDVEDDAKVLGLKERSTSEPAVP 120
DB 61 IALLGVWTSVAVVWFDLVYEEVLKGLGIYDADGDFDVEDDAKVLGLKERSTSEPAVP 120

QY 121 PEEAPHTPEEQVPVEAPQNIIEAKEQIQLSLHEMVHAEHVEGDIQQEDGPTGEQ 180
DB 121 PEEAPHTPEEQVPVEAPQNIIEAKEQIQLSLHEMVHAEHVEGDIQQEDGPTGEQ 180

Db 121 PEAEPHTPEEQVPEBAEPONIEDEAKEQIQSLHEMVAHEVEGEDLQOEDGFTGEPQ 180
Qy QEDDEFLMATDVRDREFTLEPEVSHETESYHYVEETVSQDCNODMEMSEQENPDSS 240
Db 181 QEDDEFLMATDVRDREFTLEPEVSHETESYHYVEETVSQDCNODMEMSEQENPDSS 240
Qy 241 PVVEDERLHDDTDVTVQVVEEQAVPEPLENEGIEITEVTAPPEDNPVEDSQVIVERVSI 300
Db 241 PVVEDERLHDDTDVTVQVVEEQAVPEPLENEGIEITEVTAPPEDNPVEDSQVIVERVSI 300
Qy 301 FVVEEQVPEPTNRKTDDEPKAKVKKPKLLNKPKTKIKAELEDAEKLRKRGKIEEA 360
Db 301 FVVEEQVPEPTNRKTDDEPKAKVKKPKLLNKPKTKIKAELEDAEKLRKRGKIEEA 360
Qy 361 VNAFKELVRKYQPSPRARYKGAQCEDDLAEKRRSNEVLRGAIETYQEVASLPDVPADLLK 420
Db 361 VNAFKELVRKYQPSPRARYKGAQCEDDLAEKRRSNEVLRGAIETYQEVASLPDVPADLLK 420
Qy 421 LSLKRRSDRQOFLGHMRGSLTLQRLVQLFPNDTSLKNDLGVGYLLIGDNDNAKKVYEEV 480
Db 421 LSLKRRSDRQOFLGHMRGSLTLQRLVQLFPNDTSLKNDLGVGYLLIGDNDNAKKVYEEV 480
Qy 481 LSVTPNDGFAKHVGFILKAQNKIAESIPLYKEGIESGDPGTDGREFYHLGDAMQVRGN 540
Db 481 LSVTPNDGFAKHVGFILKAQNKIAESIPLYKEGIESGDPGTDGREFYHLGDAMQVRGN 540
Qy 541 KEAYKMYELGHRGHFASVMQSRSLYVNGLKAQPMWTPKETGYTELKSLERNWKLIRDE 600
Db 541 KEAYKMYELGHRGHFASVMQSRSLYVNGLKAQPMWTPKETGYTELKSLERNWKLIRDE 600
Qy 601 GLAVMDKAKGLFLPEDENLREKGDWSOFTLWQOQRNENACKGAPKCTTLEKPEPTTGC 660
Db 601 GLAVMDKAKGLFLPEDENLREKGDWSOFTLWQOQRNENACKGAPKCTTLEKPEPTTGC 660
Qy 661 RRGQIKYSIMHPGHVPHGPTNCRMLHGLVIPKEGCKIRCANETRTWEKGKVLIFD 720
Db 661 RRGQIKYSIMHPGHVPHGPTNCRMLHGLVIPKEGCKIRCANETRTWEKGKVLIFD 720
Qy 721 DSFEHEVQDASSPRLPIFVDVWHPPELTPOQRSLPAI 758
Db 721 DSFEHEVQDASSPRLPIFVDVWHPPELTPOQRSLPAI 758

RESULT 4

ABU92053
ID ABU92053 standard; protein; 265 AA.

XX AC ABU92053;

XX XX

DT 15-JUN-2003 (first entry)

XX XX

DE Human protein modification and maintenance molecule-33 (PMW-33).

XX Human, protein modification and maintenance molecule; PMW; cancer;
KW cell proliferation disorder; atherosclerosis; neurological disorder;
KW epilepsy; Huntington's disease; stroke; immune disorder; allergy;
KW inflammatory disorder; AIDS; developmental disorder; hypothyroidism;
KW Cushing's syndrome; gastrointestinal disorder; epithelial disorder;
KW infection; cytostatic; antiarteriosclerotic; anticonvulsant; nootropic;
KW neuroprotective; cerebroprotective; anti-HIV; antiallergic; vulnerary;
KW antiinflammatory; thyromimetic.

XX OS Homo sapiens.

XX XX

XX WO2003031939-A2.

XX XX

PD 17-APR-2003.

XX XX

EF 11-OCT-2002; 2002MO-US032850.

XX XX

XX 12-OCT-2001; 2001US-0329689P.

PR 25-OCT-2001; 2001US-0335703P.

PR 09-NOV-2001; 2001US-0348887P.

XX XX

PR 28-NOV-2001; 2001US-0334145P.
PR 06-DEC-2001; 2001US-0337451P.
PR 14-DEC-2001; 2001US-0340584P.
XX (INCY-) INCYTE GENOMICS INC.
XX Rankumar J, Gorvad AE, Baughn MR, Emerling BM, Yang J, Lee SY;
PI Tran UK, Becha SD, Duggan BM, Lee EA, Griffin JA, Li JX;
PI Sprague WW, Hafalia AJA, Chawla NK, Lehr-Nason PM, Kable AE, Yue H;
PI Marquis JP, Yao MG, Richardson TW, Tang TY, Jin P, Chien D;
PI Bhattach U, Burrill JD, Lee S, Blake JJ, Ho A, Zheng W;
XX WPI; 2003-430274/40.
DR N-PSDB; ACA92448.
XX New human protein modification and maintenance molecules (PMW), useful
PT for diagnosing, treating and preventing diseases or conditions associated
PT with the aberrant PMW expression e.g. cancer, atherosclerosis, or
PT infections.
XX Claim 1; Page 273-274; 311pp; English.

XX The present invention relates to the isolation of human protein
CC modification and maintenance molecules (PMW), and the polynucleotide
CC sequences encoding them. A total of 40 PMW polypeptides (designated PMW
CC -1 to PMW-40) are disclosed. The sequences of the invention are useful
CC for diagnosing a condition or disease associated with the expression of
CC PMW in a subject, preparing a polyclonal or monoclonal antibody, and
CC generating an expression profile of a sample containing the
CC polynucleotides. The diseases or conditions associated with decreased
CC expression or overexpression of PMW are cell proliferation disorders
CC (e.g. cancer, atherosclerosis), neurological disorders (e.g. epilepsy,
CC Huntington's disease, stroke), immune/inflammatory disorders, (e.g. AIDS,
CC allergies), developmental disorders (e.g. hypothyroidism, Cushing's
CC syndrome), gastrointestinal disorders (e.g. hypothyroidism, Cushing's
CC PMW polypeptides or their fragments are useful in screening compounds
CC for effectiveness as agonists or antagonists of the polypeptides, or in
CC altering the expression of the target polynucleotide and compounds that
CC specifically bind to, or modulate the activity of the polypeptide.
CC ABU92021-ABU92060 represent the human PMW polypeptides of the invention
XX

SQ Sequence 265 AA;

Query Match

33.7%; Score 1353.5; DB 6; Length 265;

Best Local Similarity 92.5%; Pred. No. 4.2e-99;

Matches 259; Conservative 2; Mismatches 0; Indels 19; Gaps 1;

Qy 34 RETKHGKHNGRKGGLSGTSFFTWFMVIALGLGWTSAVWVFDLVYEEVLKGLIYDAD 93

Db 5 KETKHGKHNGRKGGLSGTSFFTWFMVIALGLGWTSAVWVFDLVYEEVLKGLIYDAD 64

Qy 94 GDGDFDVKVLLGLKERTSEPAVPPPEAEPTPEEQVPEAEPPQNTEDAEKQIQS 153

Db 65 GDGDFDVKVLLGLKERTSEPAVPPPEAEPTPEEQVPEAEPPQNTEDAEKQIQS 124

Qy 154 LLEHMHVHAEHVEGEDLQOEDGPTGEPQOEDDEFLMATDVRDREFTLEPEVSHETESYH 213

Db 125 LLEHMHVHAEHVEGEDLQOEDGPTGEPQOEDDEFLMATDVRDREFTLEPEVSHETESYH 184

Qy 214 VEETVSQDCNQDMEMSEQENPDSSFEPPVEDERLHDDTDVTVQVVEEQAVPEPLENEG 273

Db 185 VEET-----DSSEPVVEDERLHDDTDVTVQVVEEQAVPEPLENEG 225

Qy 274 IEITEVTAPPEDNPVEDSQVIVEEVSIFFPVEEQQVEPPT 313

Db 226 IEITEVTAPPEDNPVEDSQVIVEEVSIFFPVEEQQVEPPT 265

RESULT 5

AAV33642

ID AAV33642 standard; protein; 255 AA.

XX XX

AC AAV33642;

XX 06-JAN-2000 (first entry)
XX Human labyrinthin protein.
XX Labyrinthin; human; cancer; marker; antigen; detection; antibody;
KW MCA 44-3A6; diagnostic; vaccine; treatment; adenocarcinoma.
XX Homo sapiens.
XX WO9947683-A1.
XX 23-SEP-1999.
XX 11-MAR-1999; 99WO-US005365.
XX 17-MAR-1998; 98US-00040485.
XX (RADO/) RADOSEVICH J A.
XX Radosevich JA;
XX WPI: 1999-580307/49.
XX N-PSDB; AA223609.
XX Novel labyrinthin polynucleotides and polypeptides used as a diagnostic
PT marker for cancer and in anticancer vaccines.
XX Claim 6; Fig 2; 34pp; English.
XX This invention describes a novel polynucleotide and polypeptide sequence
CC for the antigen detected by the antibody MCA 44-3A6. This antigen is
CC designated Labyrinthin (Lab). Antibodies directed to the Labyrinthin
CC (Lab) protein are useful for the detection of Lab. The Lab protein is
CC useful in diagnostic assays for cancer, e.g. to monitor the presence and
CC amount of antibodies (this method is especially useful for cancer cells
CC that have the Lab marker). As the Lab gene is not tissue-specific, it
CC will detect cancer regardless of which organ it occurs in. Peptides
CC derived from Lab are used in the preparation of vaccines to prevent human
CC cancers and/or to treat humans with cancer. Antibody MCA 44-3A6 is able
CC to differentiate antigens associated with adenocarcinomas. However, the
CC sequence of the antigen detected by this antibody has not been elucidated
CC in the prior art. Determination of the polypeptide and polynucleotide
CC sequence of this antigen would enhance its usefulness in cancer
CC diagnosis, treatment and prevention. The present invention discloses the
CC sequences of the antigen recognized by the MCA 44-3A6 antibody. This
CC sequence represents the human lab protein described in the method of the
CC invention
XX
SQ Sequence 255 AA;
Query Match 33.2%; Score 1334; DB 2; Length 255;
Best Local Similarity 99.6%; Pred. No. 1.4e-97;
Matches 254; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 59 MVIALLGWTSVAVVWFDLVDVVEVLGKGIYDADGDGDFDVKLVGLKERSTSEPA 118
Db 1 MVIALLGWTSVAVVWFDLVDVVEVLGKGIYDADGDGDFDVKLVGLKERSTSEPA 60
QY 119 VPPEAEHPTEPEQVPVEAEFPQNTDEAKQIQSLHEMVAHVEGEDLQOEDGPTGE 178
Db 61 VPPEAEHPTEPEQVPVEAEFPQNTDEAKQIQSLHEMVAHVEGEDLQOEDGPTGE 120
QY 179 PQQEDDEFLMATDVRFTLPEVSHETSHYVEETVSQDCNDMEEMSEQENPDPS 238
Db 121 PQQEDDEFLMATDVRFTLPEVSHETSHYVEETVSQDCNDMEEMSEQENPDPS 180
QY 239 SEPVEDERLHDDTDVTVQVVEEQAVYEPLENEGIEITEVTAPEDNPNVDSQVIVEEV 298
Db 181 SEPVEDERLHDDTDVTVQVVEEQAVYEPLENEGIEITEVTAPEDNPNVDSQVIVEEV 240
QY 299 SIFPVEEQQEVPPET 313
|||

Db 241 SIFPVEEQQEVPPDT 255
RESULT 6
AAU85544
ID AAU85544 standard; protein; 255 AA.
XX AAU85544;
XX 21-MAY-2002 (first entry)
XX Clone #48005 (L979P) of lung tumour protein.
XX Lung tumour; cancer; T cell; immune response stimulator; cytostatic.
XX Homo sapiens.
XX WO200204514-A2.
XX 17-JAN-2002.
XX 10-JUL-2001; 2001WO-US022059.
XX 11-JUL-2000; 2000US-00614124.
XX 29-AUG-2000; 2000US-00651563.
XX 08-SEP-2000; 2000US-00658824.
XX 26-SEP-2000; 2000US-00671325.
XX 06-OCT-2000; 2000US-00677419.
XX 30-OCT-2000; 2000US-00702705.
XX 13-DEC-2000; 2000US-00736457.
XX 03-MAY-2001; 2001US-00849626.
XX (CORI-) CORIXA CORP.
XX Wang T, Watanabe Y, Henderson RA, Johnson JC, Retter MW;
PI Marnerakis M, Carter D, Fanger GR, Vedvick TS, Bangur CS, Mcnabb A;
PI Wang A, Fanger N, Switzer A, McNeill PD, Clapper JD;
XX WPI: 2002-164634/21.
XX N-PSDB; ABK39746.
XX Novel polynucleotide encoding a lung tumor polypeptide useful for
PT stimulating and/or expanding T cells specific for a tumor protein.
XX Claim 2; SEQ ID NO 1806; 223pp; English.
XX The invention describes an isolated polynucleotide and polypeptide useful
CC for stimulating and/or expanding T cells specific for a tumour protein
CC for determining the presence of a cancer in a patient. A composition
CC containing the polynucleotide and/or polypeptide is useful for treating a
CC lung cancer in a patient. The polypeptide is useful for removing tumour
CC cells from a biological sample. The polynucleotide is also useful as
CC probe or primer to detect the level of mRNA encoding a tumour protein.
CC This is the amino acid sequence of a lung tumour associated protein.
CC described in the method of the invention. Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 255 AA;
Query Match 32.8%; Score 1320; DB 5; Length 255;
Best Local Similarity 98.8%; Pred. No. 1.9e-96;
Matches 252; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 59 MVIALLGWTSVAVVWFDLVDVVEVLGKGIYDADGDGDFDVKLVGLKERSTSEPA 118
Db 1 MVIALLGWTSVAVVWFDLVDVVEVLGKGIYDADGDGDFDVKLVGLKERSTSEPA 60
QY 119 VPPEAEHPTEPEQVPVEAEFPQNTDEAKQIQSLHEMVAHVEGEDLQOEDGPTGE 178
Db 61 VPPEAEHPTEPEQVPVEAEFPQNTDEAKQIQSLHEMVAHVEGEDLQOEDGPTGE 120

QY 179 PQEDDEFLMATDVDDRFETLEPEVSHSETEHSYHVEETVSQDCNQDMEEMMSQENPDS 238
 DB 121 PQEDDEFLMATDVDDRFETLEPEVSHSETEHSYHVEETVSQDCNQDMEEMMSQENPDS 180
 QY 239 SEPVEERLHHDTHDDVYQVYEQAVYEPLENGIEHTEVTAPDNPVEDSQVIVEEV 298
 DB 181 SEPVEERLHHDTHDDVYQVYEQAVYEPLENGIEHTEVTAPDNPVEDSQVIVEEV 240
 QY 299 SIFPVEEQEQVPPPT 313
 DB 241 SIFPVEEQEQVPPPT 255

RESULT 7
 ABU69516
 ID ABU69516 standard; protein; 255 AA.
 AC ABU69516;
 XX
 DT 05-JUN-2003 (first entry)
 DE Human lung cancer-associated protein L979P.
 KW Human; lung cancer; lung tumour; cytostatic; vaccine; T cell expansion;
 KW CD4; CD8.
 OS Homo sapiens.
 XX
 PN US2002197669-A1.
 XX
 PD 26-DEC-2002.
 XX
 PF 03-MAY-2001; 2001US-00849626.
 XX
 PR 13-DEC-2000; 2000US-00736457.
 XX
 PA (BANG/) BANGUR C S.
 PA (FANG/) FANGER G R.
 PA (WANG/) WANG A.
 PA (WANG/) WANG T.
 PA (SWIT/) SWITZER A P.
 PA (MCNE/) MCNEILL P D.
 PA (CLAP/) CLAPPER J D.
 XX
 PI Bangur CS, Fanger GR, Wang A, Wang T, Switzer AP, Mcneill PD;
 PI Clapper JD;
 DR
 DR WPI; 2003-352750/33.
 DR N-PSDB; ACA12072.
 XX
 PT Novel lung cancer polynucleotide encoding lung cancer protein, useful for
 PT detecting the presence of lung cancer in a patient, and in pharmaceutical
 PT compositions, e.g. vaccines, for treating lung cancer.
 XX
 PS Example 5; Page; 72pp; English.
 XX

CC The invention relates to a polynucleotide encoding a lung tumour protein,
 CC comprising a sequence selected from any of the 14 sequences mentioned in
 CC the specification, or a sequence (S2) mentioned in specification,
 CC complement of S1, sequences consisting of at least 20 contiguous residues
 CC of S1, sequences that hybridise to S1, sequences having 75%, preferably
 CC 90%, identity to S1, or degenerate variants of S1. Also included are an
 CC isolated polypeptide (comprising a sequence (S3) selected from any one of
 CC the 4 amino acid sequences mentioned in the specification, a sequence
 CC preferably 90%, identity to a sequence encoded by the polynucleotide), an
 CC expression vector comprising the polynucleotide operably linked to an
 CC expression control sequence, a host cell transformed or transfected with
 CC the vector, an isolated antibody (or its antigen-binding fragment) that
 CC specifically binds to the polypeptide, detecting the presence of a cancer
 CC in a patient, a fusion protein comprising the polypeptide, an
 CC oligonucleotide that hybridises to S1 under moderately stringent
 CC conditions, stimulating and/or expanding T cells specific for a tumour

CC protein (comprising contacting T cells with the polynucleotide, protein
 CC or antigen-presenting cells, under conditions and for a time sufficient
 CC to permit the stimulation and/or expansion of T cells) and inhibiting the
 CC development of a cancer in a patient (by incubating CD4⁺ and/or CD8⁺ T
 CC cells isolated from a patient with the polynucleotide, protein or antigen
 CC presenting cells that express the polynucleotide, such that T cells
 CC proliferate, administering to the patient an effective amount of the
 CC proliferated T cells, and thus inhibiting the development of a cancer in
 CC the patient. The polynucleotide, protein and cells are useful in a
 CC composition for stimulating an immune response in a patient, and for
 CC treating a cancer in a patient (particularly lung cancer). The
 CC oligonucleotide is useful for determining the presence of a cancer in a
 CC patient. The protein and oligonucleotides are useful in pharmaceutical
 CC compositions, e.g. vaccines. The polynucleotide is also useful as a probe
 CC or primer for nucleic acid hybridisation, and in the design and
 CC preparation of ribozyme molecules for inhibiting expression of tumour
 CC polypeptides and proteins in tumour cells. An amplified portion of the
 CC polynucleotide is useful for isolating a full-length gene from a suitable
 CC library. The present sequence is a protein encoded by a cDNA (full
 CC length, extended or partial) isolated from a library derived from lung
 CC tumour/ cancer cells. Note: The sequence data for this patent did not
 CC form part of the printed specification, but was obtained in electronic
 CC format directly from the USPTO at
 CC seqdata.uspto.gov/sequence.html?docId=20020197669
 XX
 SQ Sequence 255 AA;

Query Match 32.8%; Score 1320; DB 6; Length 255;
 Best Local Similarity 98.8%; Pred. No. 1.9e-96;
 Matches 252; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 59 MVIALLGWTSVAVVWFDLVYEEVLKGLGIYDADGDGDFDVKVLLGLKERSTSEPA 118
 DB 1 MVIALLGWTSVAVVWFDLVYEEVLKGLGIYDADGDGDFDVKVLLGLKERSTSEPA 60
 QY 119 VPPEAEPTPEEQVPPVEAPQNIIDEAKEQIQSLHHEMVAHEHVEGEDLQEDGPTGE 178
 DB 61 VPPEAEPTPEEQVPPVEAPQNIIDEAKEQIQSLHHEMVAHEHVEGEDLQEDGPTGE 120
 QY 179 PQEDDEFLMATDVDDRFETLEPEVSHSETEHSYHVEETVSQDCNQDMEEMMSQENPDS 238
 DB 121 PQEDDEFLMATDVDDRFETLEPEVSHSETEHSYHVEETVSQDCNQDMEEMMSQENPDS 180
 QY 239 SEPVEERLHHDTHDDVYQVYEQAVYEPLENGIEHTEVTAPDNPVEDSQVIVEEV 298
 DB 181 SEPVEERLHHDTHDDVYQVYEQAVYEPLENGIEHTEVTAPDNPVEDSQVIVEEV 240
 QY 299 SIFPVEEQEQVPPPT 313
 DB 241 SIFPVEEQEQVPPPT 255

RESULT 8
 ABU66419
 ID ABU66419 standard; protein; 255 AA.
 AC ABU66419;
 XX
 DT 22-MAY-2003 (first entry)
 DE Lung cancer therapy and diagnosis associated protein #43.
 KW Lung cancer; cytostatic; vaccine; gene therapy; cancer.
 OS Homo sapiens.
 XX
 PN US2002172952-A1.
 XX
 PD 21-NOV-2002.
 XX
 PF 10-JUL-2001; 2001US-00902941.
 XX
 PR 30-JUN-1999; 99US-00346492.

PR 15-OCT-1999; 99US-00419356.
 PR 17-DEC-1999; 99US-00466867.
 PR 30-DEC-1999; 99US-00476300.
 PR 06-MAR-2000; 2000US-00519642.
 PR 22-MAR-2000; 2000US-00533077.
 PR 10-APR-2000; 2000US-00546259.
 PR 27-APR-2000; 2000US-00560406.
 PR 05-JUN-2000; 2000US-00589184.
 PR 11-JUL-2000; 2000US-00614124.
 PR 29-AUG-2000; 2000US-00651563.
 PR 08-SEP-2000; 2000US-00658824.
 PR 26-SEP-2000; 2000US-00671325.
 PR 06-OCT-2000; 2000US-00677419.
 PR 30-OCT-2000; 2000US-00702705.
 PR 13-DEC-2000; 2000US-00736457.
 PR 03-MAY-2001; 2001US-00849626.
 XX (CORI-) CORIXA CORP.
 PA Henderson RA, Wang T, Watanabe Y, Johnson JC, Retter MW;
 PI Durham M, Carter D, Panger GR, Vedvick TS, Bangur CS, McNabb A;
 PI
 XX WPI; 2003-328427/31.
 DR
 XX New polynucleotide, useful for preparing a composition for treating or
 PT inhibiting development of cancer, e.g. lung cancer.
 PT
 XX
 PS Example 5; SEQID NO 1807; 82pp; English.
 XX
 CC The invention describes an isolated polynucleotide comprising one of 32
 CC sequences, complement or degenerate variants of them. The polynucleotide
 CC is useful for preparing a composition e.g. a vaccine or for gene therapy,
 CC for treating or inhibiting development of cancer, e.g. lung cancer. This
 CC sequence represents a polypeptide associated with the compositions and
 CC methods for the therapy and diagnosis of lung cancer
 CC
 XX Sequence 255 AA;
 SQ
 Query Match 32.8%; Score 1320; DB 6; Length 255;
 Best Local Similarity 98.8%; Pred. No. 1.9e-96;
 Matches 252; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 59 MVIALLGWVTSVAVVDFLDVYEEVLGKGIYDADGDGDFVDDAKVILGLKERSTSEPA 118
 Db 1 MVIALLGWVTSVAVVDFLDVYEEVLGKGIYDADGDGDFVDDAKVILGLKERSTSEPA 60
 QY 119 VPPEAEAPHTPEEQVPEAEFPQNTDEAKQIQSLLEHVMVHAHVGEEDLQOEDGPTGE 178
 Db 61 VPPEAEAPHTPEEQVPEAEFPQNTDEAKQIQSLLEHVMVHAHVGEEDLQOEDGPTGE 120
 QY 179 PQQEDDEFMATDVRDRETLEPEVSHETESHVVEETVSOCCNQDMEMMSEQENPDS 238
 Db 121 PQQEDDEFMATDVRDRETLEVSHETESHVVEETVSOCCNQDMEMMSEQENPDS 180
 QY 239 SEPVEDERLHHTDDVTVQVYVEQAVVEPLENEGIEITEVTAPPEPNVEDSQVIVEEV 298
 Db 181 SEPVEDERLHHTDDVTVQVYVEQAVVEPLENEGIEITEVTVPEDNPVEDSQVIVEEV 240
 QY 299 SIFFVEEQEVPPEPT 313
 Db 241 SIFFVEEQEVPPEPT 255
 RESULT 9
 ABB61986
 ID ABB61986 standard; protein; 422 AA.
 XX
 AC ABB61986;
 XX
 DT 26-MAR-2002 (first entry)
 XX
 XX Drosophila melanogaster polypeptide SEQ ID NO 12750.
 DE
 XX

KW Drosophila; developmental biology; cell signalling; insecticide;
 KW pharmaceutical.
 XX
 OS Drosophila melanogaster.
 XX
 FN WO200171042-A2.
 XX
 XX 27-SEP-2001.
 XX
 PF 23-MAR-2001; 2001WO-US009231.
 XX
 PR 23-MAR-2000; 2000US-0191637P.
 PR 11-JUL-2000; 2000US-00614150.
 XX
 PA (PEKE) PE CORP NY.
 XX
 PI Venter JC, Adams M, Li PWD, Myers EW;
 PI
 XX WPI; 2001-656860/75.
 DR N-PSDB; ABL06089.
 XX
 XX New isolated nucleic acid detection reagent for detecting 1000 or more
 PT genes from Drosophila and for elucidating cell signalling and cell-cell
 PT interactions.
 XX
 PS Disclosure; SEQ ID NO 12750; 21pp + Sequence Listing; English.
 XX
 CC The invention relates to an isolated nucleic acid detection reagent
 CC capable of detecting 1000 or more genes from Drosophila. The invention is
 CC useful in developmental biology and in elucidating cell signalling and
 CC cell-cell interactions in higher eukaryotes for the development of
 CC insecticides, therapeutics and pharmaceutical drugs. The invention
 CC discloses genomic DNA sequences (ABL16176-ABL30511); expressed DNA
 CC sequences (ABL01840-ABL16175) and the encoded proteins (ABB57737-
 CC ABB72072). The sequence data for this patent did not form part of the
 CC printed specification, but was obtained in electronic format directly
 CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 422 AA;
 Query Match 23.2%; Score 933; DB 4; Length 422;
 Best Local Similarity 45.0%; Pred. No. 2.5e-65;
 Matches 184; Conservative 75; Mismatches 144; Indels 6; Gaps 5;
 QY 355 GKIEEAVNAEKELVRYKYPQSPRKYKACDDDLAEKERSNEVLRGAIETQEVASLPDV 414
 Db 15 GNYAQALRSFTLTNTNFAHPSAHLGRARLELLAKERSNQRLWEALDAYKRYLAFGL 74
 QY 415 PADLLKLSKERS--DROQFLGHMRGSLTLTQLRLVQLFPNDTSLKNDLGVGYLLIGDNDN 472
 Db 75 VASNQEFQTAGESCIENLRFLGHHRQATTIHELLINRLPEDPRLRNQLSLTYLVWNNLQQ 134
 QY 473 AKKYVEEVLSTPNDGFAKVHYGFIKA-QNKIAESIPYLKEGIESGPDGDDGRFYFHL 531
 Db 135 VEKAVAVETLKPWNAVAQLHYGLALRQFHADYAKALPYLYAVESGEGTQEAFFYLSL 194
 QY 532 GDAMQRCVGNK-EAYKWVELGHKRGHFASVWORSLYNVNGLKAQPMWTKPYGYTELKSL 590
 Db 195 GETWQRLSNKSEALEVYGVKAGFFASLYQRSLYNEPRLRAQPFQWPKETGYERQLEKL 254
 QY 591 ERNWKLIIRDEGLAVMDKAKGLFLPEDENLRKGDWMSQFTLMQOQGRNENACKGAPKCTCL 650
 Db 255 TLNWRRAIRDEGLALLGRS-GFFEDAEALLRDKGVWQVQVYELVYAGRRVKDCRRAPITCSL 313
 QY 651 LEKFPETTCRRGQIKYISIMHPGTHVPHPTGPTNCRRLRMHGLVLPK-EGCKIRCANTR 709
 Db 314 LEEFPESACRRGQVYKFSVMQAKTHVWPHCGPTNCRLEAHLTLAAPEPEKASLRVAEQER 373
 QY 710 TWEEGKVLIFDDSPFEHVMQDASSFRLIFIVDVVHPELTTPQRRSLPAI 758
 Db 374 TWRGELFIFDDSPFEHVMHNGSQRVLIIIDMMHPQLSAAQRRSLSPI 422

RESULT 10

AAAB73682
 ID AAB73682 standard; protein; 369 AA.
 AC AAB73682;
 XX
 XX 11-SEP-2001 (first entry)
 DT
 XX Human oxidoreductase protein ORP-15.
 DE
 XX Human oxidoreductase protein; ORP; cell proliferative disorder;
 KW arteriosclerosis; cirrhosis; psoriasis; cancer; endocrine disorder;
 KW diabetes mellitus; diabetes insipidus; dwarfism; hirsutism; amenorrhea;
 KW osteoporosis; metabolic disorder; obesity; phenylketonuria;
 KW hypercholesterolemia; reproductive disorder; infertility;
 KW ovulatory defect; menstrual cycle defect; endometriosis; chromosome 22;
 KW polycystic ovary disease; spermatogenesis disruption; impotence;
 KW neurological disorder; epilepsy; stroke; Alzheimer's disease;
 KW Huntington's disease; Parkinson's disease; Creutzfeldt-Jakob disease;
 KW meningitis; cerebral palsy; muscular dystrophy; mood disorder; anxiety;
 KW schizophrenic disorder; infection; autoimmune disorder;
 KW inflammatory disorder; acquired immunodeficiency syndrome; AIDS; asthma;
 KW allergy; Crohn's disease; atopic dermatitis; gout; multiple sclerosis;
 KW rheumatoid arthritis; ulcerative colitis; drug screening;
 KW toxicity screening; transgenic animal; SNP detection; gene therapy; ss.
 XX
 OS Homo sapiens.
 XX
 PN WC200144448-A2.
 XX
 PD 21-JUN-2001.
 XX
 XX 07-DEC-2000; 2000WO-US033158.
 XX
 XX 16-DEC-1999; 99US-0172367P.
 XX
 XX (INCY-) INCYTE GENOMICS INC.
 PA
 XX Yue H, Lal P, Tang YT, Hillman JL, Baughn MR, Azimzai Y, Lu DAM;
 XX WPI; 2001-390245/41.
 XX N-PSDB; AAH24237.
 XX
 XX Novel human oxidoreductase protein (ORP) useful for diagnosing, treating
 PT and preventing cell proliferative, neurological, viral, reproductive and
 PT autoimmune/inflammatory disorders associated with abnormal expression of
 PT ORP.
 XX
 PS Claim 1; Page 110-111; 136pp; English.
 XX
 CC Sequences AAB73668-AA73694 represent 27 novel human oxidoreductase
 CC proteins, designated ORP-1 to ORP-27 respectively, and sequences AAH24223
 CC -AAH24249 represent cDNAs encoding ORP-1 to ORP-27. Human ORP proteins
 CC and nucleic acids are useful for diagnosing, treating or preventing cell
 CC proliferative disorders (e.g. arteriosclerosis, cirrhosis, psoriasis,
 CC cancers), endocrine disorders (e.g., type I or II diabetes mellitus,
 CC diabetes insipidus, dwarfism, hirsutism, amenorrhea, osteoporosis);
 CC metabolic disorders (e.g., obesity, phenylketonuria,
 CC hypercholesterolemia); reproductive disorders (e.g., infertility,
 CC ovulatory and menstrual cycle defects, endometriosis, polycystic ovary
 CC disease, disruption of spermatogenesis, impotence); neurological
 CC disorders (e.g., epilepsy, stroke, Alzheimer's disease, Huntington's
 CC disease, Parkinson's disease, meningitis, Creutzfeldt-Jakob disease,
 CC cerebral palsy, muscular dystrophy, mood, anxiety and schizophrenic
 CC disorders); viral, bacterial, fungal and parasitic infections; and
 CC autoimmune/inflammatory disorders such as acquired immunodeficiency
 CC syndrome (AIDS), allergies, asthma, Crohn's disease, atopic dermatitis,
 CC gout, multiple sclerosis, rheumatoid arthritis or ulcerative colitis.
 CC Human ORP proteins and nucleotides can be used to identify compounds
 CC which modulate their activity or expression. ORP nucleic acid sequences
 CC may also be used for assessing the toxicity of a test compound, to detect
 CC upstream sequences such as promoters and regulatory elements, and to
 CC create knock out or knock in animals or transgenic animals to model human

CC disease. Oligonucleotide primers derived from ORP gene sequences may be
 CC used to detect single nucleotide polymorphisms (SNPs) and for mapping the
 CC naturally occurring genomic sequences. Antibodies specific for ORP
 CC proteins may be used in the diagnosis of disorders associated with
 CC aberrant ORP expression, in assays to monitor patients being treated with
 CC ORP or modulators thereof, and for assessing toxicity of potential drugs
 XX
 XX Sequence 369 AA;
 SQ
 Query Match 6.8%; Score 274.5; DB 4; Length 369;
 Best Local Similarity 30.1%; Pred. NO. 5.4e-13;
 Matches 75; Conservative 44; Mismatches 105; Indels 25; Gaps 9;
 QY 526 RFYHLGDAMQVRGNKEAYKWEYELG--HK-----RGHF-----ASVWORSLYNVNGLKAQPW 575
 DB 125 KLYHNIQBYAKR-----YSWSGMRHKGIRGQRYLNSRPSIQKPEVFFDLPTTFY 178
 QY 576 WTPKETYGYELVKSLEKNWKLIRDEGLAVNDKAKGLFLPE--DENLRKGDWNSQFTLMQ 633
 DB 179 FSRDAQKHD--VEVLERNFQTLICEPTLYKAPSNCSLPQGMKNSTPSCGEWTFYLVNQ 236
 QY 634 GRENNACKGAPKCTCTLEKFPETTCGR-RGQIKYSIMHPGTHVWHTGTNCLRMHLG 692
 DB 237 GUCVPRNCRKCPRTYRLGSLRFTICGNVFNACISVLSPGTVITHEYGPTNIRIRCHLG 296
 QY 693 LVIPKEGCKIRCANETRTWEEGKVLIFDDSFSEVHVQDASSF---RLIFTVDVWHPELTP 749
 DB 297 LKTP-NGCELVVGEGPQCWAEGRCILFDDSFLLAAFHGSAEDGPRVFWVDLWHFNVA 355
 QY 750 QQRSLPAI 758
 DB 356 AERQALDFI 364
 RESULT 11
 AAB43327
 ID AAB43327 standard; protein; 236 AA.
 AC AAB43327;
 XX
 XX 08-FEB-2001 (first entry)
 DT
 XX Human ORFX ORF3091 polypeptide sequence SEQ ID NO:6182.
 DE
 XX Human; open reading frame; ORFX; detection; cytostatic; hepatotropic;
 KW vulnery; antipsoriatic; antiparkinsonian; nootropic; neuroprotective;
 KW anticonvulsant; osteopathic; antiarthritic; immunosuppressant; cardiant;
 KW immunostimulant; thrombolytic; coagulant; vasotropic; antidiabetic;
 KW hypotensive; dermatological; immunosuppressive; antinflammatory;
 KW antiviral; antibacterial; antifungal; antirheumatic; antithyroid;
 KW antianemic; gene therapy; cancer; proliferative disorder; hypertension;
 KW neurodegenerative disorder; osteoarthritis; graft vs host disease;
 KW cardiovascular disease; diabetes mellitus; hypothyroidism; SCID; AIDS;
 KW cholesterol ester storage; systemic lupus erythematosus; infection;
 KW severe combined immunodeficiency; malaria; autoimmune disorder; asthma;
 KW allergy; aplastic anaemia; nocturnal haemoglobinuria; burn; wound;
 KW bone damage; cartilage damage; antinflammatory disease; coagulation;
 KW thrombosis; contraceptive.
 XX
 XX Homo sapiens.
 OS
 XX WO200058473-A2.
 PN
 XX 05-OCT-2000.
 PD
 XX 31-MAR-2000; 2000WO-US008621.
 PF
 XX 31-MAR-1999; 99US-0127607P.
 PR 02-APR-1999; 99US-0127636P.
 PR 05-APR-1999; 99US-0127728P.
 PR 30-MAR-2000; 2000US-00540763.
 XX (CURA-) CURAGEN CORP.

XX Shimkets RA, Leach M;
PI
XX
XX
DR WPI; 2000-602362/57.
XX N-PSDB; AAC77536.
PT Novel nucleic acids and peptides derived from open reading frame X,
PT useful for treating e.g. cancers, proliferative disorders,
PT neurodegenerative disorders and cardiovascular disease.
XX
XX
PS Claim 11; Page 5365; 5507pp; English.
XX
XX AAC74446 to AAC77606 encode the proteins given in AAB40237 to AAB43397,
CC which represent the human ORFX open reading frames 1 to 3161. The ORFX
CC sequences have activities such as: cytostatic; hepatotropic; vulnery;
CC antiproliferative; antiparkinsonian; neurotrophic; neuroprotective; osteoparalytic;
CC anticonvulsant; antiarthritic; immunosuppressive; immunostimulant;
CC cardiac; thrombolytic; coagulant; vasotropic; antidiabetic; hypotensive;
CC dermatological; immunosuppressive; antiinflammatory; antibacterial;
CC antiviral; antifungal; antirheumatic; antithyroid; and antianaemic. The
CC sequences can be used for determining the presence of or predisposition
CC to, or preventing or treating pathological conditions associated with an
CC ORFX-associated disorder. The nucleic acids can be used to express ORFX
CC proteins in gene therapy vectors. The proteins and nucleic acids may be
CC used to treat cancers, proliferative disorders, neurodegenerative
CC disorders, osteoarthritis, graft vs host disease, cardiovascular disease,
CC diabetes mellitus, hypertension, hypothyroidism, cholesterol ester
CC storage, systemic lupus erythematosus, severe combined immunodeficiency
CC (SCID), AIDS, viral, bacterial or fungal infection, malaria, autoimmune
CC disorders, asthma, allergies, aplastic anaemia, burns, wounds, bone and
CC cartilage damage, nocturnal haemoglobinuria, antiinflammatory disease; to
CC enhance coagulation; to inhibit thrombosis; and as a contraceptive
XX
XX Sequence 236 AA;
Query Match 6.8%; Score 271.5; DB 3; Length 236;
Best Local Similarity 31.2%; Pred. No. 4.7e-13;
Matches 72; Conservative 40; Mismatches 100; Indels 19; Gaps 8;
QY 544 YKMYELG--HK-----RGHF----ASVQWRLNVLNGLKAPWTKETGYTLVKSLEARN 593
Db 4 YSWGGMGRHKGIRGQYLNLSRSPQIQPEVFLPDLPTTPYFSRDAQKH--VSVLERN 61
QY 594 WKLIIRDEGLAVMDKAGLFLP--DENLREKGDWSQFTLWQGRNENACKGAPKTCILL 651
Db 62 FQTLICEFETLYKAFNSCLPQGWKNSTPSCWETFLVNGVCVPRNCRKCPRTYRL 121
QY 652 EKFPETTGCR-RGQIKYSIMHPGTHVWPTGTNCLRLMHLGLVIPKGGCKIRCANETRT 710
Db 122 GSLRTICGNVFEGNACISVLSPTGTVITEHYGPTNIRIRCHLGLKTP-NGCELVWGGEPQC 180
QY 711 WEEGKVLIFDSDSFEHEVWDASSF---RLIFIVDVVHPELTQPQRRSLPAI 758
Db 181 WAEGRCLLFDSDSLHAAPHEGSAEDGPRVVFVVDLWHPNVAARQALDFI 231
RESULT 12
ABM68322
ID ABM68322 standard; protein; 264 AA.
XX
XX
XX 20-NOV-2003 (first entry)
XX
XX Photorhabdus luminescens protein sequence #1419.
XX
XX Antibacterial; fungicide; insecticide; polymorphism; genetic analysis;
KW detection; food; gene expression; plant; animal; microorganism; toxin;
KW antibiotic; biopesticide; virulence factor; disease model; plague;
KW whooping cough.
XX
XX
OS Photorhabdus luminescens.
XX

PN WO200294867-A2.
XX
XX
PD 28-NOV-2002.
XX
XX 07-FEB-2002; 2002WO-IB003040.
PF
XX 07-FEB-2001; 2001FR-00001659.
PR
XX (INSP) INST PASTEUR.
PA (CNRS) CNRS CENT NAT RECH SCI.
XX
XX
PI Duchaud E, Taourit S, Glaser P, Frangeul L, Kunst F, Danchin A;
PI Buchrieser C;
XX WPI; 2003-148459/14.
XX
XX Genomic sequence of Photorhabdus luminescens and encoded polypeptides,
PT useful e.g. as therapeutic antimicrobials and agricultural pesticides.
XX
XX Claim 2; SEQ ID NO 1419; 1205pp; French.
XX
XX The invention relates to the isolation of genes and their encoded
CC proteins from Photorhabdus luminescens. The isolated sequences are
CC sources of probes and primers for detecting the genome of P. luminescens
CC and related species; to study polymorphisms; for gene analysis and for
CC detection/amplification of the genes. Antibodies (Ab) raised against the
CC polypeptides encoded by the genes are used for detection/identification
CC of P. luminescens, e.g. in foods. The genes, proteins, Ab and cells that
CC carry a gene-containing vector are used to select compounds that
CC modulate, regulate, induce or inhibit expression of the genes in plants,
CC animals or microorganisms other than P. luminescens and are able to alter
CC response or sensitivity to toxins and antibiotics produced by P.
CC luminescens. Cells transformed to express the genes are useful for
CC recombinant production of the proteins, particularly toxins and
CC antibacterials useful as insecticides, bactericides and fungicides. The
CC genes, proteins, vectors containing the genes and Ab are also useful
CC therapeutically (to treat microbial infection by bacteria or fungi that
CC are sensitive to P. luminescens-encoded toxins or antibiotics) and as
CC biopesticides. Other uses of the genes and the proteins are as virulence
CC factors and for identifying targets of human diseases for which P.
CC luminescens is a model (particularly plague and whooping cough). This
CC sequence represents one of the isolated P. luminescens proteins
XX
XX Sequence 264 AA;
Query Match 6.5%; Score 262; DB 6; Length 264;
Best Local Similarity 29.1%; Pred. No. 3.2e-12;
Matches 66; Conservative 39; Mismatches 114; Indels 8; Gaps 3;
QY 533 DAMQVGNKEAYKWEYELGHGKHGFASVWQSLYNVGLKAPFW-TPKBTGYTLVKSLE 591
Db 35 DCLKEVED----MFYPLQQR---APLQADAKYIMPGLSTTPFLDTSFPQLOPLVLSLM 87
QY 592 RNWKLIRDEGLAVMDKAGLFLPDEDENIREKGDWSQFTLWQGRNENACKGAPKTCILL 651
Db 88 NNADKIKOEINAVISGESQYITDYEHYLGTQKDWKALYLFKNGQPNNAVANILPATWHIF 147
QY 652 EKFPETTGCRGQIKYSIMHPGTHVWPTGTNCLRLMHLGLVIPKGGCKIRCANETRT 711
Db 148 NNELRDWHCPLELVHFSVLQPGTVIKPHCDLWNFTNLNHFVADIPASCEIIVANEACW 207
QY 712 BEGKVLIFDSDSFEHEVWDASSFRLIFIVDVVHPELTQPQRRSLPAI 758
Db 208 KEGECCLLFDYSYQHEAYNRSKHKRICLLMDIWHNLSFAEREAULVI 254
RESULT 13
AAU29679
ID AAU29679 standard; protein; 104 AA.
XX
XX AAU29679;
XX
XX 18-DEC-2001 (first entry)
DT

```
XX DE Novel human secreted protein #170.
XX KW Human; vaccination; gene therapy; nutritional supplement;
XX KW stem cell proliferation; haematopoiesis; nerve tissue regeneration;
XX KW immune suppression; immune stimulation; anti-inflammatory; leukaemia.
XX OS Homo sapiens.
XX PN WO200179449-A2.
XX PD 25-OCT-2001.
XX PF 16-APR-2001; 2001WO-US008656.
XX PR 18-APR-2000; 2000US-00552929.
XX PR 26-JAN-2001; 2001US-00770160.
XX PA (HYSE-) HYSEQ INC.
XX PI Tang YT, Liu C, Drmanac RT;
XX PI WPI; 2001-611725/70.
XX DR Nucleic acids encoding a range of human polypeptides, useful in genetic
XX PT vaccination, testing and therapy.
XX PT Claim 20; Page 179; 765pp; English.
XX CC The invention relates to novel human secreted polypeptides. The
XX CC polypeptides and antibodies to the polypeptides are useful for
XX CC determining the presence of or predisposition to a disease associated
XX CC with altered levels of polypeptide. The polypeptides are also useful for
XX CC identifying agents (agonists and antagonists) that bind to them. Cells
XX CC expressing the proteins are useful for identifying a therapeutic agent
XX CC for use in treatment of a pathology related to aberrant expression or
XX CC physiological interactions of the polypeptide. Vectors comprising the
XX CC nucleic acids encoding the polypeptides and cells genetically engineered
XX CC to express them are also useful for producing the proteins. The proteins
XX CC are useful in genetic vaccination, testing and therapy, and can be used
XX CC as nutritional supplements. They may be used to increase stem cell
XX CC proliferation; to regulate haematopoiesis; and in bone, cartilage, tendon
XX CC and/or nerve tissue growth or regeneration; immune suppression and/or
XX CC stimulation; as anti-inflammatory agents; and in treatment of leukaemias.
XX CC AAU29510-AAU33304 represent the amino acid sequences of novel human
XX CC secreted proteins of the invention
XX SQ Sequence 104 AA;
Query Match 6.0%; Score 241; DB 4; Length 104;
Best Local Similarity 54.7%; Pred. No. 3.7e-11;
Matches 47; Conservative 11; Mismatches 28; Indels 0; Gaps 0;
QY 13 SSSSGSGSTSGAGSSPGARETKHGCKNGKGGISGTSFPTFMVIALIGVWTSVAV 72
Dd 13 SAFTGTCSTSVRAAPGTPQPSMDAHTGKGRUSXTSFTTWSMTALLGVWTSVSV 72
QY 73 VWFDLVDYEEVLKGLGIYDADGDGDF 98
Dd 73 VWFDLADYDDXIXALAIYDADGDVRF 98
RESULT 14
ABU21099
ID ABU21099 standard; protein; 299 AA.
XX AC ABU21099;
XX DT 19-JUN-2003 (first entry)
XX DE Protein encoded by Prokaryotic essential gene #6626.
XX KW Antisense; prokaryotic essential gene; cell proliferation; drug design.
```

```
XX OS Burkholderia fungorum.
XX PN WO200277183-A2.
XX PD 03-OCT-2002.
XX PF 21-MAR-2002; 2002WO-US009107.
XX PR 21-MAR-2001; 2001US-00815242.
XX PR 06-SEP-2001; 2001US-00948993.
XX PR 25-OCT-2001; 2001US-0342923P.
XX PR 08-FEB-2002; 2002US-00072851.
XX PR 06-MAR-2002; 2002US-0362699P.
XX PA (ELIT-) ELITRA PHARM INC.
XX PI Wang L, Zamudio C, Malone C, Haselbeck R, Ohlsen KL, Zyskind JW;
XX PI Wall D, Trawick JD, Carr GJ, Yamamoto R, Forsyth RA, Xu HH;
XX PI WPI; 2003-029926/02.
XX DR N-PSDB; ACA24969.
XX DR New antisense nucleic acids, useful for identifying proteins or screening
XX PT for homologous nucleic acids required for cellular proliferation to
XX PT isolate candidate molecules for rational drug discovery programs.
XX PS Claim 25; SEQ ID NO 49023; 1766pp; English.
XX CC The invention relates to an isolated nucleic acid comprising any one of
XX CC the 6213 antisense sequences given in the specification where expression
XX CC of the nucleic acid inhibits proliferation of a cell. Also included are:
XX CC (1) a vector comprising a promoter operably linked to the nucleic acid
XX CC encoding a polypeptide whose expression is inhibited by the antisense
XX CC nucleic acid; (2) a host cell containing the vector; (3) an isolated
XX CC polypeptide or its fragment whose expression is inhibited by the
XX CC antisense nucleic acid; (4) an antibody capable of specifically binding
XX CC the polypeptide; (5) producing the polypeptide; (6) inhibiting cellular
XX CC proliferation or the activity of a gene in an operon required for
XX CC proliferation; (7) identifying a compound that influences the activity of
XX CC the gene product or that has an activity against a biological pathway
XX CC required for proliferation, or that inhibits cellular proliferation; (8)
XX CC identifying a gene required for cellular proliferation or the biological
XX CC pathway in which a proliferation-required gene or its gene product lies
XX CC on a gene on which the test compound that inhibits proliferation of an
XX CC organism acts; (9) manufacturing an antibiotic; (10) profiling a
XX CC compound's activity; (11) a culture comprising strains in which the gene
XX CC product is overexpressed or underexpressed; (12) determining the extent
XX CC to which each of the strains is present in a culture or collection of
XX CC strains; or (13) identifying the target of a compound that inhibits the
XX CC proliferation of an organism. The antisense nucleic acids are useful for
XX CC identifying proteins or screening for homologous nucleic acids required
XX CC for cellular proliferation to isolate candidate molecules for rational
XX CC drug discovery programs, or for screening homologous nucleic acids
XX CC required for proliferation in cells other than S. aureus, S. typhimurium,
XX CC K. pneumoniae or P. aeruginosa. The present sequence is encoded by one of
XX CC the target prokaryotic essential genes. Note: The sequence data for this
XX CC patent did not form part of the printed specification, but was obtained
XX CC in electronic format directly from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 299 AA;
Query Match 5.4%; Score 218.5; DB 6; Length 299;
Best Local Similarity 29.0%; Pred. No. 1.1e-09;
Matches 62; Conservative 29; Mismatches 96; Indels 27; Gaps 6;
QY 551 HKRGHFASVWQRSL-----YVNGLKAQPMWTPKBTGYELVKSLERWKL 596
Dd 17 HSRGKVRHGFRQLSDHSTFTAPLNGFVYLFSAIPAQFPLPSSR--FPFL-KLLKEEWRT 73
QY 597 IRDEGLAVMD-----KAKGLFLPEDENLRKGDWSQFTLMQGGRRNENACKGAPTCTLLE 652
```

Db 74 IRDEAFALRDASHIRAAATAYNDIGNSPFRNGWRFFYLKWKYGRHPHSAVALCPRTVELLG 133
 Qy 653 KFPETTCGRGQIKYSIMHPTGTHVPHGTPNCLRLMHLGLVLPK-EGCKIRCANEPTW 711
 Db 134 RIPSVKAMFALP-----PGRLGLHRDPYAGALRYHLGLATPNHWDGCAIWDGETYSW 188
 Qy 712 BEGKVLFPDDSFHEVWQDASSFLRIFIVDVWHP 745
 Db 189 RGDGDIVFEDYLVHFAFNDQEDRIILFCDIERP 222

RESULT 15
 AAU28081
 ID AAU28081 standard; protein; 324 AA.
 AC AAU28081;
 XX
 DT 18-DEC-2001 (first entry)
 XX
 DE Novel human secretory protein, Seq ID No 250.
 XX
 KW Human; secreted protein; arthritis; Crohn's disease; sepsis; shock;
 KW ischaemia-reperfusion injury; haematopoiesis; cancer; neuropathy;
 KW transgenic animal; Alzheimer's disease; Parkinson's disease; burn;
 KW amyotrophic lateral sclerosis; platelet disorder; thrombocytopenia;
 KW ulcer; osteoporosis; bone degenerative disorder; periodontal disease;
 KW gut protection; lung; liver fibrosis; immune deficiency; infection;
 KW severe combined immunodeficiency; SCID; autoimmune disorder; allergy;
 KW multiple sclerosis; rheumatoid arthritis; diabetes mellitus; asthma;
 KW fertility; analgesic; pain; antigen.
 XX
 OS Homo sapiens.
 XX
 PN WO200166689-A2.
 XX
 PD 13-SEP-2001.
 XX
 PF 05-MAR-2001; 2001WO-US004942.
 XX
 PR 07-MAR-2000; 2000US-00519705.
 PR 19-MAY-2000; 2000US-00574454.
 PR 17-JUN-2000; 2000US-00596193.
 PR 14-JUL-2000; 2000US-00616847.
 PR 19-SEP-2000; 2000US-00665363.
 PR 20-OCT-2000; 2000US-00693267.
 XX
 PA (HYSE-) HYSEQ INC.
 XX
 PI Tang YT, Liu C, Asundi V, Xu C, Wehrman T, Ren F, Ma Y, Zhou P;
 PI Zhao QA, Yang Y, Drmanac RT, Zhang J, Chen R, Xue AJ, Wang J;
 XX
 DR WPI; 2001-589934/66.
 DR N-PSDB; AAS44981.
 XX
 PT Novel polypeptides and nucleic acids obtained from cDNA libraries
 PT prepared from various human tissues, for diagnosis and treatment of
 PT cancer, neurological, inflammatory, and autoimmune disorders.
 XX
 PS Example 4; SEQ ID NO 250; 107pp; English.
 XX
 CC The invention relates to novel isolated human secreted polypeptides (I)
 CC and polynucleotides (II). (I) and (II) are useful for treating
 CC inflammatory conditions such as arthritis, nephritis, Crohn's disease,
 CC ischaemia-reperfusion injury, shock, sepsis, immune responses, and is
 CC involved in increasing haematopoiesis, stem cell survival, bone growth
 CC and remodeling. (I), (II) and modulators of (II) are useful for
 CC prophylaxis or treatment of one or more cancers. (II) is also useful for
 CC creating transgenic animals useful for studying the in vivo activities of
 CC the polypeptide as well as for studying modulators of the polypeptides.
 CC (I) induces the proliferation of neural cells and regeneration of nerve
 CC and brain tissue and is useful for the treatment of central and
 CC peripheral nervous system diseases and neuropathies, such as Alzheimer's,
 CC Parkinson's disease, Huntington's disease, and amyotrophic lateral

CC sclerosis. In addition, (I) is involved in chemotactic or chemokinetic
 CC activity, regulation of haematopoiesis and is useful for treating myeloid
 CC or lymphoid cell disorders, platelet disorders such as thrombocytopenia
 CC and for regeneration of bone cartilage, tendon, ligament and/or nerve
 CC tissue growth, and in tissue repair, healing of burns, incisions, ulcers,
 CC for treating osteoporosis, osteoarthritis, bone degenerative disorders,
 CC or periodontal disease. Furthermore, (I) is also useful for gut
 CC protection or regeneration and treatment of lung or liver fibrosis,
 CC reperfusion injury in various tissues, various immune deficiencies and
 CC disorders including severe combined immunodeficiency (SCID), bacterial or
 CC fungal infections, autoimmune disorders e.g. multiple sclerosis,
 CC rheumatoid arthritis, diabetes mellitus, myasthenia gravis, allergic
 CC reactions and conditions, such as asthma or other respiratory problems.
 CC In addition, (I) affects biorhythms or circadian cycles of rhythms,
 CC fertility, metabolism, catabolism, anabolism, storage or elimination of
 CC dietary fat, lipid, protein, carbohydrate, vitamins, minerals, provides
 CC analgesic effects or other pain reducing effects, immunoglobulin like
 CC activity and can act as an antigen in a vaccine composition to raise an
 CC immune response. AAU28020-AAU28395 represent novel human secreted protein
 CC amino acid sequences of the invention
 XX
 SQ Sequence 324 AA;
 Query Match 5.4%; Score 217.5; DB 4; Length 324;
 Best Local Similarity 36.6%; Pred. No. 1.5e-08;
 Matches 53; Conservative 19; Mismatches 56; Indels 17; Gaps 5;
 QY 625 WS-----QFTLWQGR---RNEACKGAPKCTCTLLEKFPETTCRRGQIKYSIMHFG 673
 Db 175 WSPFLAPGCGYQLLYQAGRCQPSNCRCPGAYRALRGLRSPMSAN--TFGNAGFSVLLPG 232
 QY 674 THVWPHGTTCRLRMHLGLVLPKEGCKIRCANEPTWEEGKVLIFDDSFHEVWQDAS- 732
 Db 233 ARLEGRCGPTNARVRCHLGLKIP-PGCELVVGGEPCQWAEHGCHLLVDDSLFHTVAHNSP 291
 QY 733 --SFLILFIVDVWHPDLTPQRRSL 755
 Db 292 EDGPRWFIVDLWHPNVAGAEQAL 316

Search completed: May 5, 2004, 11:02:20
 JOB time : 62 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2004, 11:00:08 ; Search time 21 Seconds
(without alignments)
3472.056 Million cell updates/sec

Title: US-09-903-216-2

Perfect score: 4022

Sequence: 1 MAQRKNAKSSGNSSSGSGS.....IVDVHHPBLTPQRRSLPAI 758

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283366 seqs, 96191526 residues

Total number of hits satisfying chosen parameters: 283366

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : PIR_78.*

1: pir1.*

2: pir2.*

3: pir3.*

4: pir4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	ID	Description
1	3966.5	98.6	757	I38423	aspartyl beta-hydr
2	3172	78.9	754	BA80H	peptide-aspartate
3	890	22.1	270	JC7792	cardiac junctate-1
4	798	19.8	872	T18861	probable peptide-a
5	263.5	6.6	186	T47148	hypothetical prote
6	216.5	5.4	1110	I51116	NF-180 - sea lamp
7	199	4.9	1271	A45555	glutamate rich pro
8	197.5	4.9	312	H83527	hypothetical prote
9	191.5	4.8	1881	H95076	zinc metalloprotei
10	189.5	4.7	1616	G64242	cytochrome-c-acces
11	188.5	4.7	792	T42962	hypothetical prote
12	187	4.6	706	A45990	junctional sarcopl
13	183	4.5	763	T08929	hypothetical prote
14	181	4.5	771	A33430	h-caldesmon - chic
15	179.5	4.5	411	S47436	flagellar antigen
16	178.5	4.4	729	S68191	triadin - human
17	177	4.4	301	A82601	aspartyl/asparagin
18	177	4.4	845	A45669	neurofilament trip
19	176	4.4	1094	S49313	protein kinase - s
20	174.5	4.3	1948	S00485	gene 11-1 protein
21	173.5	4.3	1871	D96796	probable heat shoc
22	172.5	4.3	1240	S52734	hypothetical prote
23	172	4.3	465	S46759	hypothetical prote
24	172	4.3	630	S29796	hypothetical prote
25	171.5	4.3	607	S27776	80K protein (allel
26	171	4.3	1804	T34518	nestin - golden ha
27	169.5	4.2	592	B48315	lamin B2 - mouse
28	169.5	4.2	1233	S56271	hypothetical prote
29	168.5	4.2	695	T40168	hypothetical prote

30	168.5	4.2	913	2	T52485	neurofilament prot
31	168	4.2	302	2	AF1021	probable membrane-
32	168	4.2	1192	2	A71623	probable secreted
33	167.5	4.2	1876	2	E97944	zinc metalloprotei
34	166.5	4.1	1624	2	T25592	hypothetical prote
35	165	4.1	651	2	S18874	nucleolin - Africa
36	164.5	4.1	7962	2	I38346	elastic titin - hu
37	164	4.1	1957	2	T38077	hypothetical coile
38	163.5	4.1	1132	2	T43483	translation initia
39	163	4.1	411	2	S48647	peptidylprolyl iso
40	163	4.1	501	2	C71948	hypothetical prote
41	163	4.1	1877	2	T21861	hypothetical prote
42	163	4.1	1999	1	S21801	myosin heavy chain
43	162.5	4.0	299	2	B81081	hypothetical prote
44	162.5	4.0	793	1	JH0628	caldesmon - human
45	162.5	4.0	992	2	T46337	hypothetical prote

ALIGNMENTS

RESULT 1

I38423

aspartyl beta-hydroxylase - human

C:Species: Homo sapiens (man)

C:Date: 29-May-1998 #sequence_revision 29-May-1998 #text_change 21-Jan-2000

C:Accession: I38423

R:Korioth, F.; Gieffers, C.; Frey, J.

Gene 150, 395-399, 1994

A:Title: Cloning and characterization of the human gene encoding aspartyl beta-hydroxylase

A:Reference number: I38423; MUID:95121937; PMID:7821814

A:Accession: I38423

A>Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: mRNA

A:Residues: 1-757 <RES>

A:Cross-references: EMBL:U03109; NID:9458031; PIDN:AAA2108.1; PID:9458032

C:Superfamily: peptidase-aspartate beta-dioxygenase; tetratricopeptide repeat homology

F:54-75/Domain: transmembrane #status predicted <TRM>

F:341-374/Domain: tetratricopeptide repeat homology <TTR>

Query Match	98.6%	Score	3966.5	DB 2	Length	757			
Best Local Similarity	99.2%	Pred. No.	1e-195						
Matches	752	Conservative	2	Mismatches	3	Indels	1	Gaps	1
QY	1	MAQRKNAKSSGNSSSGSGSGSTAGSSSPGARRETKHGKHNGRKGGLSGTSFFTWFMV	60						
Db	1	MAQRKNAKSSGNSSSGSGSGSTAGSSSPGARRETKHGKHNGRKGGLSGTSFFTWFMV	60						
QY	61	IALLGWMTSVAVVWFDLVVYEEVLKGLGIYDADGDGDFVDDAKVLLGLKERSTSEPAVP	120						
Db	61	IALLGWMTSVAVVWFDLVVYEEVLKGLGIYDADGDGDFVDDAKVLLGLKERSTSEPAVP	120						
QY	121	PEEAHPTEPEEQVPVEAEPQNIIEAKEQIQSLHMHVHAHVEGEDLOQEDGPTGPQPQ	180						
Db	121	PEEAHPTEPEEQVPVEAEPQNIIEAKEQIQSLHMHVHAHVEGEDLOQEDGPTGPQPQ	180						
QY	181	QEDDEFMATVDVDRFETLEPEVSHBETHSVHYEETVQDCNQDMBEMMSQEQNPDSSE	240						
Db	181	QEDDEFMATVDVDRFETLEPEVSHBETHSVHYEETVQDCNQDMBEMMSQEQNPDSSE	240						
QY	241	PVVEDERLHDDTDVTVQVYEEQAVYEPLENEGIEITEVTAPPEDNPVEDSQVIVEEVS	300						
Db	241	PVVEDERLHDDTDVTVQVYEEQAVYEPLENEGIEITEVTAPPEDNPVEDSQVIVEEVS	300						
QY	301	FPVVEEQEVPPTNRKTDDPEQAKVKKKKPKLKNKFDKTKAELDAAEKLKRGKIEEA	360						
Db	301	FPVVEEQEVPPTNRKTDDPEQAKVKKKKPKLKNKFDKTKAELDAAEKLKRGKIEEA	360						
QY	361	VNAFKELVKYPQSPRARYGKACEDDLAEKRRSNEVLRGAIETYQEVASLPDVPADLLK	420						
Db	361	VNAFKELVKYPQSPRARYGKACEDDLAEKRRSNEVLRGAIETYQEVASLPDVPADLLK	420						
QY	421	LSLKRRSDROOFLGHRGSLTLQRLVQLFPNDTSLKNDLGVGLLIGDNDNAKKVVEEV	480						

```

421 LSLKRRSDROQLGHMRGSLTLTLQRLVQLFENDTSLKNDLGVGLLIGDNDNAKKVVEV 480
481 LSVTPNDGFAKHYGFILKAQNKIAESIPYLKEGIESGDGTDGGRFYFHLGDAMQVRGN 540
481 LSVTPNDGFAKHYGFILKAQNKIAESIPYLKEGIESGDGTDGGRFYFHLGDAMQVRGN 540
541 KEAYKAYELGKHGKGFASVWQSRSLYNNVGLKAQDWTPKGTGYTELKSLERNWKLIRDE 600
541 KEAYKAYELGKHGKGFASVWQSRSLYNNVGLKAQDWTPKGTGYTELKSLERNWKLIRDE 599
601 GLAVMDKAKGLFLPEDENLREKGDWSTLWQOQRNENACKGAPKCTCTLLEKFPETTCG 660
600 GLAVMDKAKGLFLPEDENLREKGDWSTLWQOQRNENACKGAPKCTCTLLEKFPETTCG 659
661 RRGQIKYSIMHGPVHPHTGPTNCRMLHGLVPIKKGKIRCANETRTWEGKVLIFD 720
660 RRGQIKYSIMHGPVHPHTGPTNCRMLHGLVPIKKGKIRCANETRTWEGKVLIFD 719
721 DSPEHEVQDASSFRLLIFIVDVWHPHLPDQRRSLPAI 758
720 DSPEHEVQDASSFRLLIFIVDVWHPHLPDQRRSLPAI 757

RESULT 2
BABOH
peptide-aspartate beta-dioxygenase (EC 1.14.11.16) - bovine
N:Alternate names: aspartyl (asparaginyl) beta-hydroxylase
C:Species: Bos primigenius taurus (cattle)
C>Date: 31-Dec-1993 #sequence_revision 10-Feb-1995 #text_change 11-Jun-1999
C/Accession: A42969; B39470; B39470; C39470; S27948
R/Jia, S.; Vandusen, W.J.; Diehl, R.E.; Kohl, N.E.; Dixon, R.A.; Elliston, K.O.; Stern,
J. Biol. Chem. 267, 14322-14327, 1992
A:Title: cDNA cloning and expression of bovine aspartyl (asparaginyl) beta-hydroxylase.
A:Reference number: A42969; MUID:92332546; PMID:11378441
A:Accession: A42969
A:Molecule type: mRNA
A:Residues: 1-754 <JIA>
A/Cross-references: EMBL:M91213; NID:g162693; PID:AAA03563.1; PID:g162694
A:Experimental source: brain
A>Note: sequence extracted from NCB1 backbone (NCB1P:108534)
R/Wang, Q.; Vandusen, W.J.; Petroski, C.J.; Garbky, V.M.; Stern, A.M.; Friedman, P.A.
J. Biol. Chem. 266, 14004-14010, 1991
A:Title: Bovine liver aspartyl beta-hydroxylase. Purification and characterization.
A:Reference number: A39470; MUID:91310689; PMID:1856229
A:Accession: A39470
A:Molecule type: protein
A:Residues: 289-328 <WAN>
A:Accession: B39470
A:Molecule type: protein
A:Residues: 615,'X',617-630,'XX',633-634,'X',636,'XX',639-641 <WA2>
A:Accession: C39470
A:Molecule type: protein
A:Residues: 311-347,'X',349,'X',351-373,'X',375-379,'X',381-382 <WA3>
C/Comment: This enzyme uses ferrous iron as a cofactor, and while beta-hydroxylating the
C/Comment: Aspartic acid and asparagine residues in the EGF homology domain of certain F
C/Superfamily: peptide-aspartate beta-dioxygenase; tetratricopeptide repeat homology
C/Keywords: glycoprotein; oxidoreductase; transmembrane protein
F:2-56/Domain: intracellular #status predicted <INC>
F:57-78/Domain: transmembrane #status predicted <TRM>
F:289-754/Product: peptide-aspartate beta-dioxygenase, 56K form #status predicted <56K>
F:311-754/Product: peptide-aspartate beta-dioxygenase, 52K form #status predicted <52K>
F:337-370/Domain: tetratricopeptide repeat homology <TT1>
F:371-404/Domain: tetratricopeptide repeat homology <TT2>
F:13,96,466,702/Binding site: Carbohydrate (Asn) (covalent) #status predicted

Query Match 78.9%; Score 31.72; DB 1; Length 754;
Best Local Similarity 78.7%; Pred. No. 4.8e-15;
Matches 612; Conservative 45; Mismatches 77; Indels 44; Gaps 6;

QY 1 MAQRKNAKSSG--NSSSSSGSGSTAGSSSPGARRETKHGKNGKGLSGTSTFTW 57
DB 1 NMPRNKAGGGGNSSSSSSGSTGCTGCTGSSSPGARRETKGGLNKRKGLSGSSFTW 60

```

```

QY 58 FWIALLGYWTSVAVVWFLLVDVYEEVL-----GKLGTYDADGDGDFDVD 102
DB 61 FWIALLGYWTSVAVVWFLLVDVYEEVLAKAKOPRYNLSVLQKRGTYDADGDGDFDVD 120
QY 103 AKVLLGLKERSSTSEPAVPPPEAPHTPEPEEQVVEAPQNIEDAEKEQIQLLHEMVHAE 162
DB 121 AKVLLGLKEKPAKPTVPPPEADMYPLWEDQVLESFGRQNIEDVVEVQVS-LDETIVYSE 179
QY 163 HVEGEDLQBDGDTGTPQEDDEFLMATVDVDDRFETLEPEVSHETESHVHETVTSQDC 222
DB 180 --PGRNLPQEPGPAELQPDHVFVGSADDDRYEPMTGAVHEETEDSYHIBETASPAY 237
QY 223 NDMEEEMWSEQENPDSSSEPVED--ERLHHDITDDVTVQVVEEQAVVEPLENEGIEITEVT 280
DB 238 SQMEDMYEQENPDSSSEPVED--ERLHHDITDDVTVQVVEEQAVVEPLENEGIEITEVT 280
QY 281 APEDNPVEDSVIVBEVSIFPVVEEQEVPEPNRKTDDPEQAKAKVKKKPKLLNKPKDKT 340
DB 281 ---DHAVONSNTILBEPHMPPAEQEVPEPNRKTDDPEQAKAKVKKKPKLLNKPKDKT 336
QY 341 IKAELDAAEKLRKRGKIEAVNAFKELVRYKPOSPRARYKGAOCEDDLAEKRRSNEVLRG 400
DB 337 IKAELDAAEKLRKRGKIEAVNAFKELVRYKPOSPRARYKGAOCEDDLAEKRRSNEVLRR 396
QY 401 AIETYQEVASLPDVPADLLKLSLKRSDROOFLGHMRGSLTLTLQRLVQLFPNDTSLKNDL 460
DB 397 AIETYQEVASLPDVPADLLKLSLKRSDROOFLGHMRGSLTLTLQRLVQLFPNDTSLKNDL 456
QY 461 GVGYLIGDNDNAKKVVEVSVTPNDGFAKHYGFILKAQNKIAESIPYLKEGIESGDP 520
DB 457 GVGYLIGDNDNAKKVVEVSVTPNDGFAKHYGFILKAQNKIAESIPYLKEGIESGDP 516
QY 521 GTDDGRFYFHLGDAMORVGNKEAYKAYELGKHGKGFASVWQSRSLYNNVGLKAQDWTPKE 580
DB 517 GTDDGRFYFHLGDAMORVGNKEAYKAYELGKHGKGFASVWQSRSLYNNVGLKAQDWTPKE 576
QY 581 TGYTELKSLERNWKLIRDEGLAVMDKAKGLFLPEDENLREKGDWSTLWQOQRNENAE 640
DB 577 TGYTELKSLERNWKLIRDEGLAVMDKAKGLFLPEDENLREKGDWSTLWQOQRNENAE 636
QY 641 CKGAPKCTCTLLEKFPETTCGRRQIKYSIMHGPVHPHTGPTNCRMLHGLVPIKKG 700
DB 637 CKGAPKCTCTLLEKFPETTCGRRQIKYSIMHGPVHPHTGPTNCRMLHGLVPIKKG 696
QY 701 KIRCANETRTWEGKVLIFDSSFEHEVQDASSFRLLIFIVDVWHPHLPDQRRSLPAI 758
DB 697 KIRCANETRTWEGKVLIFDSSFEHEVQDASSFRLLIFIVDVWHPHLPDQRRSLPAI 754

RESULT 3
JC7792
cardiac junctate-1 - mouse
C/Species: Mus musculus (house mouse)
C/Date: 02-Apr-2002 #sequence_revision 02-Apr-2002 #text_change 03-May-2002
C/Accession: JC7792
R/Hong, C.S.; Kwak, Y.G.; Ji, J.H.; Chae, S.W.; Kim, D.H.
Biochem. Biophys. Res. Commun. 289, 882-887, 2001
A:Title: Molecular cloning and characterization of mouse cardiac junctate isoforms.
A:Reference number: JC7792
A:Contents: Heart
A:Accession: JC7792
A:Molecule type: mRNA
A:Residues: 1-270 <HON>
A/Cross-references: GB:AF302653
C/Comment: This protein, a Ca2+ binding protein, plays a role both in contractile and co
C/Keywords: cardiac muscle; heart

Query Match 22.1%; Score 890; DB 2; Length 270;
Best Local Similarity 63.9%; Pred. No. 8.8e-39;
Matches 179; Conservative 30; Mismatches 57; Indels 14; Gaps 5;

QY 34 RETKHGKNGRKGSLGSGTSTAGSSSPGARRETKHGKNGKGLSGTSTFTW 93

```


200

5

DD 130 ECENI VEEVSKITFNVNSR - - - - - ME ILEF CSSEIENETIRNDT OOEENATIRNCEOTIRNCEK 100

Qy	702	IRCANETRTWEEGKVLIFDDSFHEHVQDASSFRLIFIVDVWHP	745
		: : : : : : : : : : : : :	
Db	185	IYVDGQPYAWRDGEDVNEDETFFVHWVKNETQTRVILFCDIERP	228

RESULT 9
H95076
zinc metalloproteinase ZmpB, probable [imported] - Streptococcus pneumoniae (strain TIGR4)
C;Species: Streptococcus pneumoniae
C;Date: 03-Aug-2001 #sequence_revision 03-Aug-2001 #text_change 03-Aug-2001
C;Accession: H95076
R;Tettelin, H.; Nelson, K.E.; Paulsen, I.T.; Eisen, J.A.; Read, T.D.; Peterson, S.; Heid
on, J.D.; Umayam, L.A.; White, O.; Salzberg, S.L.; Lewis, M.R.; Radune, D.; Holtzapple,
nson, T.; Hickey, E.K.; Holt, I.E.
Science 293, 498-506, 2001
A;Title: Complete Genome Sequence of a virulent isolate of Streptococcus pneumoniae.
A;Authors: Loftus, B.J.; Yang, F.; Smith, H.O.; Venter, J.C.; Dougherty, B.A.; Morrison,
A;Reference number: A95000; MUID:21357209; PMID:11463916
A;Accession: H95076
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-1881 <KUR>
A;Cross-references: GB:AF005672; PIDN:AAK74809.1; PID:gl4972138; GSFDB:GN00164; TIGR:SP4
A;Experimental source: strain TIGR4
C;Genetics:
A;Gene: SP0664

Query Match	4.8%;	Score 191.5;	DB 2;	Length 1881;
Best Local Similarity	21.6%;	Fred. No. 0.06;		
Matches 138;	Conservative 82;	Mismatches 226;	Indels 193;	Gaps 30;
Qy	111	ERSTSEPAVPPEE--AEPHTEPEOVPEABPQNIEDAEQIQSLLHEMWHAEHVEGED	168	
Db	211	KEDSAEPA-PVEEVGGEVESPEEKAVKPSQSPDKPAESKVEQAGEPV---	265	
Qy	169	LQEDGGPTGEQQEDDEFLMATDVDDRPETTELPEVSHHEETHSHVBEVTSQDCNQ-DME	227	
Db	266	EKAPVEPEKQPEAPEEE--KAVEETPKQEESTPTDKABETVEP--KEETVNSQIEQPKVE	321	
Qy	228	EMWSEQENPDSDSEPVVEDE---RLHHDTDDVTYQVVEEQAVPEPLENEGIEIEIVTAPP	283	
Db	322	TPAVEKQETPEEPKVEQAGSPVAPREDQAPTPAVEPEKQPEVPEEEKAV---	378	
Qy	284	ED-----NPVEDSQV---IVEEVSIFPVE-----	307	
Db	379	EDKIKIGIKETPEVDKSELNNQIDKASSVPTDYSTASYNALCPVLETAAGVYASEPVKQP	438	
Qy	308	EVPPETNR-----KTD-----DPQKAKVKKKKPKLNLKFDKTTKAEILDAAEK	350	
Db	439	EVNSETNKKCTAIDALNVDKTELNNNTIADAKTKVKEHYGSDRWQNLQTEVTKAEKVAANT	498	
Qy	351	LRKRGKIBEAVNAF-----	383	
Db	499	DAKQSEVNEAVEKLTATTIEKLVELSEKPILTLTSTDKKILEREAVAKYTLE---NONKTK	555	
Qy	384	CEDDLAEKRGNEVULRGAI-----ETQO-----	407	
Db	556	IKSITAEALKKEGEVINTVVLTDCKVTTETISAAFAKXLEYYEYTLSTTWIYDRNGGEETE	615	
Qy	408	VASLPDVPADLLKLKSLK--RRSDROQFLGHMRGSLTLTQRLVOLFPNDPTSLKNDLGVYL	465	
Db	616	TLENQNIQLDLKKVELKNIKRTDLKY---ENGKETWESLTLTTPDDKSNY-----YL	665	
Qy	466	LIGDNDN-----AKKVVEVLSVTPNDGFAKVHYGFILK-AQNKIABS-IPYLKEGIES	517	
Db	666	KITSNNQKTTLLAVAKNIBETTVNGTVPVKVTAIADNLVSRRTADNFEFEYVHYIEK----	721	
Qy	518	GDPGTDDGRFXFPHLGDMQRGVNKEAYKWYELGKHGRGHPASVWQBSLYNV--NGLKAQWP	575	
Db	722	--PKVHEDNVVYFNKELVEAION-DPSKEYRUGQ-----SMSARNVPNG---KSY	766	
Qy	576	WTFKETGTVELKSLERNWKLIRDEG--LAVNMDKAKGLF	612	

Db 767 ITKEFTG-----KLLSEKQKFAITTEHPLF 793

RESULT 10

G64242

Cytadherence-accessory protein (hmw1) homolog MG386 - Mycoplasma genitalium

C:Species: Mycoplasma genitalium

C:Date: 17-Nov-1995 #sequence_revision 17-Nov-1995 #text_change 07-Dec-1999

C:Accession: G64242

R:Fraser, C.M.; Gocayne, J.D.; White, O.; Adams, M.D.; Clayton, R.A.; Fleischman, M.; Fuhrmann, J.; Nguyen, D.; Utterback, T.R.; Saudek, D.M.; Phillips, C.A.; Meri, C.A.; Venter, J.C.

Science 270, 397-403, 1995

A:Title: The minimal gene complement of Mycoplasma genitalium.

A:Reference number: A64200; MUID:96026346; PMID:7569993

A:Accession: G64242

A:Status: preliminary; nucleic acid sequence not shown; translation not shown

A:Molecule type: DNA

A:Residues: 1-1616 <TIGR>

A:Cross-references: GB:U39723; GB:I43967; NID:g1046092; PID:g1046097; TIGR:MG386

A:Experimental source: strain G-37

C:Genetics:

A:Genetic code: SGC3

Query Match 4.7%; Score 189.5; DB 2; Length 1616;
Best Local Similarity 22.3%; Pred. No. 0.063;
Matches 142; Conservative 78; Mismatches 205; Indels 213; Gaps 35;

QY	75	FDLVYDEVLGK-----LGIYD-----ADGGGDFVDDAKVL-----	106
Db	1091	FDTVKHEAVFDKQQTQTGLEEPQVSEAEVVDQTTDTVGEPEAVFDVQPEKTTVEKFD	1150
QY	107	-LGLKERSTSEPAVPPEAEHPHTEPEQVPVEAPQNIIDEAKQQLSLHEMVHAHVE	165
Db	1151	DVENQKQVISEPQVEQPGAEVPEPSAEKFDSPVESQDSQPELVEVQTQPEIQPVE	1210
QY	166	GEDIQQEDGPTGEEQOEDDFLMAITVDVDFETLE-PEVSHETSHYHVEETVSOD-CN	223
Db	1211	SQPEATFD--TVQPEQTQE-----AKFDSPVETVEQEFSEPTQQ--HVSEASFDEN	1262
QY	224	QDMEMNSEQENP--DS-----SEPVDERLHHDDTDVITYQV-----YEEQAVVEPL	269
Db	1263	YDFEPNVDQPSYSDLDQSEPEQXDVPENYDFDEPNVEIESKFSPEQFEPQVSEQP-	1321
QY	270	ENEGIEITETVAPPE-DNPVE---DSQ--VIVREVSIFFVEEQVEPPTNKRKTDDPEQK	323
Db	1322	---GEAVPEPSAEAKFDSPVESQDSQPEPLLEEVQTQPEIQPVESQPEATFTTVQPEQT	1378
QY	324	AKVKKKPKLNLKFDKTIKAELDAAEKLRKGIEEAVNAFKELVRKYPOSRRARYGKAQ	383
Db	1379	PQEA-----KFD-----AKFDSPVETVEQEFSEPTQQ--HVSEASFDEN	1387
QY	384	CEDDLAEKRRSNEYLRGAIETYQE--VASLPDVPADLLKLSLKRSDRQOQLGHMRGSL	441
Db	1388	-----VETIQEPQYSSEPV--VVQPNFEERKPE-----TVL	1417
QY	442	TLQRIVLQFP--NDTSLKNDLGVGYLLIGDNNAKKVYEEVLVTPNDGFAKVGHFIL	498
Db	1418	BEQADEIQPEASBEESLDWELLVG-----NNSYGHYEP-----DG-EWVWAGFFG	1462
QY	499	KAQ--NKIABSI PVLKEGIESGDPGTDGFRFYHL-GDAMQ-RVGNGKEAYKVELGHRG	554
Db	1463	DDQKWNKA-TVKKARE-----RDYLPILGDEVGYNNKGIEWITGFFYDESG	1509
QY	555	HFASY---WQRSLYNVLGKAQPWWTQ-----KETGYTELKSLERNWKLIRDEGLAVMDK	607
Db	1510	DWLVLDQEKMKRQPRIN--EAPKPEKXILGNEEYGYE--DNEWNW-----	1551
QY	608	AKGLFLPDEENLRKGDWSQPTLWQOGRNRNENACKGAP	645
Db	1552	-----YDGFDFSEGWLVPQSSEETENLNEIDITKIDP	1582

A45990
Junctional sarcoplasmic reticulum glycoprotein triadin - rabbit
C/Species: Oryctolagus cuniculus (domestic rabbit)
C/Date: 21-Sep-1993 #sequence_revision 18-Nov-1994 #text_change 11-Jan-2000
C/Accession: A45990; S45704
R/Kruidson, C.M.; Stang, K.K.; Moonaw, C.R.; Slaughtreir, C.A.; Campbell, K.P.
J. Biol. Chem. 268, 12646-12654, 1993
A/Title: Primary structure and topological analysis of a skeletal muscle-specific junctional sarcoplasmic reticulum glycoprotein triadin from rabbit
A/Reference number: A45990; MUID:93286104; PMID:7685347
A/Accession: A45990
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-706 <KNU>
A/Cross-references: GB:110065; NID:9347850; PIDN:AAA31488.1; PID:g347851
A/Experimental source: triads, muscle
A/Note: sequence extracted from NCBI backbone (NCBIN:133603, NCBI:P:133604)
R/Peng, M.; Fan, H.; Kirsley, T.L.; Caswell, A.H.; Schwartz, A.
FEBS Lett. 348, 17-20, 1994
A/Title: Structural diversity of triadin in skeletal muscle and evidence of its existend

```

Query Match      4.5%; Score 183; DB 2; Length 763;
Best Local Similarity 21.8%; Pred. No. 0.052;
Matches 126; Conservative 84; Mismatches 217; Indels 1
QY 112 RSTSEPAVPPEEAAPHT-----EPREQVPVEAPEQNIIDEAKEQ
Dh 35 KETQELAKEDMAEPDKNWIDAOIKKDEKAEETDKSEVKKNEDNATQ

```


GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2004, 10:56:23 ; Search time 18 Seconds
(without alignments)
2192.732 Million cell updates/sec

Title: US-09-903-216-2

Perfect score: 4022

Sequence: 1 MAQRKNAKSSGSSSSSGSGS.....IVDVHPELTPQRRSLPAI 758

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt_42.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	3966.5	98.6	757	1 ASPH_HUMAN	Q12797 homo sapien
2	3172	78.9	754	1 ASPH_BOVIN	Q28056 bos taurus
3	203	5.0	700	1 TRDN_CANFA	P82179 canis fami
4	194	4.8	4835	1 MDNI_GIALA	Q8t5t1 giardia lam
5	193	4.8	493	1 ECX1_YETMA	Q8p8t8 methanosarc
6	189.5	4.7	1616	1 P200_MTCGE	Q49429 mycoplasma
7	187	4.6	705	1 TRDN_RABIT	Q28820 myctolagus
8	181	4.5	728	1 CALD_CHICK	P12957 gallus gall
9	178.5	4.4	771	1 TRDN_HUMAN	Q13061 homo sapien
10	176.5	4.4	845	1 NFM_RAT	P12839 rattus norv
11	175	4.4	2004	1 MY53_HUMAN	Q92794 homo sapien
12	172.5	4.3	1240	1 YNJI_YEAST	P53935 saccharomyc
13	172	4.3	465	1 YH06_YEAST	P38845 saccharomyc
14	172	4.3	630	1 YCF2_OENVI	P31569 oenothera v
15	169.5	4.2	592	1 LAM2_MOUSE	P21619 mus musculu
16	169.5	4.2	1233	1 YF16_YEAST	P43597 saccharomyc
17	165	4.1	650	1 NUCLE_XENLA	P20397 xenopus lae
18	164	4.1	1357	1 SPOF_SCHPO	Q10411 schizosacch
19	163	4.1	411	1 FK03_YEAST	P38911 saccharomyc
20	162.5	4.0	793	1 CALD_HUMAN	Q05682 homo sapien
21	161.5	4.0	848	1 NFM_MOUSE	P08553 mus musculu
22	161.5	4.0	1220	1 IF2E_HUMAN	O60841 homo sapien
23	161.5	4.0	1395	1 SP41_YEAST	P38904 saccharomyc
24	161	4.0	2663	1 CENE_HUMAN	Q02224 homo sapien
25	161	4.0	4910	1 MDN1_YEAST	Q12019 saccharomyc
26	160.5	4.0	721	1 YCF2_OENPI	P31568 oenothera p
27	159	4.0	3924	1 ANK2_HUMAN	Q01484 homo sapien
28	158.5	3.9	837	1 RA50_METHH	Q26640 methanobact
29	158.5	3.9	1102	1 YG49_SCHPO	O60184 schizosacch
30	158	3.9	790	1 CDL1_HUMAN	P21127 homo sapien
31	157.5	3.9	785	1 CDL2_HUMAN	Q9uq88 homo sapien
32	157.5	3.9	1357	1 KTN1_HUMAN	Q86up2 homo sapien
33	156.5	3.9	506	1 NPL3_HUMAN	Q99457 homo sapien

RESULT 1
ASPH_HUMAN
ID ASPH_HUMAN STANDARD; PRT; 757 AA.
AC Q12797;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Aspartyl/asparaginyl beta-hydroxylase (EC 1.14.11.16) (Aspartate beta-hydroxylase) (ASP beta-hydroxylase) (peptide-aspartate beta-dioxygenase).
DE dihydroxylase).
GN ASPH.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A. MEDLINE=95121937; PubMed=7821814;
RX Koriath F., Gieffers C., Frey J.;
RA "Cloning and characterization of the human gene encoding aspartyl beta-hydroxylase".
RT Gene 150:395-399(1994).
RL
CC -!- FUNCTION: Specifically hydroxylates an Asp or Asn residue in certain epidermal growth factor-like (EGF) domains of a number of proteins.
CC -!- CATALYTIC ACTIVITY: Peptide L-aspartate + 2-oxoglutarate + O(2) = peptide 3-hydroxy-L-aspartate + succinate + CO(2).
CC -!- COFACTOR: Iron.
CC -!- SUBUNIT: Monomer (By similarity).
CC -!- SUBCELLULAR LOCATION: Type II membrane protein. Endoplasmic reticulum.
CC -!- TISSUE SPECIFICITY: Detected in all tissues tested.
CC -!- PTM: MIGHT BE PROCESSED TO THE 56 kDa (AA 274-757) OR 52 kDa (AA 315-757) FORMS IN THE LUMEN OF THE ENDOPLASMIC RETICULUM (BY SIMILARITY).

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

EMBL; U03109; AAA82108.1; -.
PIR; I38423; I38423.
Genew; HGNC:757; ASPH.
MIM; 600582; -.
GO; GO:0005789; C:endoplasmic reticulum membrane; TAS.
GO; GO:0005509; F:calcium ion binding; TAS.
GO; GO:0005489; F:electron transporter activity; TAS.
GO; GO:0004597; F:peptide-aspartate beta-dioxygenase activity; TAS.
GO; GO:0008307; F:peptide-aspartate beta-dioxygenase activity; TAS.
GO; GO:0006936; P:muscle contraction; TAS.
InterPro; IPR007943; Asp-B-Hydro N.
InterPro; IPR007803; Asp_Arg_Hydrox.

Q03661 saccharomyc
P20357 mus musculu
P22793 ovis aries
Q07283 homo sapien
P36080 saccharomyc
Q12114 saccharomyc
O57521 brachydanio
P11501 gallus gall
Q9r0x5 mus musculu
Q97593 bos taurus
Q14683 homo sapien
Q14692 homo sapien

DR InterPro; IPR008940; Prenyl_trans.
 DR InterPro; IPR001440; TPR.
 DR Pfam; PF05279; Asp-B-Hydro N; 1.
 DR Pfam; PF05118; Asp Arg_Hydrox; 1.
 KW Oxidoreductase; Dioxxygenase; Iron; Transmembrane; Signal-anchor;
 KW Endoplasmic reticulum.
 FT DOMAIN 1 54 CYTOPLASMIC (POTENTIAL).
 FT TRANSMEM 55 75 SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)
 FT (POTENTIAL).
 FT DOMAIN 76 757 LUMENAL (POTENTIAL).
 FT DOMAIN 13 20 POLY-SER.
 FT DOMAIN 323 332 POLY-LYS.
 FT CARBOHYD 452 452 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 705 705 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 705 705 N-LINKED (GLCNAC. . .) (POTENTIAL).
 SQ SEQUENCE 757 AA; 83498 MW; 1A79313A4934C430 CRC64;
 Query Match 98.6%; Score 3966.5; DB 1; Length 757;
 Best Local Similarity 99.2%; Pred. No. 3.4e-193;
 Matches 752; Conservative 2; Mismatches 3; Indels 1; Gaps 1;
 QY 1 MAQRKNAKSGNSGSGSGSTAGSSSPGARETHKGHGKRGKGLSGTSFFTFWV 60
 DB 1 MAQRKNAKSGNSGSGSGSTAGSSSPGARETHKGHGKRGKGLSGTSFFTFWV 60
 QY 61 IALLGVNTSVAVVWFDLVYEEVLKGIYDADGDGDFVDDAKVLLGLKERSTSPAVP 120
 DB 61 IALLGVNTSVAVVWFDLVYEEVLKGIYDADGDGDFVDDAKVLLGLKERSTSPAVP 120
 QY 121 PEAAPHTPEEQVPEAEFQNIIDEAKQIQSLHMHVHAHVGEEDLQOEDGPTGEPQ 180
 DB 121 PEAAPHTPEEQVPEAEFQNIIDEAKQIQSLHMHVHAHVGEEDLQOEDGPTGEPQ 180
 QY 181 QEDDEFLMATVDRETFLEPEVSHETSHYVEETVSDQCDQNMSEMQENPDSS 240
 DB 181 QEDDEFLMATVDRETFLEPEVSHETSHYVEETVSDQCDQNMSEMQENPDSS 240
 QY 241 PVVEDERLHDDTDVTVQVVEQAVYEPLENEGIEITEVTAPDNPVEDSQVIVEVSI 300
 DB 241 PVVEDERLHDDTDVTVQVVEQAVYEPLENEGIEITEVTAPDNPVEDSQVIVEVSI 300
 QY 301 FPVEEQEVPETNRTKDDPEQAKVKKKPKLNLKEDTKIKAEFDAEKLKRGKITEA 360
 DB 301 FPVEEQEVPETNRTKDDPEQAKVKKKPKLNLKEDTKIKAEFDAEKLKRGKITEA 360
 QY 361 VNAFKELVRYPOSPRARYKQACEDDLAEKRSNEVIRGAETVQEVASLPDVPADLLK 420
 DB 361 VNAFKELVRYPOSPRARYKQACEDDLAEKRSNEVIRGAETVQEVASLPDVPADLLK 420
 QY 421 LSLKRRSDRQOFLGHMRGSLTLQRLVQLFPNDTSLKNDLGVGYLLIGDNDNAKVVYEV 480
 DB 421 LSLKRRSDRQOFLGHMRGSLTLQRLVQLFPNDTSLKNDLGVGYLLIGDNDNAKVVYEV 480
 QY 481 LSVTPNDGFAKVHGFILKQNKTAESIPYLKEGIESGDPGTDGGRYFHLGDAMQVGN 540
 DB 481 LSVTPNDGFAKVHGFILKQNKTAESIPYLKEGIESGDPGTDGGRYFHLGDAMQVGN 540
 QY 541 KEAYKVELGHKRGHFAVWSRSLYVNGLKAQPWTPKETGYTELKSLERNWKLIRDE 600
 DB 541 KEAYKVELGHKRGHFAVWSRSLYVNGLKAQPWTPKETGYTELKSLERNWKLIRDE 600
 QY 601 GLAVMDKAKGLFLPEDENLREKGDWSQFTLWQOGRNENACKGAPKCTCTLLEKFPETTC 660
 DB 600 GLAVMDKAKGLFLPEDENLREKGDWSQFTLWQOGRNENACKGAPKCTCTLLEKFPETTC 660
 QY 661 RRGQIKYSIMHPGTHVPHGTNCRMLHGLVLPKGECKIRCANETRWEEGKVLIFD 720
 DB 660 RRGQIKYSIMHPGTHVPHGTNCRMLHGLVLPKGECKIRCANETRWEEGKVLIFD 720
 QY 721 DSFEHEVWQDASSRLIFIVDVWHPHLPQOORSLPAI 758
 DB 720 DSFEHEVWQDASSRLIFIVDVWHPHLPQOORSLPAI 757

RESULT 2
 ASPH_BOVIN STANDARD; PRT; 754 AA.
 ID ASPH_BOVIN Q28056;
 DT 01-NOV-1997 (Rel. 35, Created)
 DT 01-NOV-1997 (Rel. 35, Last sequence update)
 DT 15-MAR-2004 (Rel. 43, Last annotation update)
 DE Aspartyl/asparaginyl beta-hydroxylase (EC 1.14.11.16) (Aspartate beta-hydroxylase) (ASP beta-hydroxylase) (Peptide-aspartate beta-hydroxylase).
 DE DE dioxxygenase).
 GN ASPH.
 OS Bos taurus (Bovine).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
 OC Bovidae; Bovinae; Bos.
 NCBI_TaxID=9913;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Brain, and Liver;
 RX MEDLINE=92332546; PubMed=1378441;
 RA Jia S., Vandusen W.J., Diehl R.E., Kohl N.E., Dixon R.A.F.,
 RA Elliston K.O., Stern A.M., Friedman P.A.;
 RT "cDNA cloning and expression of bovine aspartyl (asparaginyl) beta-hydroxylase.";
 RL J. Biol. Chem. 267:14322-14327(1992).
 RN [2]
 RP SEQUENCE OF 289-385 AND 615-641.
 RC TISSUE=Liver;
 RX MEDLINE=91310699; PubMed=1856229;
 RA Wang Q., Vandusen W.J., Petroski C.J., Garsky V.M., Stern A.M.,
 RA Friedman P.A.;
 RT "Bovine liver aspartyl beta-hydroxylase. Purification and characterization.";
 RL J. Biol. Chem. 266:14004-14010(1991).
 CC -!- FUNCTION: Specifically hydroxylates an Asp or Asn residue in certain epidermal growth factor-like (EGF) domains of a number of proteins.
 CC -!- CATALYTIC ACTIVITY: Peptide L-aspartate + 2-oxoglutarate + O(2) = Peptide 3-hydroxy-L-aspartate + succinate + CO(2).
 CC -!- COFACTOR: Iron.
 CC -!- SUBUNIT: Monomer.
 CC -!- SUBCELLULAR LOCATION: Type II membrane protein. Endoplasmic reticulum.
 CC -!- PTM: Might be processed to the 56 kDa (AA 289-754) or 52 kDa (AA 311-754) forms in the lumen of the endoplasmic reticulum.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).
 CC -----
 CC EMBL; M91213; AAA03563.1; -.
 DR PIR; A42969; BABOH.
 DR InterPro; IPR007943; Asp-B-Hydro N.
 DR InterPro; IPR007803; Asp Arg_Hydrox.
 DR InterPro; IPR008941; TPR-like.
 DR InterPro; IPR001440; TPR.
 DR Pfam; PF05279; Asp Arg_Hydro N; 1.
 DR Pfam; PF05118; Asp Arg_Hydrox; 1.
 KW Oxidoreductase; Dioxxygenase; Iron; Transmembrane; Signal-anchor;
 KW Endoplasmic reticulum.
 FT DOMAIN 1 57 CYTOPLASMIC (POTENTIAL).
 FT TRANSMEM 58 78 SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)
 FT (POTENTIAL).
 FT DOMAIN 79 754 LUMENAL (POTENTIAL).
 FT DOMAIN 9 12 POLY-GLY.
 FT DOMAIN 14 21 POLY-SER.
 FT DOMAIN 318 328 POLY-LYS.
 FT CARBOHYD 96 96 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 466 466 N-LINKED (GLCNAC. . .) (POTENTIAL).

```
FT CARBOHYD 702 702 N-LINKED (GLCNAC. . .) (POTENTIAL).
SQ SEQUENCE 754 AA; 84998 MW; 369593A1F0B558C8 CRC64;

Query Match
Best Local Similarity 78.9%; Score 3172; DB 1; Length 754;
Matches 612; Conservative 45; Mismatches 77; Indels 44; Gaps 6;

QY 1 MAOKNAKSSG--NSSSSGSGSGSTGAGSSPGARRETKHGKNGKGGSLGTSFTW 57
Db 1 MAPKNAKGGGSSSSSSGSPCTSGSSPGARRETKGGLKNGKGGSLGSSFTW 60
QY 58 FMVIALGLWTSVAVWFDLVYDEVL-----GKLGIVYDADGDGDFD 102
Db 61 FMVIALGLWTSVAVWFDLVYDEVLAKAFRYNLSEVLQKLGIVYDADGDGDFD 120
QY 103 AKVLLGLKERSTSPAPVPEAEPTPEBQVPEAEFONIDEAKQIQSLLEHMHAE 162
Db 121 AKVLLGLKEKPAKPTVPPEADMPYMLEQVLESQGRONIDEVYEQVQS-LDETYS 179
QY 163 HVEGEDIQEDGPTGEQOEDDFLMATDVRPETLEPEVSHETSHYHVEETVSQDC 222
Db 180 --PGENLPQEPGPAELQPDHVFVGSADDRPEMGTVGAVHEETDSYHIEETAS 237
QY 223 NQDEEMWSEQENPDSEPVVED--ERLHHDTDVTVQVYEEQAVYEPLENEGIEIT 280
Db 238 SQMEDMMYEQENPDSEPVVDDAERTYQETDDVYRDEQ----- 280
QY 281 APPENPDVEDSQVIVEEVSIFPVEEQVPEVETNRKTDPPQAKVKKKPKLLNKPK 340
Db 281 ----DHAVDNSNTILEEPHMPAEQEQQVPEVETNRKTDPPQAKVKKKPKLLNK 336
QY 341 IKAELDAEKLKRGKIEEAVNAKPELVKYPQSPRARYGAQCEDDLAEKRRSNEVL 400
Db 337 IKAELDAEKLKRGKIEEAVNAPEELVKYPQSPRARYGAQCEDDLAEKRRSNEIL 396
QY 401 AIETYQEVASLPDVPADLLKLSKRRSDRQFLGHMRGSLTLQELVOLFPNDTSLKN 460
Db 397 AIETYQEAASLPDAPDLVLKLSKRRSDRQFLGHMRGSLTLQELVOLFPDDTALK 456
QY 461 GVGILLIGDNNAKVYEVLSVTPNDGFAKHGKGFILKAQNKIAESIPYLKEGIES 520
Db 457 GVGILLIGDNNAKVYEVLSVTPNDGFAKHGKGFILKAQNKIAESIPYLKEGIES 516
QY 521 GTDGRGFYHLGDAMQRYGNKEAYKWLGHKRGHFASVWQSLNVNGLKAQPMWTPKE 580
Db 517 GTDGRGFYHLGDAMQRYGNKEAYKWLGHKRGHFASVWQSLNVNGLKAQPMWTPKE 576
QY 581 TGYTELKSLERNWKLIRDEGLAVMDKAGLFLPEDENLREKGDWSQFTLMQOQRRN 640
Db 577 TGYTELKSLERNWKLIRDEGLAVMDKAGLFLPEDENLREKGDWSQFTLMQOQRRN 636
QY 641 CKGAPKCTILLEKFPETTCGRGOIKYSTMPGTHVWHTGTCNCLBMHLGLVLPKGC 700
Db 637 CKGAPKCTSLDKFPETTCGRGOIKYSTMPGTHVWHTGTCNCLRMHLGLVLPKGC 696
QY 701 KIRCANERTWEEGKVLFDSDFEHEVWQDASFRILFIVDVHHPQLPQRRSLPAI 758
Db 697 KIRCANERTWEEGKVLFDSDFEHEVWQDASFRILFIVDVHHPQLPQRRSLPAI 754

RESULT 3
ID TRDN CANFA STANDARD; PRT; 700 AA.
AC P82179;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Triadin.
GN TRDN.
OS Canis familiaris (Dog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
OC NCBI_TaxID=9615;
```

```

[1]
SEQUENCE FROM N.A., AND ALTERNATIVE SPLICING.
TISSUE=Heart, and Skeletal muscle;
MEDLINE=99428545; PubMed=10497235;
RA Kobayashi Y.M., Jones L.R.;
RT "Identification of triadin 1 as the predominant triadin isoform
expressed in mammalian myocardium."
J. Biol. Chem. 274:28660-28668(1999).
CC -I- FUNCTION: May be involved in anchoring calsequestrin to the
junctional sarcoplasmic reticulum and allowing its functional
coupling with the ryanodine receptor (By similarity).
CC -I- SUBCELLULAR LOCATION: Type II membrane protein. Sarcoplasmic
reticulum.
CC -I- ALTERNATIVE PRODUCTS:
Event=Alternative splicing; Named isoforms=3;
Name=Skeletal;
IsoId=P82179-1; Sequence=displayed;
Name=Cardiac 1;
IsoId=P82179-2; Sequence=VSP_004001, VSP_004002;
Name=Cardiac 3;
IsoId=P82179-3; Sequence=VSP_004003, VSP_004004;
-I- TISSUE SPECIFICITY: Skeletal and cardiac muscle.
-----
This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@sib-sib.ch).
-----
EMBL; AF165916; AAF00222.1; -
EMBL; AF165915; AAF00221.1; -
EMBL; AF165917; AAF00223.1; -
Transmembrane, Sarcoplasmic reticulum; Glycoprotein;
KW Alternative splicing.
FT INIT MET 0
FT DOMAIN 1 46
FT TRANSMEM 47 67
FT DOMAIN 68 700
FT CARBOHYD 74 74
FT CARBOHYD 616 616
FT VARSPLIC 257 277
FT
FT VARSPLIC 278 700
FT VARSPLIC 466 466
FT VARSPLIC 524 579
FT
FT VARSPLIC 700 AA; 78152 MW; F033E3AA1BEE0C56 CRC64;
SQ SEQUENCE 700 AA; 78152 MW; F033E3AA1BEE0C56 CRC64;

Query Match
Best Local Similarity 5.0%; Score 203; DB 1; Length 700;
Matches 141; Conservative 95; Mismatches 236; Indels 258; Gaps 28;

QY 6 NAKSSGSSSSGSGSGTSAGS-----SSPGARRETKHGKNGKGGSLG 51
Db 8 NASTTTTVIDSKNGSVKSPGKVLKRTVTEDIVTTFSSPA----- 48
QY 52 TSFTFWFVIALGLWTSVAVWFDLVYDEV-----LKLGL-----LYDA----- 92
Db 49 -----WLLVIALITWSAVAVWFDLVYKNSFASLSKIGSDPLKLVHDAVEETDWWY 103
QY 93 -----DGDGDFDVAKVLGLKERSTSEPAVPEAEPTPEEQVP 135
Db 104 GPFSLLSDISSDGDDEDDGDETDKGEI-----EPPPLKQKEIHKEAKEKEPKRIL 159
```


136 VEA---EPONIEDEAKBQIQLLHEMVAHVEGDELQOEDGPTGEPOEDDEFLMATDV 192
 160 AKVAHREKEKVEKEKSE-----KKATHKEKIEKEKPTKMAKERAKTEEKIKKEV 214
 193 -DRPFTLEPEVS-----HEETEH-----SYHVEETVSQDC 222
 215 KGGKQKQVPTAKVKEVQKTPPKAKEKSGKETAAVAKEHQKQYAFRMYDMFVHGD 274
 223 NQDMEEHM-----SEQNPDSSEPVVEDEHLHHDTHDDVTYQVVE 261
 275 RPQSPALPPLPTVQASRPTPASPTLEGKEBEKKAEBKVTSETKKKEKEDVKKSDK 334
 262 EQAV-----YEPLENEG-LEITEVTAPPEDNPVEDSQVIVEEVSIPVEEQOE 308
 335 DTAIDVEKKEPGKAPETKQGTIKVQAQAAKDEKEDSKTKTTPVEEHPKGGKQKKEK 394
 309 -VPPETNRKTD--PEOK-----AKVKKKKP-KLLNKFDFKTIKAEILDAAE 349
 395 YVEPAKSSKEHSAPEKQVAKTERAKETSAASTKAVPGKKEKTKTKVQEIE 450
 350 KLRKRGKI-----BEAVNAFKELVRKYPQSPRARGK-----ACEDD 387
 451 RKEKSGKTSTASKDKEPEIKKDEKMPKADKEVKPKPPQSQVKKKEKSESQVKKAEKPEQ 510
 388 LAEKRRS-----NEVLRGAIE-----TYQEVASLPDVPADLLKLS 422
 511 IAKPEKTVSHGKPEEKVVKQVKAATEKAAIEKTVKPKAKAEHQEKES-FTIKTDKPKPT 569
 423 LK-----RRSRDQQLGHMRGSLTLQLRLVQLFPNDTSLKNDLGVGYL 465
 570 SKETPEVTESGKKIEKSEKSEKAEKEMKHLKEEKVSTRESLQSHNVTVKAEKPARVSR 629
 466 LIGDNDAKVKYEEVLVS-----TPNDGFAKH-----YGFILKAQNKIAESIPYLK 512
 630 DLEDVSAKKAEEAEEDVSTKQKSPISPFQCYLDGYNGYGFQFPV-----TPAYR 682
 513 EGIESGDGPT 522
 683 PGSSGGQFSS 692

RESULT 4

MDNL_GIALA STANDARD; PRT; 4835 AA.
 AC Q8T5TL;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Midasin (MIDAS-containing protein).
 GN MDNL
 OS Giardia lamblia (Giardia intestinalis).
 OC Eukaryota; Diplomonadida; Hexamitidae; Giardiae; Giardia.
 OX NCBI_TaxID=5741;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=20389616; PubMed=10930750;
 RA McArthur A.G., Morrison H.G., Nixon J.E., Passamaneck N.O., Kim U.,
 RA Hinkle G., Crocker M.K., Holder M.E., Farr R., Reich C.I., Olsen G.E.,
 RA Aley S.B., Adam R.D., Gillin F.D., Sogin M.L.;
 RT "The Giardia genome project database."
 RL FEMS Microbiol. Lett. 189:271-273(2000).
 RN [2]
 RP IDENTIFICATION, GENE NAME, AND SIMILARITY WITH OTHER FAMILY MEMBERS.
 RX PubMed=12102729;
 RA Garbarino J.E., Gibbons I.R.;
 RT "Expression and genomic analysis of midasin, a novel and highly
 RT conserved AAA protein distantly related to dynein."
 RL BMC Genomics 3:18-18(2002).
 CC -!- FUNCTION: May function as a nuclear chaperone and be involved in
 CC the assembly/disassembly of macromolecular complexes in the
 CC nucleus.
 CC -!- SUBCELLULAR LOCATION: Nuclear (By similarity).
 CC -!- SIMILARITY: Contains 1 VWFA domain.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL; AF494287; AM12656.1; --
 DR InterPro; IPR003593; AAA ATPase.
 DR InterPro; IPR003959; AAA ATPase_cent.
 DR InterPro; IPR002035; VWFA.
 DR Pfam; PF00004; AAA_2.
 DR SMART; SM00382; AAA; 5.
 DR SMART; SM00327; VWFA; 1.
 DR PROSITE; PS02334; VWFA; 1.
 KW Chaperone; ATP-binding; Repeat; Nuclear protein.
 FT NP_BIND 356 363
 FT NP_BIND 814 821
 FT NP_BIND 1127 1134
 FT NP_BIND 1513 1520
 FT NP_BIND 1839 1846
 FT NP_BIND 3277 3284
 FT DOMAIN 110 113
 FT DOMAIN 3004 3007
 FT DOMAIN 4156 4161
 FT DOMAIN 4629 4818
 FT SEQUENCE 4835 AA; 539726 MW; 3A9E12417DB04A50 CRC64;

Query Match

Best Local Similarity 23.1%; Score 194; DB 1; Length 4835;

Matches 119; Conservative 74; Mismatches 203; Indels 120; Gaps 25;

QY 80 YEVVLGKGLIYD--AGDGDGFDVDDAKVLLGLKERSTSEPAVPEEAEPTEEEQVPE 137
 DB 4188 HEQADATGSTDQAQEDDYNDLDD-KNLGG-----QSDLSVPEADGEDETVNEE---LE 4238
 QY 138 AEQNIEDEAKEIQSLLHEMVAHVEGDELQOEDGPTGEPOEDDEFLMATDVDRFE 197
 DB 4239 EEQQMSDLSNPD-----QACAIEDDDDRLDSSD-----ENAEHDEHAPVDIDN-E 4288
 QY 198 TLEPEVSHEETHSYHVEETVSQDCNQDMEMMSQOE-----NPDSEPVVEDE- 247
 DB 4289 ASDEQSTYNDNRDDAINISAQQAATNDEEMQKDEYDQENITDSNPDAVEGTNDQK 4348
 QY 248 LHDDTDDVTYQVVEQAVYPELEN---EGITEVTAPPEDNPVEDSQVIVEEVSIFPV 303
 DB 4349 THEDNQFROENIEDOWEAESTENSQEGASADLKEGNDPMSLESEFQRLWKLNIHDR 4408
 QY 304 E-----EQQVPPETNRKTDDEQKA-----KVKKKKPKLLNKFDTIKAEILDAE 349
 DB 4409 ESEKDEAAEPQDMPLOSNTKTVFDDSKSGRDLGLTESKRNLTNQ-----EFDNPN 4461
 QY 350 KLRKRGKIEAVNAFKELVRKYPQSPRARGKACEDDLAE-----KRR 393
 DB 4462 EER---NVEH--NSSCETSSSHDRPPAEHLNPEISDEGESESTASDKQEQAVLSHMRES 4516
 QY 394 SNEVLRGAIEYQEVA-SLPD-----VPADL-----LKLSLKRRSDRQQLGHMRG 438
 DB 4517 SKDILNPEGEVYQELAVSLASEETKRAPEDVAAASARGNHLILLDIKQTSAAAF----- 4570
 QY 439 SLTLQLRLVOLFPNDTS-LKNDLGVGYLL-----IGNDNNAKKVYE 478
 DB 4571 SLAERLRII-LEPTVTSDLKGFRTGKKLNLRRIIPFIASEFQDKLWLRRTKPSKRVYQ 4629
 QY 479 EVLSVTNDGFAKVHYGFILKAQNKIAESIPYLK 514
 DB 4630 VLLAVDDSSSMAPL-AKVALQAITLLFNACKFLEVG 4664

RESULT 5

ECX1_METWA

ID	ECX1 METMA	STANDARD;	PRT;	493 AA.
AC	Q8PTT8;			
DT	10-OCT-2003 (Rel. 42, Created)			
DT	10-OCT-2003 (Rel. 42, Last sequence update)			
DT	10-OCT-2003 (Rel. 42, Last annotation update)			
DE	Probable exosome complex exonuclease 1 (EC 3.1.13.-).			
GN	MX2823.			
OS	Methanosarcina maezi (Methanosarcina frisia).			
OC	Archaea; Euryarchaeota; Methanomicrobia; Methanosarcinales;			
OC	Methanosarcinaceae; Methanosarcina.			
OX	NCBI_TaxID=2209;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN=Goel / Goi / ATCC BAA-199 / DSM 3647 / OCM 88;			
RX	MEDLINE=22120827; PubMed=12125824;			
RA	Deppehmer U., Johann A., Hartsch T., Merkl R., Schmitz R.A.,			
RA	Martinez-Arias R., Henne A., Wierse A., Baeumer S., Jacobi C.,			
RA	Brueggemann H., Lienard T., Christmann A., Boemcke M., Steckel S.,			
RA	Bhatnagar A., Lykidis A., Overbeek R., Klenk H.-P., Gunsalus R.P.,			
RA	Fritz H.-J., Gottschalk G.;			
RT	"The genome of Methanosarcina maezi: evidence for lateral gene			
RT	transfer between Bacteria and Archaea.";			
RL	J. Mol. Microbiol. Biotechnol. 4:453-461 (2002).			
CC	-i- FUNCTION: Probably involved in the 3'->5' degradation of a variety			
CC	of RNA species (Potential).			
CC	-i- SUBUNIT: Component of the archaeal exosome multienzyme			
CC	ribonuclease complex (Potential).			
CC	-i- SUBCELLULAR LOCATION: Cytoplasmic (Potential).			
CC	-i- SIMILARITY: Belongs to the RNase PH family.			
CC				
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration			
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation -			
CC	the European Bioinformatics Institute. There are no restrictions on its			
CC	use by non-profit institutions as long as its content is in no way			
CC	modified and this statement is not removed. Usage by and for commercial			
CC	entities requires a license agreement (See http://www.isb-sib.ch/announce/			
CC	or send an email to license@isb-sib.ch).			
CC				
DR	EMBL; AB013507; AAM32319.1; -			
DR	HMAP; MF_00591; -; 1.			
DR	InterPro; IPR001247; 3 Exonuclease.			
DR	Pfam; PF01138; RNase PH; 1.			
DR	Pfam; PF01725; RNase PH C; 1.			
KW	Exosome; Hydrolase; Nuclease; Exonuclease; Complete proteome.			
FT	DOMAIN 1 254 PROBABLE EXOSOME COMPLEX EXONUCLEASE 1.			
FT	DOMAIN 255 493 UNKNOWN.			
FT	SEQUENCE 493 AA; 55248 MW; 979A757BEF8DC090 CRC64;			
SQ				
Query Match	4.8%; Score 193; DB 1; Length 493;			
Best Local Similarity	26.3%; Pred No. 0.0056;			
Matches	97; Conservative 45; Mismatches 129; Indels 98; Gaps 17;			
QY	61 IALLGVWTSVAVVWFDVYEVVLGKLGIDYADGGDFV---DDAKVLL-----107			
DB	153 IPMKGLITSCA---FGKVDGKIVLIDNKEDNYGEADFPVAMTQDGEITLIQMGNLTPD 209			
QY	108 -----GLKRSSTSEPAV-----PPEAEPHTPE-----EQVPEAPEQ 141			
DB	210 EIKQGLVKKCKEILEITQQAIVLRKFTPEVSEETAPEKGAKEVLESPVAALVE 269			
QY	142 NTEDEAKEIQISLLHMHVHAEVGEGLDQDGPTEPOED---DEFLMAT---DVDDRPE 197			
DB	270 ETPPEAEP-----EVEISEVEAEILASVLPDPEDELEIEIEELEESEEDLETEE 323			
QY	198 TLEPEVSHEETSHYVETVQDCNQDMEMWSEQNPDSSEPVVEDE-----246			
DB	324 EFEEAELEAEAPPEDELEEDLEEDLEEDLEEDLEEDLEEDLEEDLEEDLEEDLEED 383			
QY	247 -----RLHDDTDTYQVYE-----EQAVVEPLENGEIEITEVTAPEDNPVED 290			
DB	384 ELKEPDEIARL---EKEDASIEAEERIEPEAEATEEGLEEEA-EIEETAASEEN-IEA 439			
QY	291 SQVIVEVSIFPVEEQVEPPETNRKTDTPDQKAKVKKKPKLLNFKDKTKIAELDAEK 350			

DB	440 EAAAEAEAE--FEVFAEEISTEAEAEAEPEPEB---KSEGPW-----KVKDPSAG--486			
QY	351 LAKRGKIEE 359			
DB	487 --TRGEKDE 493			
RESULT 6				
P200_MYCGE	STANDARD;	PRT;	1616 AA.	
ID	P200_MYCGE			
AC	Q49429; Q49259; Q49298; Q49352; Q49353;			
DT	01-NOV-1997 (Rel. 35, Created)			
DT	01-NOV-1997 (Rel. 35, Last sequence update)			
DT	28-FEB-2003 (Rel. 41, Last annotation update)			
DE	Protein P200.			
GN	MG386.			
OS	Mycoplasma genitalium.			
OC	Bacteria; Firmicutes; Mollicutes; Mycoplasmataceae; Mycoplasma.			
OX	NCBI_TaxID=2097;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN=ATCC 33530 / G-37;			
RX	MEDLINE=96026346; PubMed=7569993;			
RA	Fraser C.M., Gocayne J.D., White O., Adams M.D., Clayton R.A.,			
RA	Fleischmann J.L., Weidman J.F., Small K.V., Sandusky M., Fuhrmann J.L.,			
RA	Fritchman R.D., Bult C.J., Kerlavage A.R., Sutton G., Kelley J.M.,			
RA	Nguyen D.T., Utterback T.R., Saudek D.M., Phillips C.A., Merrick J.M.,			
RA	Tomb J.-F., Dougherty B.A., Bost K.F., Hu P.-C., Lucier T.S.,			
RA	Peterson S.N., Smith H.O., Hutchison C.A. III, Venter J.C.;			
RT	"The minimal gene complement of Mycoplasma genitalium.";			
RL	Science 270:397-403 (1995).			
CC	[2]			
CC	SEQUENCE OF 256-427; 432-543 AND 1083-1140 FROM N.A.			
CC	STRAIN=ATCC 33530 / G-37;			
CC	MEDLINE=94075230; PubMed=8253680;			
CC	Peterson S.N., Hu P.-C., Bost K.F., Hutchison C.A. III;			
CC	"A survey of the Mycoplasma genitalium genome by using random			
CC	sequencing.";			
CC	J. Bacteriol. 175:7918-7930 (1993).			
CC	-i- FUNCTION: COULD BE AN ACCESSORY STRUCTURAL COMPONENT IN			
CC	CYTADHERENCE (BY SIMILARITY).			
CC				
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration			
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation -			
CC	the European Bioinformatics Institute. There are no restrictions on its			
CC	use by non-profit institutions as long as its content is in no way			
CC	modified and this statement is not removed. Usage by and for commercial			
CC	entities requires a license agreement (See http://www.isb-sib.ch/announce/			
CC	or send an email to license@isb-sib.ch).			
CC				
DR	EMBL; U39720; AAC71613.1; -			
DR	EMBL; U02245; AAC03400.1; -			
DR	EMBL; U02245; -; NOT ANNOTATED_CDS.			
DR	EMBL; U02175; AAD12458.1; -			
DR	EMBL; U02126; AAD12402.1; -			
DR	PIR; G64242; G64242.			
DR	TIGR; MG386; -			
KW	Cytadherence; Structural protein; Repeat; Complete proteome.			
FT	DOMAIN 1205 1389 2 X 32 AA REPEAT.			
FT	REPEAT 1205 1389 1-1.			
FT	REPEAT 1358 1389 1-2.			
FT	DOMAIN 891 1389 2 X 26 AA REPEAT.			
FT	REPEAT 1161 1186 2-1.			
FT	REPEAT 1310 1339 2-2.			
FT	CONFLICT 256 256 P -> S (IN REF. 2).			
FT	CONFLICT 304 304 S -> F (IN REF. 2).			
FT	SEQUENCE 1616 AA; 185678 MW; 6AF76A13AC49E4FF CRC64;			
SQ				
Query Match	4.7%; Score 189.5; DB 1; Length 1616;			
Best Local Similarity	22.3%; Pred No. 0.037;			
Matches	142; Conservative 78; Mismatches 205; Indels 213; Gaps 35;			

```

QY 75 FDLVDYEEVLGK-----LGIYD-----ADGSDGDFDVKVL----- 106
Db 1091 FDTVRHEAVFDKQQTOTGLEBPQVSSEAEVDDQTTDVGPEAVFDVQPEKTEVDFD 1150
QY 107 -LGLKERSITSEPAVPERAPPHTPEEQVPEABPNQIEDAKQIQSLLHEMVHAHVYE 165
Db 1151 DVNQKQVISEPQVQPGAEVPEPSAEAKFDSQVSDQSPQVLEEVQTPQIPQVPE 1210
QY 166 GEDLQOEDGPTGEPQOEDDEFLMATDVRDFETLE-PEVSHETESHYHVEEIVSOD-CN 223
Db 1211 SQPEATFD--TVQPEQTQPE-----AKFDSPEVTEQPEFSSEPTQO--HVESEASFDEN 1262
QY 224 QDMEMMSQENP--DS-----SEPVEDERLHDHDDTDTYOV-----YEQAVVEPL 269
Db 1263 YDFDENYDFDQSYSDSDQSPQVDDPNVDPEPNVEIESKSEQPEFQVQEQP- 1321
QY 270 ENGEIETVTAPE--DNPVE-----DSQ--VIVEVSIFPVEEQVPEPPFNRTKTDPEQK 323
Db 1322 --GEAVFEPSEAEKFDSPVESQDSQPEPLLEEVQTPQIPQVSEQPEATFDTVQPEQT 1378
QY 324 AKYKKKKPKLLNKFDKTIKAELDAEAKLRKRGKIEZAVNAFKELVRKYPOSPEARYCKA 383
Db 1379 PQEA-----KFD-----SP----- 1387
QY 384 CEDDLAEKRSNEVLRGAETQOE--VASLPDVPADLLKLSKRRSDRQOQFLGHRGSL 441
Db 1388 -----VETIQEPQVSSEPEV--VVQPNFEERKPE-----TVL 1417
QY 442 TLQRLVOLFP--NDTSLKNDLGVYLLIGDNNAKKVEEVLVSTPNDGFAKHVGFIL 498
Db 1418 EEPQADIEPEASEEESLDWELLVG-----NNSYGHVEP-----DG-EWVWAGFFG 1462
QY 499 KAO--NKIAPSIPLYKIEGIEGDPDGDGRFYFHL-QDAMQ-RVGNKEAYKVELGHRG 554
Db 1463 DDQKNKDA-TVKARE-----RDYPLIGDEVYGRYNNKGEWINGVDFYDESG 1509
QY 555 HFASV---WQSLYNNVGLKAQPMWTP-----KETGYTELKSLERNKLLIRDEGLAVMDK 607
Db 1510 DWLVDVQWKNRQPRIN--EAPKFEWKLIGNEEYGYE--DNEWNW----- 1551
QY 608 AKGLFLPEDENLRKGDWSOFTLWQGRNRNACKGAP 645
Db 1552 -----YDGEFDSQGNLWVQSEETENLADITKDIP 1582

RESULT 7
TRDN RABIT STANDARD; PRT; 705 AA.
AC Q28820; Q28636; Q28637; Q28643;
DT 30-MAY-2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DE 10-OCT-2003 (Rel. 42, Last annotation update)
DB Triadin.
GN TRDN.
OS Oryctolagus cuniculus (Rabbit).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
OX NCBI_TaxID=9986;
[1]
RN SEQUENCE FROM N.A., AND PARTIAL SEQUENCE (ISOFORMS SKELETAL).
RP STRAIN=New Zealand white; TISSUE=Skeletal muscle;
RC MEDLINE=93286104; PubMed=7685347;
RA Knudson C.M., Stang K.K., Moonaw C.R., Slaughter C.A., Campbell K.P.;
RT "Primary structure and topological analysis of a skeletal muscle-
specific junctional sarcoplasmic reticulum glycoprotein (triadin).";
RL J. Biol. Chem. 268:12646-12654 (1993).
[2]
RN SEQUENCE FROM N.A., AND PARTIAL SEQUENCE (ISOFORMS SKELETAL).
RP TISSUE=Skeletal muscle;
RC MEDLINE=94298946; PubMed=8026576;
RA Peng M., Fan H., Kirley T.B., Caswell A.H., Schwartz A.;
RT "Structural diversity of triadin in skeletal muscle and evidence of
its existence in heart.";
```

```

FEBS Lett. 348:17-20 (1994).
[3]
RN SEQUENCE FROM N.A., AND PARTIAL SEQUENCE (ISOFORMS CARDIAC).
RP TISSUE=Heart muscle;
RX MEDLINE=96132942; PubMed=8550602;
RA Guo W., Jorgensen A.O., Jones L.R., Campbell K.P.;
RT "Biochemical characterization and molecular cloning of cardiac
triadin.";
RT J. Biol. Chem. 271:458-465 (1996).
[4]
RN CARBOHYDRATE-LINKAGE SITES, AND INTERCHAIN DISULFIDE BONDS.
RX MEDLINE=96066664; PubMed=7578102;
RA Fan H., Brandt N.R., Caswell A.H.;
RT "Disulfide bonds, N-glycosylation and transmembrane topology of
skeletal muscle triadin.";
RL Biochemistry 34:14902-14908 (1995).
CC -!- FUNCTION: May be involved in anchoring calsequestrin to the
junctional sarcoplasmic reticulum and allowing its functional
coupling with the ryanodine receptor.
CC -!- SUBUNIT: Homooligomer of variable subunit number; disulfide-
linked.
CC -!- SUBCELLULAR LOCATION: Type II membrane protein. Sarcoplasmic
reticulum.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=6;
CC Comment=Additional isoforms seem to exist;
CC Name=Skeletal 1; Synonyms=ST1;
CC IsoId=Q28820-1; Sequence=Displayed;
CC Name=Cardiac 1; Synonyms=CTL1;
CC IsoId=Q28820-2; Sequence=VSP_004458, VSP_004460;
CC Name=Cardiac 2; Synonyms=CTL2;
CC IsoId=Q28820-3; Sequence=VSP_004459, VSP_004461;
CC Name=Cardiac 3; Synonyms=CTL3;
CC IsoId=Q28820-4; Sequence=VSP_004466;
CC Name=Skeletal 2; Synonyms=ST2;
CC IsoId=Q28820-5; Sequence=VSP_004462, VSP_004463, VSP_004464,
VSP_004465;
CC Name=Skeletal 3; Synonyms=ST3;
CC IsoId=Q28820-6; Sequence=VSP_004464, VSP_004465;
CC -!- TISSUE SPECIFICITY: Skeletal and cardiac muscle.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
-----
EMBL; U31540; AAC48496.1; -
EMBL; L10065; AAA31488.1; -
EMBL; U31555; AAC48497.1; -
EMBL; U34201; AAC48498.1; -
DR PIR; A45990; A45990.
DR Transmembrane; Sarcoplasmic reticulum; Glycoprotein;
KW Alternative splicing.
FT INIT MET 0
FT DOMAIN 1 46 CYTOPLASMIC.
FT TRANSMEM 47 67 POTENTIAL.
FT DOMAIN 68 705 LUMENAL.
FT CARBOHYD 74 74 N-LINKED (GLCNAC...) (POTENTIAL).
FT CARBOHYD 624 624 N-LINKED (GLCNAC...).
FT VARSPPLIC 264 285 LGKKQM (in isoform Cardiac 1).
FT FTId=VSP_004458.
FT DOYAFCRYMIDIVHGDLPKQSPAPPPSPPTQASRPPTA
FT QHAFCLKGC (in isoform Cardiac 2).
FT LPT -> ECIFLSAATPQGPINRQQLNDIHCHLKYKGGN
FT /FTId=VSP_004459.
FT Missing (in isoform Cardiac 1).
FT VARSPPLIC 286 705 /FTId=VSP_004460.
FT VARSPPLIC 308 705 Missing (in isoform Cardiac 2).
FT /FTId=VSP_004461.
```


EMBL; U47742; AAC50662.1; -.
 Genew; HGNC:13013; MYST3.
 MIN; 601408; -.
 GO; GO:0006323; P:DNA packaging; TAS.
 InterPro; IPR005818; Histone.H1/H5.
 InterPro; IPR002717; MOZ_SAS.
 InterPro; IPR001965; Znf_PHD.
 Pfam; PF01853; MOZ_SAS; 1.
 Pfam; PF00628; PHD; 2.
 SMART; SM00526; H15; 1.
 SMART; SM00249; PHD; 2.
 PROSITE; PS01359; ZF_PHD_1; 1.
 PROSITE; PS0016; ZF_PHD_2; 2.
 K W Proto-oncogene; Chromosomal translocation; Zinc-finger; Repeat;
 Nucleolar protein.
 FT ZN_FING 206 265 PHD-TYPE 1.
 FT ZN_FING 259 313 PHD-TYPE 2.
 FT DOMAIN 371 379 POLY-SER.
 FT ZN_FING 538 560 C2HC-TYPE.
 FT DOMAIN 788 801 POLY-GLU.
 FT DOMAIN 989 995 POLY-GLU.
 FT DOMAIN 1019 1026 POLY-ARG.
 FT DOMAIN 1069 1078 POLY-GLU.
 FT DOMAIN 1147 1150 POLY-LYS.
 FT DOMAIN 1221 1242 GLU-RICH.
 FT DOMAIN 1267 1302 GLU-RICH.
 FT DOMAIN 1411 1414 POLY-GLU.
 FT DOMAIN 1593 1597 POLY-SER.
 FT DOMAIN 1643 1704 GLN/PRO-RICH.
 FT DOMAIN 1897 1977 MET-RICH.
 FT SITE 1546 1547
 FT SITE BREAKPOINT FOR TRANSLOCATION TO FORM
 FT MOZ-CBP.

SQ SEQUENCE 2004 AA; 225054 MW; 9FFBAC3792854BA CRC64;

Query Match 4.4%; Score 175; DB 1; Length 2004;

Best Local Similarity 22.7%; Pred. No. 0.26; Indels 88; Gaps 13;

Matches 73; Conservative 48; Mismatches 113; Indels 88; Gaps 13;

Qy 122 BEAPFPEPEQVPEAFQNIIEAKEQISLLHEMVHAEHVEGDLQQEDGPTGSPQQ 181

Db 1205 QESSETVEPKDMF-----LPEEKKE-EEQAAEAEAEAGEEDAAASVEFAAPAD 1256

Qy 182 EDDEFLMATVDVDFEILEPVSHEETHSVHVEETVSQDCNQCMEMMSQENPDSDSEP 241

Db 1257 SSN-----SPETETKEPEVEEERKPRVSEEQROSEERQLEPPEPEEEDAAAT 1308

Qy 242 VVEDERLHDDTD-----VTQVVEEQAVYPLENE-GI----- 274

Db 1309 AQND-----HADDEDDGHLESTKKKELEEQPTREDVKEEPGVQESFLDANMQRKIKD 1365

Qy 275 -EITEVTAPPEDNPVEDSQVIVEVSIFPVEEQVPPETNRKTDTPPEQAKVKKKPKL 333

Db 1366 KEETELDS-BEEQPSHDTSVVSEQMA-----GSEDDHEEDSHTKKEELIEL 1409

Qy 334 LNKEDTKIKELDAEAKLRKKGKIEEAVNAFELVRKYQSPRAYKQACEDDLAEKRR 393

Db 1410 KEE-EEIHPSELDT-----ETQVAVQSLTQEESEHEGAY--QDCBETIA----- 1451

Qy 394 SNEVLRGAIETYQEVASILPDVP 415

Db 1452 -----ACQTLQSYTQADEDP 1466

RESULT 12

YNJ1 YEAST

ID YN1 YEAST STANDARD; PRT; 1240 AA.

AC P53935;

DT 01-OCT-1996 (Rel. 34, Created)

DT 01-OCT-1996 (Rel. 34, Last sequence update)

DT 01-OCT-1996 (Rel. 34, Last annotation update)

DE Hypothetical 141.5 kDa protein in YPT53-RHO2 intergenic region.

GN YNL091W OR N2231

OS Saccharomyces cerevisiae (Baker's yeast).

OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;

OC Saccharomycetales; Saccharomycetaceae; Saccharomycetes.

OX NCBI_TaxID=4932;

RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN=S288C / FY1679;

RA MEDLINE=96367601; PubMed=8771715;

RX Garcia-Cantalejo J.M., Boskovic J., Jimenez A.;

RT "Sequence analysis of a 14.2 kb fragment of Saccharomyces cerevisiae

chromosome XIV that includes the ypt53, trnAla and gsr m2 genes and

four new open reading frames.";

RL Yeast 12:599-608(1996).

CC -1- SIMILARITY: TO S.POMBE SPAC29E6.10C.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL outstation.
 CC the European Bioinformatics Institute. There are no restrictions on its
 use by non-profit institutions as long as its content is in no way
 modified and this statement is not removed. Usage by and for commercial
 entities requires a license agreement (See http://www.ebi.ac.uk/announcements/
 or send an email to license@sib.ac.uk).

CC -----

DR EMBL; X85811; CAAS9826.1; -;

DR EMBL; Z71367; CAAS9567.1; -;

DR PIR; S52734; S52734.

DR Germline; 143097; -.

DR SGD; S0005035; YNL091W.

DR GO; GO:0009651; P:salinity response; IMP.

KW Hypothetical protein.

FT DOMAIN 756 761 POLY-GLU.

SQ SEQUENCE 1240 AA; 141513 MW; 3FE9D265822D5778 CRC64;

Query Match

Best Local Similarity 4.3%; Score 172.5; DB 1; Length 1240;

Matches 103; Conservative 66; Mismatches 175; Indels 87; Gaps 21;

Qy 144 EDEAKEIQISLLHEMVHAEHVE-GEGLQEDGPTGPEQEDFLMATVDVDRFETLEPE 202

Db 460 EDEEDYDD-----YSEVAEDSEEVSEYEGIEAVEKPEHDE-----KNGIRETLHLS 508

Qy 203 VSH-----FTEHSYHVEETVSQDCNQCMEMMSQENP-----DSSEP 241

Db 509 YDHDHFKQNHPPHHYHSTSHSED-ELSEBEYISDIELPHDPKHFRHDDDLGDDEDEP 567

Qy 242 VVEDERLHDDTDVITYQ--VVEQAVVEPLENEGEITE-----VTAPPEDNPVEDSQV- 293

Db 568 EEDENEGDDEED-TYDSGLDTRLEEGKLIQIATKLLQSPRIMASYHEKQADNRLK 626

Qy 294 IVEVSIFPVEEQVPEPPETNRKTDTPPEQAKVKKKPKLNLKPKD-----TIKAE 345

Db 627 LLOE-----LEEKKRKRKEKKKKRKEKKRKLQQLAKEEKKRKEEKKRKEEKKEL 681

Qy 346 DAEKLRK---RGKIEAVNAFELVRKYQSPRAYKQACEDDLAEKRR--SNEVLRG 400

Db 682 EEREMRREARQKRVEEA-----KKKOEERKRLEEQREEMOEKQKKEELKRR 734

Qy 401 AIETYQEVASLPDVPADLLKLSLRKRRDRQOFLGHMRGSLTLQLR--VOLFPNDTSLK- 457

Db 735 REEKKKIREQKLEQKLEQKLEQKLEQKLEQKLEQKLEQKLEQKLEQKLEQKLEQK 790

Qy 458 -NDLGVGLLIGNDNNAKYYEVLVSTPNDFPAKHYGFILKAQNKIAESIPYKLEGIE 516

Db 791 FTENGVGPNVSSQSHPNMTNYQEDNSCSINDE-----ILKMNVAASKPVPSTGPN 842

Qy 517 SGD---PGTDD 524

Db 843 VHDLLPSTNN 853

RESULT 13

YHU6 YEAST

ID YHU6 YEAST

AC P38845; STANDARD; PRT; 465 AA.

DT 01-FEB-1995 (Rel. 31, Created)
 DT 01-FEB-1995 (Rel. 31, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Hypothetical 51.1 kDa protein in DCD1-MRPL6 intergenic region.
 GN YHR146W.
 OS Saccharomyces cerevisiae (Baker's yeast).
 OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
 OC Saccharomycetales; Saccharomycetaceae; Saccharomycetes.
 OX NCBI_TaxID=4932;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=S288c / AB972;
 RX MEDLINE=94378003; PubMed=8091229;
 RA Johnston M., Andrews S., Brinkman R., Cooper J., Ding H., Dover J.,
 RA Du Z., Favello A., Fulton L., Gattung S., Geisel C., Kirsten J.,
 RA Kucaba T., Hillier L.W., Jier M., Johnston L., Langston Y.,
 RA Latreille P., Louis E.J., Macri C., Mardis E., Menezes S., Mouser L.,
 RA Nhan M., Rifkin L., Riles L., St Peter H., Trevaskis E., Vaughan K.,
 RA Vignati D., Wilcox L., Wohlman P., Waterston R., Wilson R.,
 RA Vaudin M.;
 RT "Complete nucleotide sequence of Saccharomyces cerevisiae chromosome
 VIII.";
 RL Science 265:2077-2082(1994).
 CC -!- SIMILARITY: TO YEAST YNL173C.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL; U10397; AAB68982.1; --
 DR PIR; S46759; S46759.
 DR Germline; 139464;
 DR SGD; S0001189; CRFL.
 DR GO; GO:0005634; C:nucleus; IC.
 DR GO; GO:0003677; F:DNA binding; IDA.
 KW Hypothetical protein.
 SQ SEQUENCE 465 AA; 5115 MW; 30880758F37991C7 CRC64;
 Query Match 4.3%; Score 172; DB 1; Length 465;
 Best Local Similarity 22.8%; Pred. No. 0.06;
 Matches 90; Conservative 52; Mismatches 132; Indels 124; Gaps 16;
 QY 76 DLVDYEVVLGKGIYDADGDGDFDQDGVKLLG-----LLCKPPRSAGPPTSNNKKNKNNKRSK 141
 DB 92 DLVETQVAGASRIPEAGG-----LLCKPPRSAGPPTSNNKKNKNNKRSK 141
 QY 109 LKERTSEPAVPPEAEPTPE-----EQVPEAEAPONIEDAKSQIQS 153
 DB 142 LKKKSTNNKKNKSNESLDDNEEDGVTGTTTDTVTGTSREETPL-ABPTNVSKAPGNFHI 200
 QY 154 LLHEMVHAEVGEGLQDQDGTGEP-----QQEDDFLMATDQDFFETLEPEVSH 206
 DB 201 LPID-----QADTQSGIIGGGPVLVPNPKIETETRDVDAR-----E 243
 QY 207 ETEHSYHVEETVSQDQCNQDMNMSQEN--PDSSEPVVEDERLHDDTDVTVYVEEQ 264
 DB 244 LNERLNKKEEVPPEVAGPIVSESVTEKSPALPOADQPIVETKEVAHVQELTQV---EA 300
 QY 265 VYPELENEGTEITEVTAPPEDNPVDSQIVIEVS-IPFVEEQEVPFETNKRKTDDEQK 323
 DB 301 V-TPLNE-----PPFLPTPEAQISIPSSKVEPVEGSLQ----- 334
 QY 324 AKVKKKKPKLLNKFDKTIKAEKLRKRGKIEEAVNAFNAFKELVRKYPOSP-----RAR 378
 DB 335 -----SKLVEKREST-EGVLGSKKVENKAKKDEEFTLDPIVNAKPLPLTDSQTAE 386
 QY 379 YGKAQCEDDLAEKRSNENLVRGAITYQEVASLPDVA 416
 DB 387 GRKSPAVSEKEKKKQEE--KGSKEVKRSKTSKEKKS 422

RESULT 14

YCF2_OENV1
 ID YCF2_OENV1 STANDARD; PRT; 630 AA.
 AC P31569;
 DT 01-JUL-1993 (Rel. 26, Created)
 DT 01-JUL-1993 (Rel. 26, Last sequence update)
 DT 16-OCT-2001 (Rel. 40, Last annotation update)
 DE Hypothetical protein ycf2 (ORF 2280) (Fragment).
 GN YCF2.
 OS Oenothera villaricae.
 OG Chloroplast.
 OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
 OC Myrtales; Onagraceae; Oenothera.
 OX NCBI_TaxID=3941;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=93169690; PubMed=8435856;
 RA Nimyck R., Shoendorf T., Hachtel W.;
 RT "In-frame length mutations associated with short tandem repeats are
 RT located in unassigned open reading frames of Oenothera chloroplast
 RT DNA.";
 RL Curr. Genet. 23:265-270(1993).
 CC -!- SIMILARITY: Belongs to the ycf2 family.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL; X64615; CAA45896.1; --
 DR PIR; S29796; S29796.
 KW Chloroplast; Hypothetical protein.
 FT NON TER 1
 SQ SEQUENCE 630 AA; 72781 MW; 6AEFF7DC75B0BAA CRC64;
 Query Match 4.3%; Score 172; DB 1; Length 630;
 Best Local Similarity 20.9%; Pred. No. 0.087;
 Matches 107; Conservative 82; Mismatches 168; Indels 154; Gaps 22;
 QY 52 TSFFTFW-----MVIALLGVTMSVAVVFDLV-----DYEEVLKGIYDADGDGD 97
 DB 100 SSIKKWYFELGSMKKLTLLVLLTCSAGSIAQDLSPGPDEQNLTISYGLVENDSDLV 159
 QY 98 FDVDDAKVLLGLKERSTSEPAVPPEAEPTPEEQVPEAEAPONIEDE---AKEIQSL 154
 DB 160 HGLSD--IVHGLELELGALVSGSPTEEEVEGTEEEVEGTEEEVEGTEEEVEGTE 217
 QY 155 LHEMVHA--EHVEG-----EDLQDQDGTGEPQDDEFLMATDQDFFETLEPEV--SH 205
 DB 218 EEEVEGTEEEVEGTEEEVEGTEEEVEGTEEEVEGTEEEVEGTEEEVEGTEEEVEGTE 276
 QY 206 ETEHSYHVEETVSQDQCNQDMNMSQENPDSSEPV---EDERLHDDTDVTVYVEEQ 256
 DB 277 EEEVEGTEEEVEGTEEEVEGTEEEVEGTEEEVEGTEEEVEGTEEEVEGTEEEVEGTE 336
 QY 257 -----YQVYE-----EQAVTEP--LENEGIRIT----- 277
 DB 337 PRNPLDIQRLIYHQKYESELEEDDDDDVDPAQKMLEDLFSELVWSPRIWHPWDFLLD 396
 QY 278 -EVTAPPENPVEDSQV---IVEEVSIFFPVEE-----QQEVPPEPNRK 316
 DB 397 CEAETPAEPIPEEDDELPEDALETEVAVWGVVEEGEADDEEDVLEAQOQDELLLEEDE 456
 QY 317 TDDPEQAKVKKKPKK---LLNKFDKTIKAEKLAELK 351
 DB 457 LQSEDELDEEEEPKEEDELHHEEEEEEDEEDELQENDSEBFFRVKPIIPRHWIF 516

```

QY 352 RRGKGI-----EAVNAFKELV-----RKYPQSPRARYGKAQCEDD----- 387
Db 517 RKKDQEVLSYPEATEISLRLNLPKTRDAPKPRQWTKKQDKHYELLDRQ 576
QY 388 --LAEK---RSNEVLRG--AIETVQEVASL 411
Db 577 RWLITKRSKSGNGFFRSGNTSPSEYQVLSNL 607

RESULT 15
LAM2 MOUSE
ID LAM2 MOUSE STANDARD; PRT; 592 AA.
AC P21619;
DT 01-MAY-1991 (Rel. 18, Created)
DT 01-MAY-1991 (Rel. 18, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Lamin B2.
GN LMB2.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=91106216; PubMed=2102682;
RA Hoeger T.H., Zatioukal K., Waizenegger I., Krohne G.;
RT "Characterization of a second highly conserved B-type lamin present
RT in cells previously thought to contain only a single B-type lamin.";
RL Chromosoma 99:379-390(1990).
RN [2]
RN ERRATUM.
RP MEDLINE=91339548; PubMed=2102440;
RA Hoeger T.H., Zatioukal K., Waizenegger I., Krohne G.;
RL Chromosoma 100:67-69(1990).
CC -!- FUNCTION: Lamins are components of the nuclear lamina, a fibrous
CC layer on the nucleoplasmic side of the inner nuclear membrane,
CC which is thought to provide a framework for the nuclear envelope
CC and may also interact with chromatin.
CC -!- SUBCELLULAR LOCATION: Nucleoplasmic side of the inner nuclear
CC membrane.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=2;
CC Name=B2;
CC IsoId=P21619-1; Sequence=Displayed;
CC Name=B3;
CC IsoId=P48680-1; Sequence=External;
CC Note=No experimental confirmation available;
CC -!- PTM: B-TYPE LAMINS UNDERGO A SERIES OF MODIFICATIONS, SUCH AS
CC FARNESYLATION AND PHOSPHORYLATION. INCREASED PHOSPHORYLATION OF
CC THE LAMINS OCCURS BEFORE ENVELOPE DISINTEGRATION AND PROBABLY
CC PLAYS A ROLE IN REGULATING LAMIN ASSOCIATIONS.
CC -!- MISCELLANEOUS: The structural integrity of the lamina is strictly
CC controlled by the cell cycle, as seen by the disintegration and
CC formation of the nuclear envelope in prophase and telophase,
CC respectively.
CC -!- SIMILARITY: Belongs to the intermediate filament family. THIS IS A
CC B TYPE LAMIN.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC
CC -----
CC EMBL; X54098; CAA38032.1; -
CC PIR; B48315; B48315.
CC MGD; MG1:96796; Lmb2.
CC GO; GO:0005638; C:lamin filament; IDA.
CC InterPro; IPR001664; IF.
CC InterPro; IPR001322; IF_tail_C.
CC Pfam; PF00038; filament; 1.

```

```

DR Pfam; PF00932; IF tail; 1.
DR PROSITE; PS00226; IF: 1.
KW Intermediate filament; Coiled coil; Nuclear protein; Lipoprotein;
KW Prenylation; Phosphorylation; Alternative splicing.
FT DOMAIN 1 26 HEAD.
FT DOMAIN 27 378 ROD.
FT DOMAIN 379 592 TAIL.
FT DOMAIN 27 61 COIL 1A.
FT DOMAIN 62 73 COIL 1B.
FT DOMAIN 74 207 LINKER 1.
FT DOMAIN 208 234 LINKER 2.
FT DOMAIN 235 378 COIL 2.
FT DOMAIN 414 419 NUCLEAR LOCALIZATION SIGNAL (POTENTIAL).
FT DOMAIN 561 574 ASP/GLU-RICH
FT (HIGHLY ACIDIC, COULD BE INVOLVED IN
FT CHROMATIN BINDING).
FT S-farnesyl cysteine (By similarity).
FT LIPID 589 589
FT SEQUENCE 592 AA; 67029 MW; 7D5AC51BC9A5041E CRC64;
Query Match 4.2%; Score 169.5; DB 1; Length 592;
Best Local Similarity 20.6%; Pred. No. 0.11;
Matches 129; Conservative 113; Mismatches 244; Indels 141; Gaps 29;
QY 78 VDYEVVLGKGIYDADGDGDFDDAKYLLG--LKERSTSEPAVPEPAEPHTEPEQVP 135
Db 62 VTTREVSIGIKTLYES-----ELADARRVLDETARERARLQIEIGKVAQAELEEARSAKK 115
QY 136 VEAPQNTEDAKGIQSLH-----EMVHA-----EHVEGEDLQ-----OEDGPTGEPQ 180
Db 116 REGELTVAQGRVKD--LESFHRSEAEALATALSDNEGLETEVAELRAQLAKAEDGHAVAKK 174
QY 181 QEDDEFLMATDVRDFETLEPEVSHETESHVYHEETVSQDCNQOMEMMSQENPD--SS 239
Db 175 QLEKETLMRVLDENRCQSLQELAFSKVPEEVEVRETRRRHRRRLVEVDSSRQEQVDFQM 234
QY 240 EPPVEDERLHHTDDVTYQVVEQAVYEPLENGEIEITEVTAPPEDNPVEDSQVIVEVS 299
Db 235 AQALEDLSQHQDEQVRLYRVELEQTYQAKLDNAKL----- 269
QY 300 IFFVEEQEVPPETNRTDDPEQAKAKVKKPKLINKEDTKIKAELEDAEKLKRGKIEE 359
Db 270 ---LSDQNDKAAHARE--ELKEARNRVESLSYQLLG-----LQKQASAAE--NHIHELEE 318
QY 360 AVNAFKELVRYKYPQSPRARYGKAQCEDDLAEKRRSNEVLRGAIETVQEVASLP---DVPA 416
Db 319 ALRGEDKFKWLDKAK-----EQEMTEVR-----DRMQQQLAEYQELLDIKLALDWEI 366
QY 417 DLLKLSLKRSDRQOFLGHMGSLITLQRLVOLFPNDTSLKNDLGVYLLIGDNDNAKV 476
Db 367 SAYRKLLEGEERLK-LSPSPSSRITISRA-----TSSSSSSGVG-MSVGQRGKRR 417
QY 477 YEEVLSVTPNDGFAKVHYGFILKAQNKIAESIPYLKEGIESGDPDGTDDGRF--YFHLGDA 534
Db 418 LEDT--SGSPSRA--SRVSG-----SRLAQVATGVVNIIDEVDP---EGRFVRLKNSDK 466
QY 535 MORVGNKE-----AYKW---YELGHRKHGFASVWQSRSLYNVNG-----LKAQP 574
Db 467 DQSLGNRLKRLQVLSGEDIAKFTPKYVL--RAGQTVTVWAAGAGATSPSPSTLWKMSQT 524
QY 575 WTPETGYTELKSLERLNRWKLIRDEGLAVMDKAGLFLPEDENLRKGDWSQFTLWQOG 634
Db 525 NMGPGSFRTALVSADGBEVAVKAAKHSVQGRENG-----EEEEEEAEFGEEDLFHQ- 578
QY 635 RENENACKGAPKTCITLLEKFFPETTCGR 661
Db 579 -----QGDPRTE-----TSRGR 590

```

Search completed: May 5, 2004, 11:02:51

Job time : 20 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2004, 10:59:38 ; Search time 52 Seconds
(without alignments)
4599.285 Million cell updates/sec

Title: US-09-903-216-2

Perfect score: 4022

Sequence: 1 MAQRNNAKSSGNSSSGSGS.....IDVNMHPELTPOQRSLPAI 758

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

SPTREMBL.25:*
1: sp_archaea.*
2: sp_bacteria.*
3: sp_fungi.*
4: sp_human.*
5: sp_invertebrate.*
6: sp_mammal.*
7: sp_mhc.*
8: sp_organelle.*
9: sp_phage.*
10: sp_plant.*
11: sp_rodent.*
12: sp_virus.*
13: sp_vertebrate.*
14: sp_unclassified.*
15: sp_rvirus.*
16: sp_bacteriap.*
17: sp_archaeap.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	4022	100.0	758	4	Q9Y4J0
2	3209.5	79.8	739	11	Q9EPA6
3	3208.5	79.8	741	11	Q8BSY0
4	3175.5	79.0	725	11	Q8BQK0
5	2950	73.3	658	11	Q8CBM2
6	2919.5	72.6	689	11	Q9EQ66
7	1636	40.7	313	4	Q9H2C4
8	1457.5	36.2	299	4	Q9H291
9	1376.5	34.2	270	4	Q8TB28
10	1066.5	26.5	785	5	Q9G082
11	998.5	24.8	308	11	Q9EQ65
12	972.5	24.2	292	11	Q91WG6
13	890	22.1	270	11	Q920F9
14	798	19.8	872	5	Q93178
15	779.5	19.4	259	11	Q920F8
16	708.5	17.6	258	11	Q9EQ67

ALIGNMENTS

RESULT 1

Q9Y4J0 PRELIMINARY; PRT; 758 AA.

AC Q9Y4J0; 01-NOV-1999 (Tremblrel. 12, Created)
DT 01-NOV-1999 (Tremblrel. 12, Last sequence update)
DT 01-OCT-2003 (Tremblrel. 25, Last annotation update)
DE Aspartyl(asparaginyl)beta-hydroxylase.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=96420598; PubMed=8823296;
RA Lavalisere L.; Jia S.; Nishiyama M., de la Monte S., Stern A.M.,
Wands J.R., Friedman P.A.;
RT "Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in
hepatocellular carcinoma and cholangiocarcinoma.";
RL J. Clin. Invest. 98:1313-1323 (1996).
DR EMBL; S83325; AAB50779.1; -
DR InterPro; IPR007943; Asp-B-Hydro N.
DR InterPro; IPR007803; Asp Arg Hydrex.
DR InterPro; IPR008940; Prenyl_trans.
DR Pfam; PF05279; Asp-B-Hydro N; 1.
DR Pfam; PF05118; Asp-Arg_Hydro; 1.
SQ SEQUENCE 758 AA; 85890 MW; 4AF6F0AB4500AF0C CRC64;

Query Match 100.0%; Score 4022; DB 4; Length 758;
Best Local Similarity 100.0%; Pred. No. 9.1e-232;
Matches 758; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAQRNNAKSSGNSSSGSGSGSAGSSPGARRTKGGHKNKRGKGLSGTSPFTFMV 60
Db 1 MAQRNNAKSSGNSSSGSGSGSAGSSPGARRTKGGHKNKRGKGLSGTSPFTFMV 60
QY 61 IALLGVWTSVAVWVEDLYEVLKLIYDADGGDDVDKVLGLKERSTSEPAVP 120

Q920F7 mus musculus
Q9eq63 mus musculus
Q9eq62 mus musculus
Q8ch79 mus musculus
Q9nr11 homo sapien
Q28264 canis famil
Q9nr10 homo sapien
Q9cr06 mus musculus
Q9d7j8 mus musculus
Q53792 streptomyce
Q8ovp9 mus musculus
Q9h117 streptomyce
Q9uh39 homo sapien
Q9nsn3 homo sapien
Q9nie7 oryctolagus
Q9cu22 mus musculus
Q9eq69 mus musculus
Q8n4h3 homo sapien
Q8n316 homo sapien
Q8i1w63 homo sapien
Q96h00 homo sapien
Q91255 petromyzon
Q9gtx2 plasmodium
Q95ym2 procamburus
Q9vh10 drosophila
Q9dun0 kaposi's sa
Q8ij56 plasmodium
Q25860 plasmodium

```
Db 61 IALLGVWTSVAVVWFDLVYEEVLGKLGIDYDADGDGDFDVKADKVLGLKERSTSEAVP 120
QY 121 PEAEPHTEPEEQVPVPAEAEQNIQSLHHEWVHAHVEGEDLOQEDGPTGEPQ 180
Db 121 PEAEPHTEPEEQVPVPAEAEQNIQSLHHEWVHAHVEGEDLOQEDGPTGEPQ 180
QY 181 QEDDEFMLATDVDDRFETLPEVSHETSHYVEETVSCQNDMEEMSEQENPDSSSE 240
Db 181 QEDDEFMLATDVDDRFETLPEVSHETSHYVEETVSCQNDMEEMSEQENPDSSSE 240
QY 241 PVVEDERLHHDTDVTVYQVVEEQVAYEPELENEGIEIETVAPPDNPVBSQVIVEVSI 300
Db 241 PVVEDERLHHDTDVTVYQVVEEQVAYEPELENEGIEIETVAPPDNPVBSQVIVEVSI 300
QY 301 FPVEEQVEPEPEINRKTDDPEQAKVKKKKPKLLNKFDKTIKABLDAAELKRGKLEEA 360
Db 301 FPVEEQVEPEPEINRKTDDPEQAKVKKKKPKLLNKFDKTIKABLDAAELKRGKLEEA 360
QY 361 VNAFELVRKYPOSPRARYKAQCEDDLAEKRRSNEVLRGAIETYQEVASLPDVPADLLK 420
Db 361 VNAFELVRKYPOSPRARYKAQCEDDLAEKRRSNEVLRGAIETYQEVASLPDVPADLLK 420
QY 421 LSLKRRSDROQFLGHMGSLLTLQRLVQLPNDTSLKNDLGVGVLGGLDNDNAKKVYEEV 480
Db 421 LSLKRRSDROQFLGHMGSLLTLQRLVQLPNDTSLKNDLGVGVLGGLDNDNAKKVYEEV 480
QY 481 LSVTPNDGFAKHYGFILKAQNKIAESIPLYKEGIESGDPGTDDGRFYFHLGDAMQVGN 540
Db 481 LSVTPNDGFAKHYGFILKAQNKIAESIPLYKEGIESGDPGTDDGRFYFHLGDAMQVGN 540
QY 541 KEAYKAYELGKRGHGFASVWQSRSLYNVGLKAQPWTPKETYTELKYSERNWKLIRDE 600
Db 541 KEAYKAYELGKRGHGFASVWQSRSLYNVGLKAQPWTPKETYTELKYSERNWKLIRDE 600
QY 601 GLAVMDKAKGLFLPEDENLEKGDWSOFTLWQOGRNENACKGAPKCTCTLLEKPEPTGC 660
Db 601 GLAVMDKAKGLFLPEDENLEKGDWSOFTLWQOGRNENACKGAPKCTCTLLEKPEPTGC 660
QY 661 RRGQIKYSIMHPGTHVWPHGTPNCRMLRMLGLVLPKEGCKIRCANETRTWEGKVLIFD 720
Db 661 RRGQIKYSIMHPGTHVWPHGTPNCRMLRMLGLVLPKEGCKIRCANETRTWEGKVLIFD 720
QY 721 DSPEHEWQDASSFRLLIFIVDVWHPHLPDTPQRRSLPAI 758
Db 721 DSPEHEWQDASSFRLLIFIVDVWHPHLPDTPQRRSLPAI 758
```

RESULT 2
Q9EPA6 ID Q9EPA6 PRELIMINARY; PRT; 739 AA.
AC Q9EPA6; STRAIN=BALB/c; TISSUE=Liver;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Aspartyl beta-hydroxylase 6.6 kb transcript (Aspartyl beta-hydroxylase
DE 4.5 kb transcript).
GN 2310005F16RIK OR ASPH.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
[1]
RP SEQUENCE FROM N.A.
RC STRAIN=BALB/c; TISSUE=Liver;
RX MEDLINE=20564328; PubMed=10956665;
RA Dinchuk J.E., Henderson N.L., Burn T.C., Huber R., Ho S.P., Link J.,
RA O'Neil K.T., Focht R.J., Scully M.S., Hollis J.M., Hollis G.F.,
RA Friedman P.A.;
RT "Aspartyl beta -Hydroxylase (Asph) and an Evolutionarily Conserved
RT Isoform of Asph Missing the Catalytic Domain Share Exons with
RT Junction".
RL J. Biol. Chem. 275:39543-39554 (2000).
DR ENBL; AF289467; AAC40809.1; -.

```
DR ENBL; AF289467; AAC40809.1; -.
DR MGD; MGI:1914186; Asph.
DR InterPro; IPR007943; Asp-B-hydro N.
DR InterPro; IPR007803; Asp_Arg_Hydrox.
DR InterPro; IPR001440; TPR.
DR InterPro; IPR008941; TPR-like.
DR Pfam; PF05279; Asp-B-Hydro N; 1.
DR Pfam; PF05118; Asp_Arg_Hydrox; 1.
SQ SEQUENCE 739 AA; 82841 MW; 4DF9F642512CA4EB CRC64;

Query Match 79.8%; Score 3209.5; DB 11; Length 739;
Best Local Similarity 80.7%; Pred. No. 2.8e-183;
Matches 619; Conservative 41; Mismatches 70; Indels 37; Gaps 8;

QY 1 MAORKNAK -SSGNSSSSGSGSGS-----TSAGSSSPCARRETYKHGKHKRGKGLSG 51
Db 1 MAPRKNAKGGGNSSSSGSGSGSGSPSTGSSSSSPGARREAKHGKHKRGKRGISG 60
QY 52 TSFTTFWMTALLGVWTSVAVVWFDLVYEEVLGKLGIDYDADGDGDFDVKADKVLGLKE 111
Db 61 GSFTTFWMTALLGVWTSVAVVWFDLVYEEVLGKLGIDYDADGDGDFDVKADKVLGLKE 120
QY 112 RSTSEPAVPEEAPEHTEPEEQVPAEAEQNIQSLHHEWVHAHVEGEDLOQ 171
Db 121 RSPSERTFPP -EAETHAELEEQAPEGADIQNVEDEVKEIQSLIQESVHTDH----DL-E 174
QY 172 EDGPTGPEQEDDEFMLATDVDDRFETLPEVSHETSHYVEETVSCQNDMEEMWS 231
Db 175 ADGLAGEPOEVEDFUTVTDSDDRFEDLBPFTVHEIEDTYHYVEDTASQNHPNDEMETN 234
QY 232 EQENPDSSFPVVEDERLHHDTDVTVYQVVEEQVAYEPELENEGIEIETVAPPDNPVEDS 291
Db 235 EQENSDPSEAVTDAGVLLPHAEVVRHQDYDE -PVYEPSEHGVETIS-----DNTIDS 286
QY 292 QVTVEVSVFPVEEQVEPEPEINRKTDDPEQAKVKKKKPKLLNKFDKTIKABLDAAELK 351
Db 287 SIIEEINVASVEEQDQTPP-----VKKKKPKLLNKFDKTIKABLDAAELK 332
QY 352 RKRGKLEEVAVNAPELVRKYPOSPRARYKAQCEDDLAEKRRSNEVLRGAIETYQEVASL 411
Db 333 RKRGKLEEVAVNAPELVRKYPOSPRARYKAQCEDDLAEKRRSNEVLRGAIETYQEVASL 392
QY 412 PDVPADLLKLSKRRSDROQFLGHMGSLLTLQRLVQLPNDTSLKNDLGVGVLGGLDND 471
Db 393 PDAPTLVKLSKRRSERQOFLGHMGSLLTLQRLVQLPNDTSLKNDLGVGVLGGLDND 452
QY 472 NAKVYEEVLSVTPNDGFAKHYGFILKAQNKIAESIPLYKEGIESGDPGTDDGRFYFHL 531
Db 453 SAKVYEEVLSVTPNDGFAKHYGFILKAQNKIAESIPLYKEGIESGDPGTDDGRFYFHL 512
QY 532 GDAMQVGNKEAYKAYELGKRGHGFASVWQSRSLYNVGLKAQPWTPKETYTELKYSLE 591
Db 513 GDAMQVGNKEAYKAYELGKRGHGFASVWQSRSLYNVGLKAQPWTPKETYTELKYSLE 572
QY 592 RNWKLIRDEGLAVMDKAKGLFLPEDENLEKGDWSOFTLWQOGRNENACKGAPKCTCTLL 651
Db 573 RNWKLIRDEGLAVMDKAKGLFLPEDENLEKGDWSOFTLWQOGRNENACKGAPKCTCALL 632
QY 652 EKPEPTGTCRRGOIKYSIMHPGTHVWPHGTPNCRMLRMLGLVLPKEGCKIRCANETRTW 711
Db 633 EKPEPTGTCRRGOIKYSIMHPGTHVWPHGTPNCRMLRMLGLVLPKEGCKIRCANETRTW 692
QY 712 EBGKVLIFDPSPEHEWQDASSFRLLIFIVDVWHPHLPDTPQRRSLPAI 758
Db 693 EBGKVLIFDPSPEHEWQDASSFRLLIFIVDVWHPHLPDTPQRRSLPAI 739

RESULT 3
Q8BSY0 ID Q8BSY0 PRELIMINARY; PRT; 741 AA.
AC Q8BSY0;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
```


Db 318 LKRGKIEEAVNAFEELVRKYPOSPRARYKACEDDLAEKQSRNEVIRAIETYQEAAD 377
 QY 411 LPDVPADLLKLSIKRSDROQFLGHRGSLTTLQRLVQLPNDTSKNDLGVGYLLIGN 470
 Db 378 LPDAPDLDVLSIKRSESRQOFLGHRGSLTTLQRLVQLPNDTSKNDLGVGYLLIGN 437
 QY 471 DNAAKVVVEVLSTPNDFAKVHYGFLKAKNKAIESIPYLKEGIESGDPGTDGFRFYPH 530
 Db 438 DSAKKVVEVLSTPNDFAKVHYGFLKAKNKAIESIPYLKEGIESGDPGTDGFRFYPH 497
 QY 531 LGDAMORVGNKEAYKMYELGHKGHGFASVWQSRSLYVNGLKAKQPMWTPRETGYTELKSL 590
 Db 498 LGDAMORVGNKEAYKMYELGHKGHGFASVWQSRSLYVNGLKAKQPMWTPRETGYTELKSL 557
 QY 591 ERNWKILRDEGLAVMDKAKGLFLPEDENLREKGDWSOFTLWQGRNENACKGAPKTCIL 650
 Db 558 ERNWKILRDEGLAVMDKAKGLFLPEDENLREKGDWSOFTLWQGRNENACKGAPKTCIL 617
 QY 651 LEKFETTCRRGQIKYSIMHPGTHVWPHGTPNCRLRMLGLVLPKEGCKIRCANEETR 710
 Db 618 LEKFETTCRRGQIKYSIMHPGTHVWPHGTPNCRLRMLGLVLPKEGCKIRCANEETR 677
 QY 711 WEEGKVLIFDSSPEHEVWQDASSFRFLIFIVDVWHPHLPQRRSLPAI 758
 Db 678 WEEGKVLIFDSSPEHEVWQDASSFRFLIFIVDVWHPHLPQRRSLPAI 725

RESULT 5
 Q8CEM2

ID Q8CEM2 PRELIMINARY; PRT; 658 AA.
 AC Q8CEM2;
 DT 01-MAR-2003 (T-EMBLrel. 23, Created)
 DT 01-MAR-2003 (T-EMBLrel. 23, Last sequence update)
 DT 01-OCT-2003 (T-EMBLrel. 25, Last annotation update)
 DE Aspartate-beta-hydroxylase.
 GN ASPH.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OC NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=C57BL/6J; TISSUE=Urinary bladder;
 RX MEDLINE=22354683; PubMed=12466851;
 RA The FANTOM Consortium,
 RA the RIKEN Genome Exploration Research Group Phase I & II Team;
 RT "Analysis of the mouse transcriptome based on functional annotation of
 RT 60,770 full-length cDNAs."
 RL Nature 420:563-573 (2002).
 DR EMBL; AK035735; BAC29171.1;
 DR MGD; MGI:1914186; Asph.
 DR InterPro; IPR007943; Asp-B-hydro N.
 DR InterPro; IPR007803; Asp_Arg_Hydrox.
 DR InterPro; IPR008940; Prenyl_trans.
 DR InterPro; IPR001440; TPR.
 DR Pfam; PF05279; Asp-B-Hydro N; 1.
 DR Pfam; PF05118; Asp Arg Hydrox; 1.
 DR SMART; SM00028; TPR; 2.
 SQ SEQUENCE 658 AA; 75127 MW; 2BA0A5C8E06801C8 CRC64;

Query Match 73.3%; Score 2950; DB 11; Length 658;
 Best local similarity 80.7%; Pred. No. 7.3e-168;
 Matches 566; Conservative 36; Mismatches 53; Indels 44; Gaps 7;
 QY 59 MVIALLGWTSVAVVWFDLVYEVGLKGLYDADGDFDVEDDAKVLGLKERSISEPA 118
 Db 1 MVIALLGWTSVAVVWFDLVYEVGLKGLYDADGDFDVEDDAKVLGLKERSISEPT 60
 QY 119 VPP-EEAEPTPEEQVFPVEAEQNIIDEAEQIQSLHVMHAEHVEGEDLOEQDQPTG 177
 Db 61 FPPEEAEHAELEEQAPEGADIQNVEDEKQIQSLQSVHTDH---DL-EADGLAG 115

QY 178 EPQOEDEFLMATDVEDRLEPEVSHETSHVHEETVSQDQCNQDMEEMWSEQENPD 237
 Db 116 EPQOEDEFLMATDVEDRLEPEVSHETSHVHEETVSQDQCNQDMEEMWSEQENPD 173
 QY 238 SSEPVEDERLHHTDDVTYQVVEEQAVPEPLENEGIEITEVTPAPPEDNPVEDSQVIVEE 297
 Db 174 -----SEEVHRQDYDE-PVPESEHEGVAIS-----DNTIDSSIISEE 211
 QY 298 VSIFPVEEQOQVPPETNRTKDDDEQAKVKKKPKLLNKFPDKTIKAELOAAEKLRKGI 357
 Db 212 INVASVEEQOQTPP-----VKKKPKLLNKFPDKTIKAELOAAEKLRKGI 257
 QY 358 EEAVALFELVRKYPOSPRARYKACEDDLAEKQSRNEVIRAIETYQEAASLPDVPAD 417
 Db 258 EEAVALFELVRKYPOSPRARYKACEDDLAEKQSRNEVIRAIETYQEAASLPDVPAD 317
 QY 418 LLKLSIKRSDROQFLGHRGSLTTLQRLVQLPNDTSKNDLGVGYLLIGNDNKVVY 477
 Db 318 LVKLSIKRSESRQOFLGHRGSLTTLQRLVQLPNDTSKNDLGVGYLLIGNDNKVVY 377
 QY 478 EEVLSYTPNDGFAKVHYGFLKAKNKAIESIPYLKEGIESGDPGTDGFRFYPHLDGAMQR 537
 Db 378 EEVLSYTPNDGFAKVHYGFLKAKNKAIESIPYLKEGIESGDPGTDGFRFYPHLDGAMQR 437
 QY 538 VGNKEAYKMYELGHKGHGFASVWQSRSLYVNGLKAKQPMWTPRETGYTELKSLERNWKLI 597
 Db 438 VGNKEAYKMYELGHKGHGFASVWQSRSLYVNGLKAKQPMWTPRETGYTELKSLERNWKLI 497
 QY 598 RDEGLAVMDKAKGLFLPEDENLREKGDWSOFTLWQGRNENACKGAPKTCILLEKFPET 657
 Db 498 RDEGLAVMDKAKGLFLPEDENLREKGDWSOFTLWQGRNENACKGAPKTCILLEKFPET 557
 QY 658 TGCRRGQIKYSIMHPGTHVWPHGTPNCRLRMLGLVLPKEGCKIRCANEETRWEKVL 717
 Db 558 TGCRRGQIKYSIMHPGTHVWPHGTPNCRLRMLGLVLPKEGCKIRCANEETRWEKVL 617
 QY 718 IFDSSPEHEVWQDASSFRFLIFIVDVWHPHLPQRRSLPAI 758
 Db 618 IFDSSPEHEVWQDASSFRFLIFIVDVWHPHLPQRRSLPAI 658

RESULT 6
 Q9EQ66

ID Q9EQ66 PRELIMINARY; PRT; 689 AA.
 AC Q9EQ66;
 DT 01-MAR-2001 (T-EMBLrel. 16, Created)
 DT 01-MAR-2001 (T-EMBLrel. 16, Last sequence update)
 DT 01-OCT-2003 (T-EMBLrel. 25, Last annotation update)
 DE Aspartyl beta-hydroxylase.
 GN ASPH.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OC NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=20564328; PubMed=10956665;
 RA Dinchuk J.E., Henderson N.L., Burn T.C., Huber R., Ho S.P., Link J.,
 RA O'Neil K.T., Pocht R.J., Scully M.S., Hollis J.M., Hollis G.F.,
 RA Friedman P.A.;
 RT "Aspartyl beta-hydroxylase (Asph) and an evolutionarily conserved
 RT isoform of asph missing the catalytic domain share exons with
 RT junction."
 RL J. Biol. Chem. 275:39543-39554 (2000).
 RN [2]
 RP SEQUENCE FROM N.A.
 RA Henderson N.L., Dinchuk J.E., Burn T.C., Hollis G.F., Friedman P.A.;
 RL Submitted (MAR-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AF289215; AAG39913.1;
 DR EMBL; AF289205; AAG39913.1; JOINED.
 DR EMBL; AF289206; AAG39913.1; JOINED.
 DR EMBL; AF289207; AAG39913.1; JOINED.
 DR EMBL; AF289208; AAG39913.1; JOINED.

DR	EMBL; AF289209; AAC39913.1; JOINED.	
DR	EMBL; AF289210; AAC39913.1; JOINED.	
DR	EMBL; AF289211; AAC39913.1; JOINED.	
DR	EMBL; AF289212; AAC39913.1; JOINED.	
DR	EMBL; AF289213; AAC39913.1; JOINED.	
DR	EMBL; AF289214; AAC39913.1; JOINED.	
DR	MCD; MGI.1914186; Asph.	
DR	InterPro; IPR007943; Asp-B-hydro N.	
DR	InterPro; IPR007803; Asp_Arg_Hydrox.	
DR	InterPro; IPR001440; TPR.	
DR	InterPro; IPR008941; TPR-like.	
DR	Pfam; PF05279; Asp-B-Hydro N. 1.	
DR	Pfam; PF05118; Asp_Arg_Hydrox; 1.	
DR	SEQUENCE 689 AA; 77319 MW; 9CB916DF109F432C CRC64;	
QY	Query Match	72.6%; Score 2919.5; DB 11; Length 689;
QY	Best Local Similarity	74.7%; Pred. No. 5.2e-166;
QY	Matches 573; Conservative 39; Mismatches 68; Indels 87; Gaps 9	
QY	1 MAQRKNAK-SGNSSSSGSGSGS-----TSAGSSSPGARRETKHGHNKRGKGLSG 51	
Db	1 MAPRKNAKGGGNSSSSGSGSGSPSTGSSSSSGSGARR----- 43	
QY	52 TSPTFTWPIALGVWTSVAVMFVLVDVYBEVLKGLGIYDADGGDFDVKVLLGLKE 111	
Db	44 -----GKLGIVDADGGDFDVKVLLGLKE 70	
QY	112 RSTSEPAVPPEEAEPHTPEPQVPEAEAPONIEDEAKEQIQLSLHEVMYHAEHVEGEDLQQ 171	
Db	71 RSPSERTFPP-EAETHAELEQAPGADIQNVDEVKEQIQLSLQESVHTDH-----DL-E 124	
QY	172 EDGPTGBPQEDDFLMATDVDDRPETLEPEVSHETEHSYHVEETVSQDNCQNMDEEWS 231	
Db	125 ADGLAGSPQPEVEDFLWTSDDRFDELPGTVHVEIEDTVHVEDTASQNHFNDEMETN 184	
QY	232 EQNPDSSEPVEDERLHHDDTDDVYQVYERCAVYEPLENGIEETITETAPEDPNPVDS 291	
Db	185 EQNSDSEAVTDAGVLLPHAEVVRHQDYDE-PVYEPSEHGRGVEIS-----DNTIDDS 236	
QY	292 QVTAVEEVSIFPVEQBQVPVPTNKRKTDDPEQAKVKKKKPKLLANKFKDTIKAEIDAAEKL 351	
Db	237 SIIEEINVASVEEQDTPP-----VKKKKPKLLNKFDNTIKAEIDAAEKL 282	
QY	352 RKSGKTEAVNAFKELYRKYPQSPRARKYGAQCEDDLAEKRSNEVIRGAETTYQEVASL 411	
Db	283 RKSGKTEAVNAFPEELVKYPQSPRARKYGAQCEDDLAEKORSNEVIRRAETTYQEAADL 342	
QY	412 PDVPADLLKSLKRSDRQDFLGHMRSLLTLQRLVQLFPNDTSLKNDLGVGYLLIGND 471	
Db	343 PDAPTDLVKLSLKRSSRQDFLGHMRSLLTLQRLVQLFPDSTTLKNDLGVGYLLIGND 402	
QY	472 NAKKYEEVLVTPNDGFAKVHYGFILKAQNKIAESIPYLKEGIESGDPGTDGDFYFPHL 531	
Db	403 SAKKYEEVLNVTPNDGFAKVHYGFILKAQNKI SESIPYLKEGIESGDPGTDGDFYFPHL 462	
QY	532 GDAMQRVGNKEAYKWYELGHRKGHFASVWQRSLYNVNGLKAQPMWTPKETGYTELVKSL 591	
Db	463 GDAMQRVGNKEAYKWYELGHRKGHFASVWQRSLYNVNGLKAQPMWTPRETGYTELVKSL 522	
QY	592 RNWKILRDEGLAVMDKAGLFLPDEENIREKGDWSQFTLWQGRNENENACKGAPKTKTLL 651	
Db	523 RNWKILRDEGLAVMDKAGLFLPDEENIREKGDWSQFTLWQGRNENENACKGAPKTCALL 582	
QY	652 EKPPETTGCRGQIKYSIMHPGTHVPHGTPTNCLRMLHGLVITPEKGCCKIRCANETRTW 711	
Db	583 EKPSSETTGCRGQIKYSIMHPGTHVPHGTPTNCLRMLHGLVITPEKGCCKIRCANETRTW 642	
QY	712 EEGKVLIFDGSFEHEVWQDASSFLRIFIVDVVHPELTTPQQRSLPAI 758	
Db	643 EEGKVLIFDGSFEHEVWQDASSFLRIFIVDVVHPELTTPQQRSLPAI 689	

RESULT 7

RT Chromosomal Localization, and Gene Structure of Junctate, a Novel
RT Integral Calcium Binding Protein of Sarco(endo)plasmic Reticulum
RT Membrane.";

DR J. Biol. Chem. 275:39555-39568 (2000).

DR EMBL; AF306765; AAG42257.1; -

DR GO; GO:0005789; C:endooplasmic reticulum membrane; NAS.

DR GO; GO:0005509; F:calcium ion binding; NAS.

DR InterPro; IPR007943; Asp-B-hydro_N.

DR Pfam; PF05279; Asp-B-Hydro_N; 1.

SQ SEQUENCE 299 AA; 3385 MW; 658F88C34BC2CA37 CRC64;

Query Match 36.2%; Score 1457.5; DB 4; Length 299;

Best Local Similarity 94.2%; Pred. No. 3.1e-79;

Matches 278; Conservative 2; Mismatches 0; Indels 15; Gaps 1;

QY 34 RETKGGHNGKRGKGLSGTSFTTWPMVIALLGWTSVAVVWFDLVDYERVL----- 84

DB 5 KETKGGHNGKRGKGLSGTSFTTWPMVIALLGWTSVAVVWFDLVDYERVLAKAKDFRYN 64

QY 85 -----GKLGIVDADGDGDFDVKAKVLLGLKSTSEPAVPEEAPEHTEPEEQVPEA 138

DB 65 LSEVLOGKLGIVDADGDGDFDVKAKVLLGLKSTSEPAVPEEAPEHTEPEEQVPEA 124

QY 139 EPQNIIDEAKEQISLLHEMVAEHVEGEDLQEDGPTGEPQEDDEFMLATDVRPPT 198

DB 125 EPQNIIDEAKEQISLLHEMVAEHVEGEDLQEDGPTGEPQEDDEFMLATDVRPPT 184

QY 199 LPEVSHETESHYHVEETVSDCNDMEEMSEQENPDSPVVEDERLHDDTDVYQ 258

DB 185 LPEVSHETESHYHVEETVSDCNDMEEMSEQENPDSPVVEDERLHDDTDVYQ 244

QY 259 VVEEQAVYPLENEGIEITEVTAPPDNPVEDSQVIVEEIPVPEEQVEPPT 313

DB 245 VVEEQAVYPLENEGIEITEVTAPPDNPVEDSQVIVEEIPVPEEQVEPPT 299

RESULT 9

Q8TB28 PRELIMINARY; PRT; 270 AA.

AC Q8TB28;

DT 01-JUN-2002 (TrEMBLrel. 21, Created)

DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)

DE 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)

DE Similar to aspartate beta-hydroxylase.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OX NCBI_TaxID=9606;

[1]

SEQUENCE FROM N.A.

TISSUE=Pancreas;

RA Strausberg R.;

RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.

DR EMBL; BC025236; AH25236.1; -

DR InterPro; IPR007943; Asp-B-hydro_N.

DR Pfam; PF05279; Asp-B-Hydro_N; 1.

SQ SEQUENCE 270 AA; 29757 MW; 8551773C7272202A CRC64;

Query Match 34.28; Score 1376.5; DB 4; Length 270;

Best Local Similarity 85.94; Pred. No. 1.8e-74;

Matches 269; Conservative 1; Mismatches 0; Indels 43; Gaps 1;

QY 1 MAQRKNAKSSGSSGSGSGSTSGAGSSPGARRETKHGKHNGKRGKGLSGTSFTTFMW 60

DB 1 MAQRKNAKSSGSSGSGSGSGSTSGAGSSPGARRETKHGKHNGKRGKGLSGTSFTTFMW 60

QY 61 IALLGWTSVAVVWFDLVDYEEVLGKLGIVDADGDGDFDVKAKVLLGLKSTSEPAVP 120

DB 61 IALLGWTSVAVVWFDLVDYEEVLGKLGIVDADGDGDFDVKAKVLLGLKSTSEPAVP 120

QY 121 PEEAEPTEPEEQVPEAEPQNIIDEAKEQIOSLLHEMVAEHVEGEDLQEDGPTGEPQ 180

DB 121 PEEAEPTEPEEQVPEAEPQNIIDEAKEQIOSLLHEMVAEHVEGEDLQEDGPTGEPQ 163

QY 181 QEDDEFMLATDVRPPTLEPVEVSHETESHYHVEETVSDCNDMEEMSEQENPDSPSE 240

DB 164 -----ETEHSYHVEETVSDCNDMEEMSEQENPDSPSE 197

QY 241 PVVEDERLHDDTDVYQVVEEQAVYPLENEGIEITEVTAPPDNPVEDSQVIVEEVS 300

DB 198 PVVEDERLHDDTDVYQVVEEQAVYPLENEGIEITEVTAPPDNPVEDSQVIVEEVS 257

QY 301 PVVEEQVEPPT 313

DB 258 PVVEEQVEPPT 270

RESULT 10

Q8QB28 PRELIMINARY; PRT; 785 AA.

AC Q8QB28;

DT 01-MAR-2001 (TrEMBLrel. 16, Created)

DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)

DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)

DE Aspartyl beta-hydroxylase variant 1 (CG8421-PA).

GN ASPH OR CG8421 OR CG18658.

OS Drosophila melanogaster (Fruit fly).

OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;

OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;

OC Ephydroidea; Drosophilidae; Drosophila.

OX NCBI_TaxID=7227;

[1]

SEQUENCE FROM N.A.

MEDLINE=20564328; PubMed=10956655;

RA Dinchuk J.E., Henderson N.L., Burn T.C., Huber R., Ho S.P., Link J.,

RA O'Neil K.T., Focht R.J., Scully M.S., Hollis J.M., Hollis G.F.,

RA Friedman P.A.;

RT "Aspartyl beta -hydroxylase (Asph) and an Evolutionarily Conserved

RT Isoform of Asph Missing the Catalytic Domain Share Exons with

RT Junction.";

RL J. Biol. Chem. 275:39543-39554 (2000).

[2]

SEQUENCE FROM N.A.

STRAIN=Berkeley;

RC MEDLINE=20196006; PubMed=10731132;

RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,

RA Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,

RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,

RA Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,

RA Brandon R.C., Rogers Y.-H.C., Blaise R.G., Champe M., Pfeiffer B.D.,

RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,

RA Abril J.P., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,

RA Ballaw R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,

RA Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,

RA Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,

RA Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,

RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,

RA de Pablo S., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,

RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,

RA Durbin K.J., Evangelista C.C., Ferraz C., Ferreira S., Fleischmann W.,

RA Fessler K., Gabrielian A.B., Garg N.S., Gelbart W.M., Glasser K.,

RA Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,

RA Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Houck J.,

RA Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,

RA Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,

RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,

RA Lasko P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,

RA Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,

RA Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,

RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,

RA Nelson D.R., Nelson K.A., Nixon K., Nusser D.R., Pacleb J.M.,

RA Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,

RA Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,

RA Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,

RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,

RA Spiers R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2004, 11:01:09 ; Search time 23 Seconds
(without alignments)
1701.412 Million cell updates/sec

Title: US-09-903-216-2

Perfect score: 4022

Sequence: 1 MAQRKNAKSGNSGSSGSGS.....IVDVHPELTQRRSLPAI 758

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents AA.*

- 1: /cgn2_6/ptodata/2/iaa/5A_COMB.pep.*
- 2: /cgn2_6/ptodata/2/iaa/5B_COMB.pep.*
- 3: /cgn2_6/ptodata/2/iaa/6A_COMB.pep.*
- 4: /cgn2_6/ptodata/2/iaa/6B_COMB.pep.*
- 5: /cgn2_6/ptodata/2/iaa/PTUS_COMB.pep.*
- 6: /cgn2_6/ptodata/2/iaa/backfiles.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1334	33.2	255	3	US-09-040-485-2
2	1320	32.8	255	4	US-09-702-705-1806
3	1320	32.8	255	4	US-09-736-457-1806
4	1320	32.8	255	4	US-09-671-325-1806
5	1199	4.9	783	6	5231168-2
6	197.5	4.9	320	4	US-09-252-991A-29355
7	197.5	4.9	1018	1	US-08-072-610-2
8	197.5	4.9	1018	2	US-08-719-822B-2
9	197.5	4.9	1018	3	US-09-092-458-2
10	190.5	4.7	1162	4	US-08-728-323A-2
11	190.5	4.7	1162	4	US-09-298-568-2
12	190.5	4.7	1162	4	US-09-410-399-2
13	189.5	4.7	312	4	US-09-328-352-8015
14	177.5	4.4	565	3	US-08-961-083-218
15	177.5	4.4	565	3	US-09-536-784-218
16	177	4.4	327	4	US-09-489-039A-10158
17	172.5	4.3	700	4	US-09-107-532A-5094
18	163	4.1	411	2	US-08-741-134-6
19	163	4.1	2662	4	US-09-595-684B-31
20	162.5	4.0	310	4	US-09-252-991A-26511
21	162	4.0	1282	4	US-09-543-681A-5419
22	160	4.0	688	3	US-09-141-047-8
23	156.5	3.9	506	2	US-08-820-170A-19
24	156.5	3.9	506	3	US-09-055-699-19
25	156.5	3.9	506	3	US-09-273-565-19
26	156.5	3.9	506	4	US-09-565-538-19
27	156.5	3.9	506	4	US-09-661-468-19

28	156.5	3.9	506	4	US-09-976-165-19	Sequence 19, Appl
29	154.5	3.8	1196	4	US-09-107-532A-3944	Sequence 3944, Ap
30	153.5	3.8	1898	1	US-08-056-200-94	Sequence 94, Appl
31	153.5	3.8	1898	2	US-08-800-644-94	Sequence 94, Appl
32	152.5	3.8	984	1	US-08-242-932-2	Sequence 2, Appl
33	152.5	3.8	984	1	US-08-714-481-2	Sequence 2, Appl
34	152.5	3.8	984	5	PCT-US95-06111-2	Sequence 2, Appl
35	151.5	3.8	1972	4	US-08-875-435B-4	Sequence 4, Appl
36	151	3.8	404	4	US-09-554-080A-3	Sequence 3, Appl
37	151	3.8	436	4	US-09-554-080A-2	Sequence 3, Appl
38	150.5	3.7	3878	4	US-09-914-259-11	Sequence 11, Appl
39	150	3.7	571	4	US-09-216-393B-327	Sequence 327, App
40	149.5	3.7	1164	3	US-08-923-992A-10	Sequence 10, Appl
41	149	3.7	967	4	US-09-914-259-21	Sequence 21, Appl
42	148.5	3.7	816	2	US-08-533-306A-6	Sequence 6, Appl
43	148.5	3.7	816	2	US-08-742-923A-6	Sequence 6, Appl
44	148	3.7	258	3	US-08-961-083-90	Sequence 90, Appl
45	148	3.7	258	4	US-09-536-784-90	Sequence 90, Appl

ALIGNMENTS

RESULT 1

US-09-040-485-2
; Sequence 2, Application US/09040485
; Patent No. 6166176
; GENERAL INFORMATION:
; APPLICANT: Radosevich, James A.
; TITLE OF INVENTION: A GENE ENCODING A NOVEL MARKER FOR
; TITLE OF INVENTION: CANCER
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BRINKS, HOFER, GILSON & LIONE
; STREET: NBC Tower - Suite 3600, 455 N. Cityfront
; STREET: Plaza Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60611-5599
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/040,485
; FILING DATE: 17-MAR-1998
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Martin, Alice O.
; REGISTRATION NUMBER: 35,601
; REFERENCE/DOCKET NUMBER: 8998/3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312-321-4200
; TELEFAX: 312-321-4299
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 255 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-09-040-485-2

Query Match 33.2%; Score 1334; DB 3; Length 255;

Best Local Similarity 99.6%; Pred. No. 1.6e-100;

Matches 254; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 59 MYIALIGVWTSVAVVFDLVYEEVGLGIYDADGDGDFVDDAKVLGLKERSTSEPA 118

Db 1 MYIALIGVWTSVAVVFDLVYEEVGLGIYDADGDGDFVDDAKVLGLKERSTSEPA 60

QY 119 VPPEAEPTHEPEQVPVEAEFQNIEDAEKIQISLLHEMVHAEHVEGDLOQEDGPTGE 178

```
Db 61 VPPEAEPTPEEQVPEAPQNIIEDEAKEQISLLHEMVHAEHVEGEDLQQEDGPTGE 120
QY 179 PQQEDDEFLMATDVDDRFETLEPEVSHHEEHSYHVEETVSQDCNQDMEEMMSEQENPDS 238
Db 121 PQQEDDEFLMATDVDDRFETLEPEVSHHEEHSYHVEETVSQDCNQDMEEMMSEQENPDS 180
QY 239 SEPVEDERLHDDTDDVTYQVYEEQAVYEPLENEGIEITEVTAPPENPVEDSQVIVEEV 298
Db 181 SEPVEDERLHDDTDDVTYQVYEEQAVYEPLENEGIEITEVTAPPENPVEDSQVIVEEV 240
QY 299 SIFPVEEQEQVPPPT 313
Db 241 SIFPVEEQEQVPPPT 255

RESULT 2
US-09-702-705-1806
; Sequence 1806, Application US/09702705
; Patent No. 6504010
; GENERAL INFORMATION:
; APPLICANT: Wang, Tongtong
; APPLICANT: Bangur, Chaitanya S.
; APPLICANT: Lodes, Michael A.
; APPLICANT: Fanger, Gary
; APPLICANT: Vedvick, Tom
; APPLICANT: Carter, Darrick
; APPLICANT: Retter, Marc
; APPLICANT: Mannion, Jane
; APPLICANT: Fan, Liqun
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY AND
; FILE REFERENCE: 210121.478C14
; CURRENT APPLICATION NUMBER: US/09/702,705
; CURRENT FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 1833
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 1806
; LENGTH: 255
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-702-705-1806

Query Match 32.8%; Score 1320; DB 4; Length 255;
Best Local Similarity 98.8%; Pred. No. 2.1e-99;
Matches 252; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 59 MVIALLGWTSVAVVWFDLVDEEVLGKGIYDADGDFDQDDAKVLLGLKERSTSEPA 118
Db 1 MVIALLGWTSVAVVWFDLVDEEVLGKGIYDADGDFDQDDAKVLLGLKERSTSEPA 60
QY 119 VPPEAEPTPEEQVPEAPQNIIEDEAKEQISLLHEMVHAEHVEGEDLQQEDGPTGE 178
Db 61 VPPEAEPTPEEQVPEAPQNIIEDEAKEQISLLHEMVHAEHVEGEDLQQEDGPTGE 120
QY 179 PQQEDDEFLMATDVDDRFETLEPEVSHHEEHSYHVEETVSQDCNQDMEEMMSEQENPDS 238
Db 121 PQQEDDEFLMATDVDDRFETLEPEVSHHEEHSYHVEETVSQDCNQDMEEMMSEQENPDS 180
QY 239 SEPVEDERLHDDTDDVTYQVYEEQAVYEPLENEGIEITEVTAPPENPVEDSQVIVEEV 298
Db 181 SEPVEDERLHDDTDDVTYQVYEEQAVYEPLENEGIEITEVTAPPENPVEDSQVIVEEV 240
QY 299 SIFPVEEQEQVPPPT 313
Db 241 SIFPVEEQEQVPPPT 255

US-09-702-705-1806
```

```
Query Match 32.8%; Score 1320; DB 4; Length 255;
Best Local Similarity 98.8%; Pred. No. 2.1e-99;
Matches 252; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 59 MVIALLGWTSVAVVWFDLVDEEVLGKGIYDADGDFDQDDAKVLLGLKERSTSEPA 118
Db 1 MVIALLGWTSVAVVWFDLVDEEVLGKGIYDADGDFDQDDAKVLLGLKERSTSEPA 60
QY 119 VPPEAEPTPEEQVPEAPQNIIEDEAKEQISLLHEMVHAEHVEGEDLQQEDGPTGE 178
Db 61 VPPEAEPTPEEQVPEAPQNIIEDEAKEQISLLHEMVHAEHVEGEDLQQEDGPTGE 120
QY 179 PQQEDDEFLMATDVDDRFETLEPEVSHHEEHSYHVEETVSQDCNQDMEEMMSEQENPDS 238
Db 121 PQQEDDEFLMATDVDDRFETLEPEVSHHEEHSYHVEETVSQDCNQDMEEMMSEQENPDS 180
QY 239 SEPVEDERLHDDTDDVTYQVYEEQAVYEPLENEGIEITEVTAPPENPVEDSQVIVEEV 298
Db 181 SEPVEDERLHDDTDDVTYQVYEEQAVYEPLENEGIEITEVTAPPENPVEDSQVIVEEV 240
QY 299 SIFPVEEQEQVPPPT 313
Db 241 SIFPVEEQEQVPPPT 255
```

```
RESULT 3
US-09-736-457-1806
; Sequence 1806, Application US/09736457
; Patent No. 6509448
; GENERAL INFORMATION:
```

```
; APPLICANT: Wang, Tongtong
; APPLICANT: Bangur, Chaitanya S.
; APPLICANT: Lodes, Michael A.
; APPLICANT: Fanger, Gary
; APPLICANT: Vedvick, Tom
; APPLICANT: Carter, Darrick
; APPLICANT: Retter, Marc
; APPLICANT: Mannion, Jane
; APPLICANT: Fan, Liqun
; APPLICANT: Wang, Aijun
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY AND
; FILE REFERENCE: 210121.478C15
; CURRENT APPLICATION NUMBER: US/09/736,457
; CURRENT FILING DATE: 2000-12-13
; NUMBER OF SEQ ID NOS: 1864
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 1806
; LENGTH: 255
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-736-457-1806

Query Match 32.8%; Score 1320; DB 4; Length 255;
Best Local Similarity 98.8%; Pred. No. 2.1e-99;
Matches 252; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 59 MVIALLGWTSVAVVWFDLVDEEVLGKGIYDADGDFDQDDAKVLLGLKERSTSEPA 118
Db 1 MVIALLGWTSVAVVWFDLVDEEVLGKGIYDADGDFDQDDAKVLLGLKERSTSEPA 60
QY 119 VPPEAEPTPEEQVPEAPQNIIEDEAKEQISLLHEMVHAEHVEGEDLQQEDGPTGE 178
Db 61 VPPEAEPTPEEQVPEAPQNIIEDEAKEQISLLHEMVHAEHVEGEDLQQEDGPTGE 120
QY 179 PQQEDDEFLMATDVDDRFETLEPEVSHHEEHSYHVEETVSQDCNQDMEEMMSEQENPDS 238
Db 121 PQQEDDEFLMATDVDDRFETLEPEVSHHEEHSYHVEETVSQDCNQDMEEMMSEQENPDS 180
QY 239 SEPVEDERLHDDTDDVTYQVYEEQAVYEPLENEGIEITEVTAPPENPVEDSQVIVEEV 298
Db 181 SEPVEDERLHDDTDDVTYQVYEEQAVYEPLENEGIEITEVTAPPENPVEDSQVIVEEV 240
QY 299 SIFPVEEQEQVPPPT 313
Db 241 SIFPVEEQEQVPPPT 255

US-09-736-457-1806

RESULT 4
US-09-671-325-1806
; Sequence 1806, Application US/09671325
; Patent No. 6667154
; GENERAL INFORMATION:
; APPLICANT: Wang, Tongtong
; APPLICANT: Bangur, Chaitanya S.
; APPLICANT: Lodes, Michael A.
; APPLICANT: Fanger, Gary
; APPLICANT: Vedvick, Tom
; APPLICANT: Carter, Darrick
; APPLICANT: Retter, Marc
; APPLICANT: Mannion, Jane
; APPLICANT: Fan, Liqun
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY AND
; FILE REFERENCE: 210121.478C12
; CURRENT APPLICATION NUMBER: US/09/671,325
; CURRENT FILING DATE: 2000-09-26
; NUMBER OF SEQ ID NOS: 1825
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 1806
; LENGTH: 255
; TYPE: PRT
; ORGANISM: Homo sapiens
```


US-09-671-325-1806

Query Match 32.8%; Score 1320; DB 4; Length 255;
Best Local Similarity 98.8%; Pred. No. 2.1e-99;
Matches 252; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 59 MVIALGVTWTSVAVVDFLDVYEEVGLKGIYDADGDFDQDDAKVLLGLKERSTSEPA 118
DB 1 MVIALGVTWTSVAVVDFLDVYEEVGLKGIYDADGDFDQDDAKVLLGLKERSTSEPA 60

QY 119 VPPEAEHPTEPEQVPEAEQNIEDAEKQIQLLHEMVAHVGEGLQEDGPTGE 178
DB 61 VPPEAEHPTEPEQVPEAEQNIEDAEKQIQLLHEMVAHVGEGLQEDGPTGE 120

QY 179 PQQDEDEFLMATDVRDFTLEPEVSHETESHVVEETVSDCQNDMEEMSEQENPDS 238
DB 121 PQQDEDEFLMATDVRDFTLEPEVSHETESHVVEETVSDCQNDMEEMSEQENPDS 180

QY 239 SEPVEDERLHHDTDVTVYQVVEQAVPEPLNEGIEITETVAPPEDNPVEDSQVIVREV 298
DB 181 SEPVEDERLHHDTDVTVYQVVEQAVPEPLNEGIEITETVAPPEDNPVEDSQVIVREV 240

QY 299 SIFPVEEQQVPPET 313
DB 241 SIFPVEEQQVPPET 255

RESULT 5

5231168-2

Patent No. 5231168
; APPLICANT: DZIEGIEL, MORTEN; BORRE, MARTIN; JEPSEN, SOREN;
; YUUST, JENS; RIENECK, KLAUS; WIND, ANNETTE; JAKOBSEN, PALLE H.
; TITLE OF INVENTION: MALARIA ANTIGEN
; NUMBER OF SEQUENCES: 19
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/409,658
; FILING DATE: 18-SEP-1989
; SEQ ID NO:2:
; LENGTH: 783
5231168-2

Query Match 4.9%; Score 199; DB 6; Length 783;
Best Local Similarity 20.6%; Pred. No. 1.6e-07;
Matches 143; Conservative 134; Mismatches 237; Indels 180; Gaps 36;

QY 81 BEVLGKLGIDYADGDFD-----DVDDAKVL---LGLKERSTSPAPVPE--BAE 125
DB 119 DRESGESGLVDNE-SGDPEEPNHEFEFPQNDSELSNELVSEKSVSEPAHVIVSEK 177

QY 126 PHTPEEQVPEAEQNIEDAEKQIQLLHEMVAHVGEGLQEDGPTG----- 177
DB 178 SVSEPAHVEIVSEKST--SEPAHVESV-----SEQNNPSEKKOGFVPSKPFEBIE 229

QY 178 ---EPQEDDEFLMATDVRDFTLEP-----EVSHEETESHVVEETVSDCQD 224
DB 230 KVDVQPKIVDLQIIPENFVDSQNPQEPVPEPVSEKVPSEENKHA-SVDEPVEK--KE 286

QY 225 DMEEMSEQENPDSSE---PVVEDERLHHDTDV--TYQVVEQAVVEPLENEGIEITETV 280
DB 287 NVSEVVEEKQNSQESVEEIPVNEDE-----FEDVHTEQLDLHKTVP---EIVEVEEIP 338

QY 281 APPENDNPVEDSQVI--VEEVSIFP-----VEPQEQVPEPTEPNK 316
DB 339 SELHENEVAHPEIVEIEEV--FPPEPNQNEFOINEDDKSAHIQHEIVEVEEILPEDDKN 396

QY 317 TDDPEQKAVKKPKLLINKFDKTKAELEDAE-----KLKRGKIEEAVNAFKELVRK 370
DB 397 EKVEHIVEVEEILPE-----DNKEGQHEIVEVEEILPEDDKNEKVEHIVEVEEILPE 451

QY 371 YPQSPRARYGKAQCEDDLAEKRSNVLRGALITYQEVASLPDVPAD-----LLKLK 422
DB 452 -DKNEGQHEIVEVEEILPEDK--NEKVEHIVEVEEII-----LPEDKNEKQHEIVEVE 503

QY 423 LKRRSDROQFLGHRGSLTLQLRVQLFPNDTSLKNDLG-----VGYLLIGDNDNAKV 476
DB 504 EILPEDKNEKQVH-----EIVEVEEILPED-----KNEKGQHEIVEVEEILPEDKNEKQ 554

QY 477 YE--EVLVSVTNDGPAKHYGFI-----LKAQNKTAESIPYLKEGIESGDPTGD 523
DB 555 HEIVEVEEILPEDKNEKQHEIVEVEEILPEDKNEKQHEIVEVEEILPEIVE----- 607

QY 524 DGRFYHLGDAMQVRGNKEAVKWEGLGHRGHFASVWORSLYN---VNLKAQPMWTPK- 579
DB 608 -----TEEVPSONNNENIETIKPEEKNEF-SVEKAIPQEPVPTLNENENWTPXP 659

QY 580 ---ETGYTELKSLERNWKLIRD-----EGLAVMDKAKGL--FLPEDENLREKGDWSQFT 629
DB 660 SEGESTKPDIVQI-----KIVQENKPNKKEPVDVGPXKHEVQNIQEDDDEDDDDIDFE 714

QY 630 LW-----QOGRRENENACKGAPKTCITLLEKFFETT 658
DB 715 GLSRKXDEKSDSNKNKKKSSFTIYSTKKFKKVS 748

RESULT 6

US-09-252-991A-29355

Sequence 29355, Application US/09252991A
Patent No. 6851795
GENERAL INFORMATION:
APPLICANT: Marc J. Rubenfield et al.
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
FILE REFERENCE: 107196.136
CURRENT APPLICATION NUMBER: US/09/252,991A
CURRENT FILING DATE: 1999-02-18
PRIOR APPLICATION NUMBER: US 60/074,788
PRIOR FILING DATE: 1998-02-18
PRIOR APPLICATION NUMBER: US 60/094,190
PRIOR FILING DATE: 1998-07-27
NUMBER OF SEQ ID NOS: 33142
SEQ ID NO 29355
LENGTH: 320
TYPE: PRT
ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-29355

Query Match 4.9%; Score 197.5; DB 4; Length 320;
Best Local Similarity 25.9%; Pred. No. 5.7e-08;
Matches 58; Conservative 34; Mismatches 85; Indels 47; Gaps 9;

QY 551 HKRGHFASVWQSRSLYVNVGLKAQPMWTPKETYTEL-----VKSL 590
DB 31 HFRGRARLPFLRQLVNHSA-----WFAP---YNSLMYLFSSVPSPKPYLDRSRFPDELDEL 81

QY 591 ERNWKILRDEGLAVMDKAKGLFLPEDENLRKKG-----DWSQFTL-WOQGRRENACK 642
DB 82 KNNWQTIRREALNLFDG---YIRALANNNEAGFGSPFKGKWRFLYTWYDGL-PSAQ 137

QY 643 GAKPTCTLLEKFPETTCGRRGQIKYSIMHPGTHVWHPGTPNCRIMHGLVLP-KEGCK 701
DB 138 LCPKTVELVSRIPNVKGA-----MFTLLPGGSHLPHRDPFGGSLRYHLGLSTPNSDNCR 192

QY 702 IRCANETRTWEGKVLIEDSFEHEVWQDASSFLIFIVDVWHP 745
DB 193 IYVQGPYAMRDGEDVMPFETVFWHWKNETEQTRVILFCDIERP 236

RESULT 7

US-08-072-610-2

Sequence 2, Application US/08072610
Patent No. 5532133
GENERAL INFORMATION:
APPLICANT: Barnwell, John
TITLE OF INVENTION: Plasmodium vivax Blood Stage Antigens,
TITLE OF INVENTION: Monoclonal Antibodies, and Diagnostic Assays
NUMBER OF SEQUENCES: 2

; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Darby and Darby
 ; STREET: 805 Third Ave.
 ; CITY: New York
 ; STATE: New York
 ; COUNTRY: USA
 ; ZIP: 10022-7513
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patent In Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/072,610
 ; FILING DATE: 19930602
 ; CLASSIFICATION: 435
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Gogoris, Adda
 ; REGISTRATION NUMBER: 29,714
 ; REFERENCE/DOCKET NUMBER: 5986/07686
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (212)527-7700
 ; TELEFAX: (212)753-6237
 ; TELEX: 236687
 ; INFORMATION FOR SEQ ID NO: 2:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 1018 amino acids
 ; TYPE: AMINO ACID
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: protein
 ; HYPOTHEICAL: YES
 ; ANTI-SENSE: NO
 ; FRAGMENT TYPE: C-terminal
 ; ORIGINAL SOURCE:
 ; ORGANISM: Plasmodium vivax
 ; IMMEDIATE SOURCE:
 ; CLONE: PwMB3.3.1
 ; US-08-072-610-2

Query Match 4.9%; Score 197.5; DB 1; Length 1018;
 Best Local Similarity 23.2%; Pred. No. 3.1e-07;
 Matches 128; Conservative 86; Mismatches 205; Indels 133; Gaps 27;

QY 109 LKERSTSEPAVPEEAE-----HTEPEEQVPAEPQNIED-----EAKQIQSL 155
 Db 533 LKDPDAGEAVTPSKAPVQVPAVGAQVPTTELMQLQEDDFELEGTAEPGEGLVL 592
 QY 156 HEMVHAHVHVEDLQOEDGP--TGEPOQED--DEFLMATDDDRFEITLPEVSHETESHY 212
 Db 593 -----EGEGPTEEPREGEPTGEVPEELEATPEDD--FELEP--TGEVEETV 640
 QY 213 HVETVSDQCNDQMEMMSQENPDSPVVEDERLHHDTHDDVTVQYERQAVVEPLENE 272
 Db 641 EGEETAEE--GEEVEVPAEVE-----EVEEVPAAVEEVEEVEEVEEVEV 681
 QY 273 GIEITVETAPPNDPVEDSIVIVVEYSIPFVERQEQVPPETNRKTDPPQKAVKKKKPK 332
 Db 682 PAEVEEVEEVEE-----VEEVP-----EVEEVPAAVEEVEEVEEVEEVEV 728
 QY 333 LNKFKDTIKAEILDAAEKLRKRGKIEAVNAFKELVRKVPQSPRAYGKAQCDDDLAEKR 392
 Db 729 AVVEVEVPAVVEEVEEVEEVEEVEEVEEVEEVLQVIPSEEDIQDKPK--KDEIGSGI 787
 QY 393 RS-----NEVLGATITVQEVASLPDVPADLLKLSKRSDRQQLGHRMGSLLTLQRL 446
 Db 788 LSIIDMHYQDVPKFEWEEEBETAAPLKPEDF-----AKEDSQSTEMLTIFQLEGWEXL 843
 QY 447 VQLFPNDTSI-----KNDLGVGYLLIGNDAKKVYEVLSVTND--GFQKVVH 494
 Db 844 -----EVSUNKAREWMEQRNKWAGWLRLIENKWE--YSQI-STKQKDPAGLRKREW 894
 QY 495 G-----FTLKQNKIARSIPYLKGIESGDGDTGDFYFLHGDAMQVRGKAEKAY 547

Db 895 SDEKWKWFKFAEVKSQIDS---HLKKWMD-----THSNLFKILVKD--MSQFENKTKTKEWL 946
 QY 548 -----ELGKHKGHF-----ASVWORSLYNVNGLKQAQ--PWWTPKRETCY-- 583
 Db 947 MNHWKKNRGYSGSESEFVMTTSLKNVAKSREWVRANPNINRRERELMKWFLKENEYLG 1006
 QY 584 --TELKSLERN 593
 Db 1007 QRMEKMDSLEKS 1018

RESULT 8

US-08-719-822B-2
 ; Sequence 2, Application US/06719822B
 ; Patent No. 5874527
 ; GENERAL INFORMATION:
 ; APPLICANT: Barnwell, John
 ; TITLE OF INVENTION: Plasmodium vivax Blood Stage Antigens
 ; NUMBER OF SEQUENCES: 4
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Darby and Darby
 ; STREET: 805 Third Ave.
 ; CITY: New York
 ; STATE: New York
 ; COUNTRY: USA
 ; ZIP: 10022-7513
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patent In Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/719,822B
 ; FILING DATE: 09/30/96
 ; CLASSIFICATION: 435
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Gogoris, Adda
 ; REGISTRATION NUMBER: 29,714
 ; REFERENCE/DOCKET NUMBER: 5986/17686US2
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (212)527-7700
 ; TELEFAX: (212)753-6237
 ; TELEX: 236687
 ; INFORMATION FOR SEQ ID NO: 2:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 1018 amino acids
 ; TYPE: amino acid
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: protein
 ; HYPOTHEICAL: YES
 ; ANTI-SENSE: NO
 ; FRAGMENT TYPE: C-terminal
 ; ORIGINAL SOURCE:
 ; ORGANISM: Plasmodium vivax
 ; IMMEDIATE SOURCE:
 ; CLONE: PwMB3.3.1
 ; US-08-719-822B-2

Query Match 4.9%; Score 197.5; DB 2; Length 1018;
 Best Local Similarity 23.2%; Pred. No. 3.1e-07;
 Matches 128; Conservative 86; Mismatches 205; Indels 133; Gaps 27;
 QY 109 LKERSTSEPAVPEEAE-----HTEPEEQVPAEPQNIED-----EAKQIQSL 155
 Db 533 LKDPDAGEAVTPSKAPVQVPAVGAQVPTTELMQLQEDDFELEGTAEPGEGLVL 592
 QY 156 HEMVHAHVHVEDLQOEDGP--TGEPOQED--DEFLMATDDDRFEITLPEVSHETESHY 212
 Db 593 -----EGEGPTEEPREGEPTGEVPEELEATPEDD--FELEP--TGEVEETV 640
 QY 213 HVETVSDQCNDQMEMMSQENPDSPVVEDERLHHDTHDDVTVQYERQAVVEPLENE 272
 Db 641 EGEETAEE--GEEVEVPAEVE-----EVEEVPAAVEEVEEVEEVEEVEV 681

QY 273 GIEITEVTAPEDNPVEDSQVIVBEVSIFPVEEQOVPETNRKTDDEQAKVKKKKPK 332
Db 682 PAEEVEEVEEVEE-----VEEVP-----EEVEEVEEVEEVEEVEEVEEVEVP 728
QY 333 LNKFDKTIKALDAEAKLRGKIEEAVNAFAKELVRKYPOSRRARYKACQEDDLAEKR 392
Db 729 AVVEVEPAVVEEVEEVEEVEEVEEVEEVEEVEEVEEVEEVEEVEEVEEVEEVEE 787
QY 393 RS-----NEVLGAIETQYQVASLPDVPADLLKLSKRRSDROQFLGHMGSLLTLQRL 446
Db 788 LSIIDMHYQDVPEEVEEETAVPLKPEF-----AKEDSQSTEWLTFIQGLEGDWBL 843
QY 447 VOLFPNDTSL-----KNDLGVGYLLIGDNDNAKVVEEVLSTPND--GFAKVHY 494
Db 844 -----EVSINKARERWMEQNKWAGWLRLENKWSB--YSQI-STKGKDPAGLRKEW 894
QY 495 G-----FILKAQNKIAESIPYLKEGIESDPTDGRFHFHGLDAMQVRGNKEAYKY 547
Db 895 SDEKWKWFAEVSQIDS---HLKKWMD---THSNLFKILVKD-MSQFENKTKEWL 946
QY 548 -----ELGHRGHE-----ASVWORSLYNVNGLKAO--PWTPKETGY-- 583
Db 947 MNHWKNERGYGSSFEVMTSKLLNVAKSREWTRANPNINRRERLMMKFLKENEYLG 1006
QY 584 --TELKSLERN 593
Db 1007 QRMKMDSLEKS 1018

RESULT 9

US-09-092-458-2
; Sequence 2, Application US/09092458
; Patent No. 6231861
; GENERAL INFORMATION:
; APPLICANT: Barnwell, John
; TITLE OF INVENTION: Plasmodium vivax Blood Stage Antigens,
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Darby and Darby
; STREET: 805 Third Ave.
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10022-7513
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/092,458
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/719,821
; FILING DATE: 09/30/96
; ATTORNEY/AGENT INFORMATION:
; NAME: Gogoris, Agda
; REGISTRATION NUMBER: 29,714
; REFERENCE/DOCKET NUMBER: 5986/17686US3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)527-7700
; TELEFAX: (212)753-6237
; TELEX: 236687
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1018 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; HYPOTHETICAL: YES

ANTI-SENSE: NO
FRAGMENT TYPE: C-terminal
ORIGINAL SOURCE: Plasmodium vivax
ORGANISM: Plasmodium vivax
IMMEDIATE SOURCE:
CLONE: PMB3.3.1
US-09-092-458-2

Query Match 4.9%; Score 197.5; DB 3; Length 1018;

Best Local Similarity 23.2%; Pred. No. 3.1e-07;
Matches 128; Conservative 86; Mismatches 205; Indels 133; Gaps 27;
QY 109 LKERSTSEPAVPPSEAP-----HTEPEEQVPAEAPONIED-----EAKEQIQLL 155
Db 533 LKPDAGEAVTVPSKEAPVQVPAVGAQVPTBELMQLQEDDELEGTAPAGEGLVL 592
QY 156 HEMVHABHEVEDLQOEDGP--TGSPQOED--DEFIMATVDVDRFETLEPEVSHBETESY 212
Db 593 -----EGEGFTPEEPREGPTGEVPEEELATPEDD--FELEBP--TGEEVEETV 640
QY 213 HVEETVSQDCNQDMEMMSQENPDSSEPVVEDRLHDDTDVTVQVVEEQAVYEPLENE 272
Db 641 EGEETAE---GEERVEEPAEVE-----EVEEPAEVEEVEEVEEVEEVEE 681
QY 273 GIEITEVTAPEDNPVEDSQVIVBEVSIFPVEEQOVPETNRKTDDEQAKVKKKKPK 332
Db 682 PAEEVEEVEEVEE-----VEEVP-----EEVEEVEEVEEVEEVEEVEEVEVP 728
QY 333 LNKFDKTIKALDAEAKLRGKIEEAVNAFAKELVRKYPOSRRARYKACQEDDLAEKR 392
Db 729 AVVEVEPAVVEEVEEVEEVEEVEEVEEVEEVEEVEEVEEVEEVEEVEEVEEVEE 787
QY 393 RS-----NEVLGAIETQYQVASLPDVPADLLKLSKRRSDROQFLGHMGSLLTLQRL 446
Db 788 LSIIDMHYQDVPEEVEEETAVPLKPEF-----AKEDSQSTEWLTFIQGLEGDWBL 843
QY 447 VOLFPNDTSL-----KNDLGVGYLLIGDNDNAKVVEEVLSTPND--GFAKVHY 494
Db 844 -----EVSINKARERWMEQNKWAGWLRLENKWSB--YSQI-STKGKDPAGLRKEW 894
QY 495 G-----FILKAQNKIAESIPYLKEGIESDPTDGRFHFHGLDAMQVRGNKEAYKY 547
Db 895 SDEKWKWFAEVSQIDS---HLKKWMD---THSNLFKILVKD-MSQFENKTKEWL 946
QY 548 -----ELGHRGHE-----ASVWORSLYNVNGLKAO--PWTPKETGY-- 583
Db 947 MNHWKNERGYGSSFEVMTSKLLNVAKSREWTRANPNINRRERLMMKFLKENEYLG 1006
QY 584 --TELKSLERN 593
Db 1007 QRMKMDSLEKS 1018

RESULT 10

US-08-728-323A-2
; Sequence 2, Application US/08728323A
; Patent No. 5948676
; GENERAL INFORMATION:
; APPLICANT: Chang, Yuan
; APPLICANT: Bohenzky, Roy A.
; APPLICANT: Russo, James J.
; APPLICANT: Edelman, Isidore S.
; APPLICANT: Moore, Patrick S.
; TITLE OF INVENTION: Immediate Early Protein From Kaposi's
; TITLE OF INVENTION: Sarcoma-Associated Herpesvirus, DNA
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooper & Dunham LLP
; STREET: 1185 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: U.S.A.

ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
FILING DATE: US/08/728,323A
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 0575/52268/JPW/MSC/SKS
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-278-0400
TELEFAX: 212-391-0525
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 1162 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-728-323A-2

Query Match 4.7%; Score 190.5; DB 2; Length 1162;
Best Local Similarity 22.9%; Pred. No. 1.4e-06;
Matches 70; Conservative 68; Mismatches 123; Indels 45; Gaps 11;
QY 122 EEAEPHTEPEQVPVEAEAPONIEDEAKEQIQSLLEHVMHAEHVEGEDLOQEDGPTGEPQ 181
Db 698 DEQEQQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQ 743
QY 182 EDDEFLMATDVDRFETLEPEVSHETESHYHVEETVSQDCNQDMEM-----MSEQENP 236
Db 744 QDEQ-----QQQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQ 798
QY 237 DSSEPVVEDER-LHHTDDVTYQVYEQAVYEPLENEGIEITETVAPPENPVDSQVIV 295
Db 799 EQQELEEQEQLLEEQEQLLEEQEQLLEEQEQLLEEQEQLLEEQEQLLEEQEQLLEEQE 858
QY 296 EEVSIFFVEEQVPPETNRKTDPEQAKVKKKKPKLKNKFKTKIKAEIDAAEKLKRG 355
Db 859 EQEELVEVEQ-----EQEQQEQQEQQEQQEQQEQQEQQEQQEQQEQQEQQEQQEQQ 912
QY 356 KIEAVNAFKELVKYPQ-----SPRAYKGAQCEDDLAEKRRSNEVLRGAIETYQEVASL 411
Db 913 ELEVEEQEQGVQEQETVEERPIILHGSSS-EDEM-----EVDYPPVSTHEQIASS 964
QY 412 PDVPAD 417
Db 965 P--PGD 968

RESULT 11
US-09-298-568-2
Sequence 2, Application US/09298568
Patent No. 6322792
GENERAL INFORMATION:
APPLICANT: Kieff, Elliott D.
APPLICANT: Ballestas, Mary E.
APPLICANT: Kaye, Kenneth M.
TITLE OF INVENTION: RHADINO VIRUS LANA ACTS IN TRANS ON A UNIT OF RHADINO
TITLE OF INVENTION: VIRUS DNA TO MEDIATE EFFICIENT EPISOME PERSISTENCE
FILE REFERENCE: 16412-10001R
CURRENT APPLICATION NUMBER: US/09/298,568
CURRENT FILING DATE: 1999-04-21
EARLIER APPLICATION NUMBER: US 60/109,422
EARLIER FILING DATE: 1998-11-19
NUMBER OF SEQ ID NOS: 3
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 2
LENGTH: 1162

TYPE: PRT
ORGANISM: Kaposi's sarcoma-associated herpesvirus
US-09-298-568-2
Query Match 4.7%; Score 190.5; DB 4; Length 1162;
Best Local Similarity 22.9%; Pred. No. 1.4e-06;
Matches 70; Conservative 68; Mismatches 123; Indels 45; Gaps 11;
QY 122 EEAEPHTEPEQVPVEAEAPONIEDEAKEQIQSLLEHVMHAEHVEGEDLOQEDGPTGEPQ 181
Db 698 DEQEQQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQ 743
QY 182 EDDEFLMATDVDRFETLEPEVSHETESHYHVEETVSQDCNQDMEM-----MSEQENP 236
Db 744 QDEQ-----QQQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQ 798
QY 237 DSSEPVVEDER-LHHTDDVTYQVYEQAVYEPLENEGIEITETVAPPENPVDSQVIV 295
Db 799 EQQELEEQEQLLEEQEQLLEEQEQLLEEQEQLLEEQEQLLEEQEQLLEEQEQLLEEQE 858
QY 296 EEVSIFFVEEQVPPETNRKTDPEQAKVKKKKPKLKNKFKTKIKAEIDAAEKLKRG 355
Db 859 EQEELVEVEQ-----EQEQQEQQEQQEQQEQQEQQEQQEQQEQQEQQEQQEQQEQQ 912
QY 356 KIEAVNAFKELVKYPQ-----SPRAYKGAQCEDDLAEKRRSNEVLRGAIETYQEVASL 411
Db 913 ELEVEEQEQGVQEQETVEERPIILHGSSS-EDEM-----EVDYPPVSTHEQIASS 964
QY 412 PDVPAD 417
Db 965 P--PGD 968
RESULT 12
US-09-410-399-2
Sequence 2, Application US/09410399
Patent No. 6482587
GENERAL INFORMATION:
APPLICANT: Robertson, Erle S.
APPLICANT: Cottar, Murray A.
TITLE OF INVENTION: Methods to Inhibit or Enhance the Binding of Viral DNA
TITLE OF INVENTION: to Genomic Host DNA
FILE REFERENCE: UM-03778
CURRENT APPLICATION NUMBER: US/09/410,399
CURRENT FILING DATE: 1999-10-01
NUMBER OF SEQ ID NOS: 6
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 2
LENGTH: 1162
TYPE: PRT
ORGANISM: Kaposi's sarcoma-associated herpesvirus
US-09-410-399-2
Query Match 4.7%; Score 190.5; DB 4; Length 1162;
Best Local Similarity 22.9%; Pred. No. 1.4e-06;
Matches 70; Conservative 68; Mismatches 123; Indels 45; Gaps 11;
QY 122 EEAEPHTEPEQVPVEAEAPONIEDEAKEQIQSLLEHVMHAEHVEGEDLOQEDGPTGEPQ 181
Db 698 DEQEQQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQ 743
QY 182 EDDEFLMATDVDRFETLEPEVSHETESHYHVEETVSQDCNQDMEM-----MSEQENP 236
Db 744 QDEQ-----QQQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQDEQ 798
QY 237 DSSEPVVEDER-LHHTDDVTYQVYEQAVYEPLENEGIEITETVAPPENPVDSQVIV 295
Db 799 EQQELEEQEQLLEEQEQLLEEQEQLLEEQEQLLEEQEQLLEEQEQLLEEQEQLLEEQE 858
QY 296 EEVSIFFVEEQVPPETNRKTDPEQAKVKKKKPKLKNKFKTKIKAEIDAAEKLKRG 355
Db 859 EQEELVEVEQ-----EQEQQEQQEQQEQQEQQEQQEQQEQQEQQEQQEQQEQQEQQ 912
QY 356 KIEAVNAFKELVKYPQ-----SPRAYKGAQCEDDLAEKRRSNEVLRGAIETYQEVASL 411
Db 913 ELEVEEQEQGVQEQETVEERPIILHGSSS-EDEM-----EVDYPPVSTHEQIASS 964
QY 412 PDVPAD 417
Db 965 P--PGD 968


```

QY 181 QEDDEFLMATDVDDRETTLEPEVSHBETEHSHVVEETVSQDCNQDMEMMSQENPDSS 240
DB 181 QEDDEFLMATDVDDRETTLEPEVSHBETEHSHVVEETVSQDCNQDMEMMSQENPDSS 240
QY 241 PVVEDRLHDDTDDVTVQVVEQAVVEPLENEGIEITEVTAPEDNPVEDSQVIVEVSI 300
DB 241 PVVEDRLHDDTDDVTVQVVEQAVVEPLENEGIEITEVTAPEDNPVEDSQVIVEVSI 300
QY 301 FPVEEQEVPETNRKTDDEPEQAKVKKPKLLNFKDKTKIAELDAAEKLKRGKIEEA 360
DB 301 FPVEEQEVPETNRKTDDEPEQAKVKKPKLLNFKDKTKIAELDAAEKLKRGKIEEA 360
QY 361 VNAFKELVRKYPOSPRARYKQACEDDLAEKRSNEVLRGAIETYQEVASLPDVPADLLK 420
DB 361 VNAFKELVRKYPOSPRARYKQACEDDLAEKRSNEVLRGAIETYQEVASLPDVPADLLK 420
QY 421 LSLKRRSDRQOQFLGHRGSLTTLQRLVQLFPNDTSLKNDLGVGYLLIGDNDNAKVVYEV 480
DB 421 LSLKRRSDRQOQFLGHRGSLTTLQRLVQLFPNDTSLKNDLGVGYLLIGDNDNAKVVYEV 480
QY 481 LSVTPNDGFAKVHYGFLKQAKVKKPKLLNFKDKTKIAELDAAEKLKRGKIEEA 540
DB 481 LSVTPNDGFAKVHYGFLKQAKVKKPKLLNFKDKTKIAELDAAEKLKRGKIEEA 540
QY 541 KEAYKVELGHRGHPASVWORSYLVNGLKAPWMTPKETGYTELKSLERNWKLIRDE 600
DB 541 KEAYKVELGHRGHPASVWORSYLVNGLKAPWMTPKETGYTELKSLERNWKLIRDE 600
QY 601 GLAVMDKAKGLFLPEDENLREKGDWSQFTLWQOGRNENACKGAPKCTTILEKFPETTGC 660
DB 601 GLAVMDKAKGLFLPEDENLREKGDWSQFTLWQOGRNENACKGAPKCTTILEKFPETTGC 660
QY 661 RRGQIKYSIMHPGTHVWPHGTNCRMLHGLVPIKGGCKIRCANETRTWESGKVLIFD 720
DB 661 RRGQIKYSIMHPGTHVWPHGTNCRMLHGLVPIKGGCKIRCANETRTWESGKVLIFD 720
QY 721 DSFEHEVWQDASSFRLLIFIVDVVWHPHLPDQRRSLPAI 758
DB 721 DSFEHEVWQDASSFRLLIFIVDVVWHPHLPDQRRSLPAI 758

RESULT 2
US-09-859-604-2
; Sequence 2, Application US/09859604
; Patent No. US2002011059A1
; GENERAL INFORMATION:
; APPLICANT: Wands, Jack R.
; APPLICANT: Deutch, Alan H
; APPLICANT: Ghanbari, Hossein A
; TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS
; FILE REFERENCE: 21486-032 CIP
; CURRENT APPLICATION NUMBER: US/09/859,604
; PRIOR FILING DATE: 2001-05-17
; PRIOR APPLICATION NUMBER: 09/436,184
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 758
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-859-604-2

Query Match 100.0%; Score 4022; DB 9; Length 758;
Best Local Similarity 100.0%; Pred. No. 1.5e-282;
Matches 758; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAQRNKAQSSNGSSSGSGSTAGSSPGARRETHKGHGKNGKGLSGTSFPTWFMV 60
DB 1 MAQRNKAQSSNGSSSGSGSTAGSSPGARRETHKGHGKNGKGLSGTSFPTWFMV 60

```

```

QY 61 IALLGWTSVAVVWFEDLVYEEVLGKLIYDADGDGDFDVEDAKVLLGLKERSTSPAYP 120
DB 61 IALLGWTSVAVVWFEDLVYEEVLGKLIYDADGDGDFDVEDAKVLLGLKERSTSPAYP 120
QY 121 PEEAEPHTPEEQVPVEAEPQNIIEDEAKEQI QSLIHEMVHABHVEGEDIQQEDGPTGEPQ 180
DB 121 PEEAEPHTPEEQVPVEAEPQNIIEDEAKEQI QSLIHEMVHABHVEGEDIQQEDGPTGEPQ 180
QY 181 QEDDEFLMATDVDDRETTLEPEVSHBETEHSHVVEETVSQDCNQDMEMMSQENPDSS 240
DB 181 QEDDEFLMATDVDDRETTLEPEVSHBETEHSHVVEETVSQDCNQDMEMMSQENPDSS 240
QY 241 PVVEDRLHDDTDDVTVQVVEQAVVEPLENEGIEITEVTAPEDNPVEDSQVIVEVSI 300
DB 241 PVVEDRLHDDTDDVTVQVVEQAVVEPLENEGIEITEVTAPEDNPVEDSQVIVEVSI 300
QY 301 FPVEEQEVPETNRKTDDEPEQAKVKKPKLLNFKDKTKIAELDAAEKLKRGKIEEA 360
DB 301 FPVEEQEVPETNRKTDDEPEQAKVKKPKLLNFKDKTKIAELDAAEKLKRGKIEEA 360
QY 361 VNAFKELVRKYPOSPRARYKQACEDDLAEKRSNEVLRGAIETYQEVASLPDVPADLLK 420
DB 361 VNAFKELVRKYPOSPRARYKQACEDDLAEKRSNEVLRGAIETYQEVASLPDVPADLLK 420
QY 421 LSLKRRSDRQOQFLGHRGSLTTLQRLVQLFPNDTSLKNDLGVGYLLIGDNDNAKVVYEV 480
DB 421 LSLKRRSDRQOQFLGHRGSLTTLQRLVQLFPNDTSLKNDLGVGYLLIGDNDNAKVVYEV 480
QY 481 LSVTPNDGFAKVHYGFLKQAKVKKPKLLNFKDKTKIAELDAAEKLKRGKIEEA 540
DB 481 LSVTPNDGFAKVHYGFLKQAKVKKPKLLNFKDKTKIAELDAAEKLKRGKIEEA 540
QY 541 KEAYKVELGHRGHPASVWORSYLVNGLKAPWMTPKETGYTELKSLERNWKLIRDE 600
DB 541 KEAYKVELGHRGHPASVWORSYLVNGLKAPWMTPKETGYTELKSLERNWKLIRDE 600
QY 601 GLAVMDKAKGLFLPEDENLREKGDWSQFTLWQOGRNENACKGAPKCTTILEKFPETTGC 660
DB 601 GLAVMDKAKGLFLPEDENLREKGDWSQFTLWQOGRNENACKGAPKCTTILEKFPETTGC 660
QY 661 RRGQIKYSIMHPGTHVWPHGTNCRMLHGLVPIKGGCKIRCANETRTWESGKVLIFD 720
DB 661 RRGQIKYSIMHPGTHVWPHGTNCRMLHGLVPIKGGCKIRCANETRTWESGKVLIFD 720
QY 721 DSFEHEVWQDASSFRLLIFIVDVVWHPHLPDQRRSLPAI 758
DB 721 DSFEHEVWQDASSFRLLIFIVDVVWHPHLPDQRRSLPAI 758

RESULT 3
US-09-903-063-2
; Sequence 2, Application US/09903063
; Patent No. US20020114810A1
; GENERAL INFORMATION:
; APPLICANT: Wands, Jack R.
; APPLICANT: de la Monte, Suzanne M.
; APPLICANT: Ince, Nedim
; APPLICANT: Carlson, Rolf I.
; TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS
; FILE REFERENCE: 21486-032 DIV3
; CURRENT APPLICATION NUMBER: US/09/903,063
; CURRENT FILING DATE: 2001-10-11
; PRIOR APPLICATION NUMBER: 09/436,184
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 758
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-903-063-2

Query Match 100.0%; Score 4022; DB 9; Length 758;

```

```

; SEQ ID NO 2
; LENGTH: 758
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-903-216--2

Query Match 100.0%; Score 4022; DB 9; Length 758;
Best Local Similarity 100.0%; Pred. No. 1.5e-282;
Matches 758; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAQRKAKSGNSSSSGSGSGSTSAGSSSPGARRETKHGGHKNGKRGKGLSGTSPFTWFMV 60
DB 1 MAQRKAKSGNSSSSGSGSGSTSAGSSSPGARRETKHGGHKNGKRGKGLSGTSPFTWFMV 60
QY 61 IALLGVWTSVAVVWFDLVYEEVLGKGIYDADGDGDFDVEDDQKVLGLKERSTSEPAVP 120
DB 61 IALLGVWTSVAVVWFDLVYEEVLGKGIYDADGDGDFDVEDDQKVLGLKERSTSEPAVP 120
QY 121 PERAEPTHEPEEQVPVBAEPQNIHDEAKEQIQSLHEMVAHVEGEDLOQEDGPTGPEQ 180
DB 121 PERAEPTHEPEEQVPVBAEPQNIHDEAKEQIQSLHEMVAHVEGEDLOQEDGPTGPEQ 180
QY 181 QEDDEFWATDVDDRFTLPEVSHETESHYHVEETVSQCNODMEMMSEQENPDOSSE 240
DB 181 QEDDEFWATDVDDRFTLPEVSHETESHYHVEETVSQCNODMEMMSEQENPDOSSE 240
QY 241 PVFEDERLHHDTDVTVQVVEEQAVYPLENEGIEITETVTTAPEDNPVEDSQVIVEEVS 300
DB 241 PVFEDERLHHDTDVTVQVVEEQAVYPLENEGIEITETVTTAPEDNPVEDSQVIVEEVS 300
QY 301 PVPVEEQEVPPTNRKTDPPQAKVKKKPKLLNKFDKTIKAEIDAAEKLKRGKIEEA 360
DB 301 PVPVEEQEVPPTNRKTDPPQAKVKKKPKLLNKFDKTIKAEIDAAEKLKRGKIEEA 360
QY 361 VNAFKELVRKYPQSPRARYKAQCEDDLAEKRRSNEVLRGAIETTYQEVASLPDVPADLLK 420
DB 361 VNAFKELVRKYPQSPRARYKAQCEDDLAEKRRSNEVLRGAIETTYQEVASLPDVPADLLK 420
QY 421 LSLKRRSDROQFLGHRGSLTLTQRLVQIFPNDTSLKNDLGVGYLLIGDNDNAKKVYEEV 480
DB 421 LSLKRRSDROQFLGHRGSLTLTQRLVQIFPNDTSLKNDLGVGYLLIGDNDNAKKVYEEV 480
QY 481 LSVTPNDGFAKVHYGFIILKAQNKIAESIPYLKEGIESGDPGTDGGRFYFHLGDAMQVRVN 540
DB 481 LSVTPNDGFAKVHYGFIILKAQNKIAESIPYLKEGIESGDPGTDGGRFYFHLGDAMQVRVN 540
QY 541 KEAYKWEYLGHKRGHFASVWQRSLYNVNGLKAQPPWTPKETGYTELTVKSLERNWKLIRDE 600
DB 541 KEAYKWEYLGHKRGHFASVWQRSLYNVNGLKAQPPWTPKETGYTELTVKSLERNWKLIRDE 600
QY 601 GLAVMDKAGLFLPEDENIREKGDWSQFTLWQOGRNENACAKGAPKTCFLLEKFPETTCG 660
DB 601 GLAVMDKAGLFLPEDENIREKGDWSQFTLWQOGRNENACAKGAPKTCFLLEKFPETTCG 660
QY 661 RRGQIKYSIMHPGTHVWPHGTPTNCLRMLHLGLVIPKEGCKIRCANETRTWBEQKVLIFD 720
DB 661 RRGQIKYSIMHPGTHVWPHGTPTNCLRMLHLGLVIPKEGCKIRCANETRTWBEQKVLIFD 720
QY 721 DSFEHEVWQDASSFRLLIFLVVWHPBELTPQORRSIPAI 758
DB 721 DSFEHEVWQDASSFRLLIFLVVWHPBELTPQORRSIPAI 758

```

RESULT 5
US-09-903-199-2
; Sequence 2, Application US/09903199
; Patent NO. US2002012802A1
; GENERAL INFORMATION
; APPLICANT: Wands, Jack R.
; APPLICANT: de la Monte, Suzanne M.
; APPLICANT: Ince, Nedim
; APPLICANT: Carlson, Rolf I.
; TITLE OF INVENTION: DIAGNOSIS AND T

```

; FILE REFERENCE: 21486-032 DIV4
; CURRENT APPLICATION NUMBER: US/09/903,199
; CURRENT FILING DATE: 2001-07-11
; PRIOR APPLICATION NUMBER: 09/436,184
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 758
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-903-199-2

Query Match      100.0%; Score 4022; DB 9; Length 758;
Best Local Similarity 100.0%; Pred. No. 1.5e-282;
Matches 758; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAQRKNAKSGNSSSSGSGSGSTSGAGSSSPGARRETKHGKHGKRGKGLSGTSTFTWFMV 60
DB 1 MAQRKNAKSGNSSSSGSGSGSTSGAGSSSPGARRETKHGKHGKRGKGLSGTSTFTWFMV 60
QY 61 IALLGWTSAVAVWFDLVDYEEVLKGLIYDADGGDFDVDADKAVLLGLKERSISEPVP 120
DB 61 IALLGWTSAVAVWFDLVDYEEVLKGLIYDADGGDFDVDADKAVLLGLKERSISEPVP 120
QY 121 PEEAEPHTEPEEQVPVEAEPONIDEAKEQIQSLIHEMVHAHEHVEGDLQEDGPTGEPQ 180
DB 121 PEEAEPHTEPEEQVPVEAEPONIDEAKEQIQSLIHEMVHAHEHVEGDLQEDGPTGEPQ 180
QY 181 QEDDEFIMATVDVDRFETLEPEVSHETEHSYHVEETVQSCNQDMMEEMGEQENPDSSSE 240
DB 181 QEDDEFIMATVDVDRFETLEPEVSHETEHSYHVEETVQSCNQDMMEEMGEQENPDSSSE 240
QY 241 PVVEDERLHHDTDVTVQVVEEQVAYPELENEGIEITETVAPPEDNPVEDSQVIVVEEVS 300
DB 241 PVVEDERLHHDTDVTVQVVEEQVAYPELENEGIEITETVAPPEDNPVEDSQVIVVEEVS 300
QY 301 FVVEEQVEVPETNKRKTDDEPQAKVKKKKPKLLNKFDTTKAELDAAEKLRKRGKIEEA 360
DB 301 FVVEEQVEVPETNKRKTDDEPQAKVKKKKPKLLNKFDTTKAELDAAEKLRKRGKIEEA 360
QY 361 VNAPEKELVRKYPQSPRARYGKAQCEDDLAEKRRSNEVLRGALETVQEVASLPDVPADLLK 420
DB 361 VNAPEKELVRKYPQSPRARYGKAQCEDDLAEKRRSNEVLRGALETVQEVASLPDVPADLLK 420
QY 421 LSLKRRSDRQOFLGHMRGSLTLQLRVOLFNDTSLKNDLGVGYLLIGDNNAKKVEEV 480
DB 421 LSLKRRSDRQOFLGHMRGSLTLQLRVOLFNDTSLKNDLGVGYLLIGDNNAKKVEEV 480
QY 481 LSVTPNDGFAKVHYGFTILKAQNKTAESIPYLKEGIESGDPCTDGRFFVHGLDAMQVGN 540
DB 481 LSVTPNDGFAKVHYGFTILKAQNKTAESIPYLKEGIESGDPCTDGRFFVHGLDAMQVGN 540
QY 541 KEAYKAYELGHKRGHFASVWQSRSLYNNGLKAQPPWTPKETGYTLVKLSLRNKKLIRDE 600
DB 541 KEAYKAYELGHKRGHFASVWQSRSLYNNGLKAQPPWTPKETGYTLVKLSLRNKKLIRDE 600
QY 601 GLAYVMDKAKGLFLPEDENLRKGDWSQFTLWQOGRNENACKGAPKTTLLKEKFPETTC 660
DB 601 GLAYVMDKAKGLFLPEDENLRKGDWSQFTLWQOGRNENACKGAPKTTLLKEKFPETTC 660
QY 661 RRGQIKYSIMHPGTHVWPHTGPTNCLRMLHGLVTPKEGCKIRCANEFTWEEGKVLIFD 720
DB 661 RRGQIKYSIMHPGTHVWPHTGPTNCLRMLHGLVTPKEGCKIRCANEFTWEEGKVLIFD 720
QY 721 DSFBEHVWQDASSFLRIFIVDVVHPBELTPQQRSLPAI 758
DB 721 DSFBEHVWQDASSFLRIFIVDVVHPBELTPQQRSLPAI 758

```

Query Match	100.0%;	Score 4022;	DB 9;	Length 758;
Best Local Similarity	100.0%;	Pred. No. 1.5e-282;	Indels 0;	Gaps 0;
Matches 758;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy	1	MAQKNAKSGNSSSSGSGSGSTSAGSSSPGARRETKHGHKHNKRGKGLSGTSFTFMV	60	
Db	1	MAQKNAKSGNSSSSGSGSGSTSAGSSSPGARRETKHGHKHNKRGKGLSGTSFTFMV	60	
Qy	61	IALLGWTSVAVVWFDLVDVVEVLKGIYDADGGDFVDVDDAKVLLGLKERSSTSEPAVP	120	
Db	61	IALLGWTSVAVVWFDLVDVVEVLKGIYDADGGDFVDVDDAKVLLGLKERSSTSEPAVP	120	
Qy	121	PEEAEPHTEPEEQVPVEAEQNIIDEAKBOIQSLLEHMVHAEHVEGEDLQEDGPTGBPP	180	
Db	121	PEEAEPHTEPEEQVPVEAEQNIIDEAKBOIQSLLEHMVHAEHVEGEDLQEDGPTGBPP	180	
Qy	181	QEDDEFMATDVDDRFETLPEVSHBETEHSHYVEETVSCQCNQDMMEEMGEQNPDSSE	240	
Db	181	QEDDEFMATDVDDRFETLPEVSHBETEHSHYVEETVSCQCNQDMMEEMGEQNPDSSE	240	
Qy	241	PVVEDERLHDDTDVTVTVVEEQAVYPLENEGIEITEVTAPPEDNPVEDSQVIVEEVS	300	
Db	241	PVVEDERLHDDTDVTVTVVEEQAVYPLENEGIEITEVTAPPEDNPVEDSQVIVEEVS	300	
Qy	301	FPVEEQEVPPETNKRKTDDPEQAKVKKKKPKLLINKFDKTIKAELEDAEKLKRGKIEEA	360	
Db	301	FPVEEQEVPPETNKRKTDDPEQAKVKKKKPKLLINKFDKTIKAELEDAEKLKRGKIEEA	360	
Qy	361	VNAFKEIVRKYPQSPFRARYGKACEDDLAEKRSNEVLGRGAIETVQEVASIPDVPADLLK	420	
Db	361	VNAFKEIVRKYPQSPFRARYGKACEDDLAEKRSNEVLGRGAIETVQEVASIPDVPADLLK	420	
Qy	421	LSLKRRSDRQOFLGHMRGSLTLQLRVQLFPNDTSLKNDLGVGLLIGDNDNAKKVVEV	480	
Db	421	LSLKRRSDRQOFLGHMRGSLTLQLRVQLFPNDTSLKNDLGVGLLIGDNDNAKKVVEV	480	
Qy	481	LSVTPNDGFAKHVGFILKAQNKIAESIPIYLKEGIESGDPDGDGRFFPHLGDMQRVGN	540	
Db	481	LSVTPNDGFAKHVGFILKAQNKIAESIPIYLKEGIESGDPDGDGRFFPHLGDMQRVGN	540	
Qy	541	KEAYKVTYELGHRGHFASVWORSIYNNVGLKAQPPWTPKETGYTTELKSLERNWKLIRDE	600	
Db	541	KEAYKVTYELGHRGHFASVWORSIYNNVGLKAQPPWTPKETGYTTELKSLERNWKLIRDE	600	
Qy	601	GLAYVMDKAGLFLPEDENLREKGDWSQFTLWQOGRNENACKGAPKTCITLLEKFPETGTC	660	
Db	601	GLAYVMDKAGLFLPEDENLREKGDWSQFTLWQOGRNENACKGAPKTCITLLEKFPETGTC	660	
Qy	661	RRGQIKYSIMHPGTHVPHPTGPTNCLRMLHGLVIPKEGCKIRCANETFWEEGKVLIFD	720	
Db	661	RRGQIKYSIMHPGTHVPHPTGPTNCLRMLHGLVIPKEGCKIRCANETFWEEGKVLIFD	720	
Qy	721	DSFEHEVMQDASSFRLIFIVDVWHPHETLPQORRSILPAI	758	


```

; CURRENT FILING DATE: 2002-03-28
; NUMBER OF SEQ ID NOS: 2011
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1806
; LENGTH: 255
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-113-872-1806

Query Match          32.8%; Score 1320; DB 14; Length 255;
Best Local Similarity 98.8%; Pred. No. 1.9e-87;
Matches 252; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 59 MVTALIGVWTSVAVWFDLVVDYEEVLGKGIYDADGDDVDADKVLGLKERSTSEPA 118
Db 1  MVTALIGVWTSVAVWFDLVVDYEEVLGKGIYDADGDDVDADKVLGLKERSTSEPA 60

QY 119 VPPEEAHPHTEPEEQVPVEAPQNIEDAEKEIQSLIHEMVHAEHVGEDELQQEDGPTGE 178
Db 61  VPPEEAHPHTEPEEQVPVEAPQNIEDAEKEIQSLIHEMVHAEHVGEDELQQEDGPTGE 120

QY 179 PQQEDDEFMATDVDRRFETLSEPVSHSETEHSYHVEETVSQCNQDMEEMMSQENPDS 238
Db 121 PQQEDDEFMATDVDRRFETLSEPVSHSETEHSYHVEETVSQCNQDMEEMMSQENPDS 180

QY 239 SEPVVEDERLHDTDDVTYQVYBEQAVYEPLENEGIEITETVAPPENPVEDSOVIVVEEV 298
Db 181 SEPVVEDERLHDTDDVTYQVYBEQAVYEPLENEGIEITETVAPPENPVEDSOVIVVEEV 240

QY 299 SIFPVEBQQEVPPEP 313
Db 241 SIFPVEBQQEVPPEP 255

RESULT 14
US-10-156-761-8153
; Sequence 8153, Application US/10156761
; Publication No. US20030119018A1
; GENERAL INFORMATION:
; APPLICANT: OMURA, SATOSHI
; APPLICANT: IKEDA, HARUO
; APPLICANT: ISHIKAWA, JUN
; APPLICANT: HORIKAWA, HIROSHI
; APPLICANT: SHIBA, TADAYOSHI
; APPLICANT: SAKAKI, YOSHIYUKI
; APPLICANT: HATTORI, MASAHIRA
; TITLE OF INVENTION: NOVEL POLYNUCLEOTIDES
; FILE REFERENCE: 249-262
; CURRENT APPLICATION NUMBER: US/10/156,761
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: JP 2001-204089
; PRIOR FILING DATE: 2001-05-30
; PRIOR APPLICATION NUMBER: JP 2001-272697
; PRIOR FILING DATE: 2001-08-02
; NUMBER OF SEQ ID NOS: 15109
; SEQ ID NO 8153
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Streptomyces avermitilis
US-10-156-761-8153

Query Match          6.8%; Score 275; DB 14; Length 250;
Best Local Similarity 33.3%; Pred. No. 9.2e-12;
Matches 65; Conservative 31; Mismatches 91; Indels 8; Gaps 4;

QY 569 GLKAPQWMTPKETGYTEL---VKSLERNWKLIRDEGLAVMDKAKGULFPEDENLRKGDW 625
Db 48  GLSPTPWMDP--YAYAEALPVVHELEASHQAKEELKVAWSARREAFSDYEHVLTREQDNW 105

QY 626 SOFTLWQOGRNENACKGAPKTCITLLEKPPETG--CRRGQIKYSIMHPTGTHVWPHGTGT 683
Db 106  OALVLPFRGGTTEBSAATVPIAYOVLDKVDVDTGKICPLLECHFSFTLLPGAVIEPHCDLW 165

```

684 NCRLRHILGLVTPKEGCKIRCANETRTWEEKVLIFDDSFHEVWQDASSFRLIIFVDVW 743 QY
166 NPSINFIHIAVDIIP-DGCSITVAGETRSWEKGKLLFDYSFEHEARNTGTPRTCLLIDLW 224 nh

Qy 744 HP^{EL}TP^QRRSLPAI 758
||| :||| :
Db 225 HP^{ET}VP^{ER}ALVAL 239

RESULT 15

```

US-10-168-274-15
; Sequence 15, Application US/10168274
; Publication No. US20030124106A1
; GENERAL INFORMATION:
; APPLICANT: INCYTE GENOMICS, INC.
; APPLICANT: YUE, Henry
; APPLICANT: LAL, Preeti
; APPLICANT: TANG, Y. Tom
; APPLICANT: HILLMAN, Jennifer
; APPLICANT: BAUGHN, Mariah R.
; APPLICANT: AZIMZAI, Yalda
; APPLICANT: LU, Dyung Aina M.
; TITLE OF INVENTION: HUMAN OXIDOREDUCTASE PROTEINS
; FILE REFERENCE: PF-0754 PCT
; CURRENT APPLICATION NUMBER: US/10/168,274
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 60/172,367
; PRIOR FILING DATE: 1999-12-16
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PERL Program
; SEQ ID NO 15
; LENGTH: 369
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc.feature
; OTHER INFORMATION: Incyte ID No. US20030124106A1 2754425CD1
US-10-168-274-15

```

Query Match	6.8%;	Score 274.5;	DB 14;	Length 369;
Best Local Similarity	30.1%;	Pred. NO. 1.7e-11;		
Matches	75;	Conservative 44;	Mismatches 105;	Indels 25; Gaps 9;
Qy	526	RFYFHLGDAMQVGNKEAYKWEYLG--HK-----RGHF-----ASVMQRSLYNVNGLKQAPW	575	
Db	125	KLYHNLQEYAKR-----YNSNGMGRIIHKGIREQGRYLNRSFISQIKPEVFPLPOLPTTPY	178	
Qy	576	WTPKETGYTELKSLERNWKLIRDEGLAVMDKAKGLFLPE--DENLRKGDWSQFTLWQQ	633	
Db	179	FSRDAQKHD--VEVLERNFQTLCEFTLYKAFNSCSLPQGWKMNSTSGSWFFLYLVNQ	236	
Qy	634	GRRNENACKGAPKCTLLEKFPETTGCR--RQIQKYSIMHPGTHVWPHGTPTNCRLRMHLG	692	
Db	237	GVCVPRNCKCPRTYRLGLSLRTCTIGNNVFGNACISVLSPGTIVTEHYGPTNIRIRCHLG	296	
Qy	693	LVIKPEGCKIRCANETRWEGKVLIFDSSPEHEVWQDASSP---RLIFIVDVWHPELTP	749	
Db	297	LKTP--NGCELVVGGEPQCBWAGRCLLFDDFSFLHAAAFHEGSGAEDGRPVFMVDLWHPNVAA	355	
Qy	750	QQRSLPAI	758	
Db	356	AEROALDFI	364	

Search completed: May 5, 2004, 11:09:57
Job time : 50 secs